
<html lang="en"     class="pb-page"  data-request-id="6dad76cd-e282-42bb-94b5-1e2b88469f66"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b01624"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist" /></meta><meta name="dc.Creator" content="Mikko  Gynther" /></meta><meta name="dc.Creator" content="Ilaria  Proietti Silvestri" /></meta><meta name="dc.Creator" content="Jacob C.  Hansen" /></meta><meta name="dc.Creator" content="Kasper B.  Hansen" /></meta><meta name="dc.Creator" content="Tarja  Malm" /></meta><meta name="dc.Creator" content="Yevheniia  Ishchenko" /></meta><meta name="dc.Creator" content="Younes  Larsen" /></meta><meta name="dc.Creator" content="Liwei  Han" /></meta><meta name="dc.Creator" content="Silke  Kayser" /></meta><meta name="dc.Creator" content="Seppo  Auriola" /></meta><meta name="dc.Creator" content="Aleksanteri  Petsalo" /></meta><meta name="dc.Creator" content="Birgitte  Nielsen" /></meta><meta name="dc.Creator" content="Darryl S.  Pickering" /></meta><meta name="dc.Creator" content="Lennart  Bunch" /></meta><meta name="dc.Description" content="The most common solid tumors show intrinsic multidrug resistance (MDR) or inevitably acquire such when treated with anticancer drugs. In this work, we describe the discovery of a peripherally restr..." /></meta><meta name="Description" content="The most common solid tumors show intrinsic multidrug resistance (MDR) or inevitably acquire such when treated with anticancer drugs. In this work, we describe the discovery of a peripherally restr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 5, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01624" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01624" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01624" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01624" /></link>
        
    
    

<title>Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01624" /></meta><meta property="og:title" content="Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0016.jpeg" /></meta><meta property="og:description" content="The most common solid tumors show intrinsic multidrug resistance (MDR) or inevitably acquire such when treated with anticancer drugs. In this work, we describe the discovery of a peripherally restricted, potent, competitive NMDA receptor antagonist 1l by a structure–activity study of the broad-acting ionotropic glutamate receptor antagonist 1a. Subsequently, we demonstrate that 1l augments the cytotoxic action of sorafenib in murine hepatocellular carcinoma cells. The underlying biological mechanism was shown to be interference with the lipid signaling pathway, leading to reduced expression of MDR transporters and thereby an increased accumulation of sorafenib in the cancer cells. Interference with lipid signaling pathways by NMDA receptor inhibition is a novel and promising strategy for reversing transporter-mediated chemoresistance in cancer cells." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01624"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01624">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01624&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01624&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01624&amp;href=/doi/10.1021/acs.jmedchem.7b01624" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9885-9904</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01590" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01248" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive <i>N</i>-Methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) Receptor Antagonist</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mikko++Gynther">Mikko Gynther</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ilaria++Proietti+Silvestri">Ilaria Proietti Silvestri</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacob+C.++Hansen">Jacob C. Hansen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kasper+B.++Hansen">Kasper B. Hansen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-3303-4819" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tarja++Malm">Tarja Malm</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yevheniia++Ishchenko">Yevheniia Ishchenko</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Younes++Larsen">Younes Larsen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Liwei++Han">Liwei Han</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silke++Kayser">Silke Kayser</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Seppo++Auriola">Seppo Auriola</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aleksanteri++Petsalo">Aleksanteri Petsalo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Birgitte++Nielsen">Birgitte Nielsen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Darryl+S.++Pickering">Darryl S. Pickering</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-8687-6094" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lennart++Bunch">Lennart Bunch</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-0180-4639" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Biomedical and Pharmaceutical Sciences and Center for Biomolecular Structure and Dynamics, University of Montana, Missoula, Montana 59812, United States</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211 Kuopio, Finland</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#e18d848394a192948f85cf8a94cf858a"><span class="__cf_email__" data-cfemail="dbb7beb9ae9ba8aeb5bff5b0aef5bfb0">[email protected]</span></a>. Phone: +45 35 33 62 44.</div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#74191d1f1f1b5a130d1a001c1106340111125a121d"><span class="__cf_email__" data-cfemail="1a7773717175347d63746e727f685a6f7f7c347c73">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01624&amp;href=/doi/10.1021%2Facs.jmedchem.7b01624" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9885–9904</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 5, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 November 2017</li><li><span class="item_label"><b>Published</b> online</span>5 December 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 December 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01624" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01624</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9885%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMikko%2BGynther%252C%2BIlaria%2BProietti%2BSilvestri%252C%2BJacob%2BC.%2BHansen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D23%26contentID%3Dacs.jmedchem.7b01624%26title%3DAugmentation%2Bof%2BAnticancer%2BDrug%2BEfficacy%2Bin%2BMurine%2BHepatocellular%2BCarcinoma%2BCells%2Bby%2Ba%2BPeripherally%2BActing%2BCompetitive%2BN-Methyl-d-aspartate%2B%2528NMDA%2529%2BReceptor%2BAntagonist%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9904%26publicationDate%3DDecember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01624"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">926</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01624" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mikko&quot;,&quot;last_name&quot;:&quot;Gynther&quot;},{&quot;first_name&quot;:&quot;Ilaria&quot;,&quot;last_name&quot;:&quot;Proietti Silvestri&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;C. Hansen&quot;},{&quot;first_name&quot;:&quot;Kasper&quot;,&quot;last_name&quot;:&quot;B. Hansen&quot;},{&quot;first_name&quot;:&quot;Tarja&quot;,&quot;last_name&quot;:&quot;Malm&quot;},{&quot;first_name&quot;:&quot;Yevheniia&quot;,&quot;last_name&quot;:&quot;Ishchenko&quot;},{&quot;first_name&quot;:&quot;Younes&quot;,&quot;last_name&quot;:&quot;Larsen&quot;},{&quot;first_name&quot;:&quot;Liwei&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Silke&quot;,&quot;last_name&quot;:&quot;Kayser&quot;},{&quot;first_name&quot;:&quot;Seppo&quot;,&quot;last_name&quot;:&quot;Auriola&quot;},{&quot;first_name&quot;:&quot;Aleksanteri&quot;,&quot;last_name&quot;:&quot;Petsalo&quot;},{&quot;first_name&quot;:&quot;Birgitte&quot;,&quot;last_name&quot;:&quot;Nielsen&quot;},{&quot;first_name&quot;:&quot;Darryl&quot;,&quot;last_name&quot;:&quot;S. Pickering&quot;},{&quot;first_name&quot;:&quot;Lennart&quot;,&quot;last_name&quot;:&quot;Bunch&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;9885-9904&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01624&quot;},&quot;abstract&quot;:&quot;The most common solid tumors show intrinsic multidrug resistance (MDR) or inevitably acquire such when treated with anticancer drugs. In this work, we describe the discovery of a peripherally restricted, potent, competitive NMDA receptor antagonist 1l by a structure–activity study of the broad-acting ionotropic glutamate receptor antagonist 1a. Subsequently, we demonstrate that 1l augments the cytotoxic action of sorafenib in murine hepatocellular carcinoma cells. The underlying biological mechanism was shown to be interference with the lipid signaling pathway, leading to reduced expression of MDR transporters and thereby an increased accumulation of sorafenib in the cancer cells. Interference with lipid signaling pathways by NMDA receptor inhibition is a novel and promising strategy for reversing transporter-mediated chemoresistance in cancer cells.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01624&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01624" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01624&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01624" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01624&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01624" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01624&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01624&amp;href=/doi/10.1021/acs.jmedchem.7b01624" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01624" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01624" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01624%26sid%3Dliteratum%253Aachs%26pmid%3D29205034%26genre%3Darticle%26aulast%3DGynther%26date%3D2017%26atitle%3DAugmentation%2Bof%2BAnticancer%2BDrug%2BEfficacy%2Bin%2BMurine%2BHepatocellular%2BCarcinoma%2BCells%2Bby%2Ba%2BPeripherally%2BActing%2BCompetitive%2BN-Methyl-d-aspartate%2B%2528NMDA%2529%2BReceptor%2BAntagonist%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D23%26spage%3D9885%26epage%3D9904%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291137" title="Lipids">Lipids</a>,</li><li><a href="/action/doSearch?ConceptID=290723" title="Solutions">Solutions</a>,</li><li><a href="/action/doSearch?ConceptID=292200" title="Layers">Layers</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/jmcmar.2017.60.issue-23/20171214/jmcmar.2017.60.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The most common solid tumors show intrinsic multidrug resistance (MDR) or inevitably acquire such when treated with anticancer drugs. In this work, we describe the discovery of a peripherally restricted, potent, competitive NMDA receptor antagonist <b>1l</b> by a structure–activity study of the broad-acting ionotropic glutamate receptor antagonist <b>1a</b>. Subsequently, we demonstrate that <b>1l</b> augments the cytotoxic action of sorafenib in murine hepatocellular carcinoma cells. The underlying biological mechanism was shown to be interference with the lipid signaling pathway, leading to reduced expression of MDR transporters and thereby an increased accumulation of sorafenib in the cancer cells. Interference with lipid signaling pathways by NMDA receptor inhibition is a novel and promising strategy for reversing transporter-mediated chemoresistance in cancer cells.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55818" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55818" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Over time, solid tumors inevitably acquire resistance against anticancer therapy, a phenomenon known as multidrug resistance (MDR).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, more devastating are cancers, such as hepatocellular carcinoma (HCC), that exert intrinsic drug-resistance.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> A key mechanism underlying MDR is increased expression of ATP-binding cassette (ABC) transporters, which expel a broad range of chemotherapeutic agents from the cancer cells.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> According to current knowledge, the principal ABC transporters responsible for chemoresistance in humans are ATP-binding cassette subfamily B member 1 (ABCB1, Pgp), ATP-binding cassette subfamily G member 2 (ABCG2, BCRP), and ATP-binding cassette subfamily C (ABCC, MRP).<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4-7)</a> In regard to HCC, these transporters are responsible for expelling the first line HCC drug sorafenib from the cancer cells.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a> The general strategy to reverse MDR has been to coadminister ABC transporter inhibitors with anticancer drugs.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, several complications limit the use of ABC transporter inhibitors, among them the fact that ABC transporters are also present in normal cells, leading to undesired drug accumulation.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Thus, a change of strategy is needed to overcome ABC transporter-mediated chemoresistance.</div><div class="NLM_p">One such strategy is to downregulate efflux transporter expression by alternating the cell lipid signaling pathway by blocking the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptors.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> NMDA receptors are a subclass of ionotropic glutamate receptors (iGluRs), which also comprises the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and the kainic acid (KA) receptors.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> NMDA receptor activation increases calcium entry, which activates cytoplasmic phospholipase A2 (cPLA2), leading to increased production of arachidonic acid (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> This fatty acid is further converted to the proinflammatory lipid, prostaglandin-E2 (PGE<sub>2</sub>), and actively transported into the extracellular space by ABCC transporters, where it binds to the prostaglandin E receptors (EP-Rs), leading to NF-κB activation and creating a positive feedback loop creating an inflammation microenvironment.<a onclick="showRef(event, 'ref12 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref14">(12, 14)</a> It has been shown that NF-κB activation results in increased cancer cell survival and proliferation as well as chemoresistance due to elevated ABC transporter and CYP enzyme expression.<a onclick="showRef(event, 'ref12 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref12 ref16 ref17">(12, 16, 17)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Activation of the lipid signaling pathway by GluN1/GluN2A receptor and the creation of transporter mediated drug resistance. NMDA binding to the GluN1/GluN2A receptor allows the influx of Ca<sup>2+</sup> into the cell, which leads to cPLA2 activation and the release of arachidonic acid (AA) from phospholipids. Arachidonic acid is metabolized to PGE<sub>2</sub>, which is transported by ABCC transporters out of the cell allowing the PGE<sub>2</sub> binding to EP-R. The EP-R activation leads to nuclear translocation of NF-κB followed by ABCG2 protein transcription and MDR.<a onclick="showRef(event, 'ref12 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref12 ref14 ref15 ref16 ref17">(12, 14-17)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">NMDA receptors are overexpressed on the cell membrane of many types of cancer cells, including HCC.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The noncompetitive NMDA receptor antagonist MK-801 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) has previously been shown to augment the antiproliferative efficacy of antiestrogens in melanoma cells<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and suppress the growth of HCC cells.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The antiproliferative effect of MK-801 in HCC cells was shown to be mediated through the FOXO/XTNIP pathway, which is not connected to pro-inflammatory lipid signaling. Moreover, the impact of NMDA receptor antagonists on transporter expression, anticancer drug accumulation, and efficacy in cancers has not been studied. Most importantly, a competitive NMDA receptor antagonist for use as an augmentative drug for the treatment of peripheral solid tumors must not be capable of crossing the blood–brain barrier (BBB), as this would otherwise lead to severe adverse effects, including psychosis.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of Glu, selective uncompetitive NMDA receptor antagonist MK-801, selective competitive NMDA receptor antagonists D-AP5, (<i>R</i>)-CPP, and competitive iGluR antagonist <b>1a</b>, including published analogs <b>1b,c</b> with relevance to the SAR study reported herein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the present study, we report the design and synthesis of the novel peripherally acting potent NMDA receptor antagonist <b>1l</b>. We describe the ability of <b>1l</b> to modulate the cPLA2 activation-dependent lipid signaling pathway, downregulate ABC transporter expression, and thereby augment the cytotoxic efficacy of the anticancer drug sorafenib in murine HCC cells.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The two commonly studied competitive NMDA receptor antagonists that do not penetrate the BBB are D-AP5 and (<i>R</i>)-CPP (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Both are amino acid analogs and highly polar with calculated partition coefficient values in octanol/water (cLogP(o/w)) well below zero (−1.7 and −2.2, respectively). In comparison with recommended cLogP(o/w) values of −0.4 to 5.6<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> for oral bioavailability, we believed that these NMDA receptor antagonists were not attractive candidates for this study.</div><div class="NLM_p">We therefore turned to the previously reported nonselective iGluR antagonist <b>1a</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> and <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The facts that <b>1a</b> does not penetrate the BBB in mouse in situ brain perfusion and that its cLogP(o/w) value is calculated at 1.3 make it an attractive starting point for the purpose of developing an orally available, peripherally restricted, competitive NMDA receptor antagonist.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Affinities of <b>1a</b>–<b>n</b> at Native AMPA, KA, and NMDA Receptors (Rat Synaptosomes) and Cloned Homomeric Receptors GluK1–3<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0015.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>Table a</sup><p class="last">–: not tested. Radio ligands: AMPA, [<sup>3</sup>H]AMPA; KA, [<sup>3</sup>H]KA; NMDA, [<sup>3</sup>H]CGP-39653; GluK1, [<sup>3</sup>H]SYM2081; GluK2 and GluK3, [<sup>3</sup>H]KA. Data are mean values of three to six individual experiments performed in triplicate. For AMPA and KA: pIC<sub>50</sub> values with SEM in brackets. For NMDA: p<i>K</i><sub>i</sub> values with SEM in brackets.</p></div></div><div></div></div><div class="NLM_p">We have previously reported the first structure–activity relationship (SAR) study on <b>1a</b>, which disclosed the 4-position on the aryl ring as a hotspot for induction of KA receptor subtype selectivity (compound <b>1b</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> and <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Also, it was seen that simple lipophilic substituents in the 5-position did not lead to any significant improvement in receptor selectivity or higher affinity (structures not shown).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The 3-carboxylic acid functionality was displaced with a phosphonic acid group, compound <b>1c</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), which led to a significant reduction in binding affinity at the iGluRs (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">With this SAR information in hand, we set out to investigate two strategies with the aim of improving iGluR class selectivity. First, we wanted to substitute the 3-carboxylic acid functionality with different functional groups (analogs <b>1d</b>–<b>j</b>). While it is well-accepted that the γ-carboxylate functionality in Glu is mandatory for agonist activity at the iGluRs,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> it remains an open question if nonionizable distal functional groups can stabilize the NMDA receptor in its open antagonist state. Based on synthetic tractability, the following seven analogs were thus designed: 3-chloro (<b>1d</b>), 3-trifluoromethyl (<b>1e</b>), 3-amino (<b>1f</b>), 3-cyano (<b>1g</b>), 3-carbamido (<b>1h</b>), 3-boronic acid (<b>1i</b>), and 3,4-dihydroxy (<b>1j</b>). The synthesis of <b>1d</b>–<b>j</b> was carried out by a stereoselective rhodium(I)-catalyzed addition of an arylboronic acid to protected enone <b>2</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> as the key step (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Hereby, the 2,3-<i>trans</i> stereochemistry on the proline ring was set, and subsequent functional group transformations in accordance with earlier reported strategies (<b>1d</b>–<b>f</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>; <b>1g,h</b>, <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>; <b>1i</b>, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>; <b>1j</b>, <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) gave the free amino acids <b>1d</b>–<b>j</b> ready for pharmacological evaluation.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Key Alcohol Intermediates <b>6b,d–f,j</b> via Rhodium(I)-Catalyzed 1,4 Addition of Respective Boronic Acids <b>3a,b,d–f,j</b> to Enone <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) [Rh(cod)Cl]<sub>2</sub>, H<sub>2</sub>O, Cs<sub>2</sub>CO<sub>3</sub>, enone <b>2</b>, THF or dioxane, rt (52–67%); (b) LiBEt<sub>3</sub>H, THF, −78 °C; (c) HSiEt<sub>3</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, DCM, −78 °C (31–78%).</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>1d</b>–<b>f</b> from Alcohols <b>6d</b>–<b>f</b>, Respectively<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O, NaIO<sub>4</sub>, EtOAc/MeCN/H<sub>2</sub>O (49–86%); (b) TFA, DCM, rt; (c) 1 M HCl (12–78%).</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 3-Cyano Analog <b>1g</b> from Alcohol <b>6b</b> and 3-Carbamido Analog <b>1h</b> from <b>7g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TBSCl, imidazole, DMF, rt (73%, three steps from <b>4b</b>); (b) Zn(CN)<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, DMA, 120 °C; (c) TBAF, THF, rt (71%, two steps); (d) RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O, NaIO<sub>4</sub>, EtOAc/MeCN/H<sub>2</sub>O (76%); (e) TFA, DCM, rt; (f) 1 M HCl (81%, two steps); (g) 30% H<sub>2</sub>O<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, EtOH/H<sub>2</sub>O, rt (66%); (h) TFA, DCM, rt; (i) 1 M HCl (59% after three steps).</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 3-Boronic Acid Analog <b>1i</b>, Starting from Bromine <b>8b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) KOAc, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, DMF (61%); (b) TBAF, THF, rt (60%); (c) RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O, NaIO<sub>4</sub>, EtOAc/MeCN/H<sub>2</sub>O (65%); (d) TFA, DCM, rt; (e) 1 M HCl (40%, two steps).</p></p></figure><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>1j</b> from Alcohol <b>6j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IBX, DMSO, rt; (b) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, 2-methyl-2-butene, <i>tert</i>-BuOH/H<sub>2</sub>O, rt (66%, two steps); (c) BBr<sub>3</sub>, DCM (8% after recrystallization from MeOH).</p></p></figure><div class="NLM_p">The second series of analogs, compounds <b>1k</b>–<b>n</b>, aimed to further explore the impact of substituents in the 4-position of the aryl ring. We have previously shown that introduction of a 4-hydroxy group (analog <b>1b</b>) resulted in generally enhanced affinity for iGluRs with a 10-fold improvement for the GluK3 subunit (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Given the hydrogen bond donor and acceptor abilities of the 4-hydroxyl group, three new analogs were designed to address the influence of these features: 4-fluoro (<b>1k</b>), 4-chloro (<b>1l</b>), and 4-methyl (<b>1m</b>). For <b>1k</b> and <b>1l</b>, the syntheses were based on the stereoselective conjugate addition of an in situ formed aryl cuprate to enone <b>2</b>,<a onclick="showRef(event, 'ref24 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref26">(24, 26)</a> whereas for <b>1m</b> the afore-applied protocol of rhodium(I)-catalyzed addition of a boronic ester to enone <b>2</b> was used (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). Subsequent functional group transformations to obtain the free amino acids <b>1k</b>–<b>m</b> followed the strategy for comparable analogs previously reported by us.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a></div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>1k</b>–<b>l</b> via Copper(I)-Catalyzed Addition to Enone <b>2</b> and <b>1m</b> via Rhodium(I)-Catalyzed Addition to Enone <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) for <b>3k,l</b>, <i>n</i>-BuLi, CuCN, then enone <b>2</b>, Et<sub>2</sub>O, −78 to −42 °C (46% and 73%); (b) for <b>3m</b>, (Bpin)<sub>2</sub>, KOAc, (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub> (quant); (c) [Rh(cod)Cl]<sub>2</sub>, H<sub>2</sub>O, Cs<sub>2</sub>CO<sub>3</sub>, enone <b>2</b>, rt (41%); (d) for <b>4k,l</b>, LiBEt<sub>3</sub>H, THF, −78 °C, then HSiEt<sub>3</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, DCM, −78 °C; (e) for <b>4m</b>, BH<sub>3</sub>·SMe<sub>2</sub>, THF, reflux; (f) TBAF, THF, rt. (20% and 49%); (g) RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O, NaIO<sub>4</sub>, EtOAc/MeCN/H<sub>2</sub>O (20–97%); (h) TFA, DCM, rt; (i) 1 M HCl (56–60%).</p></p></figure><div class="NLM_p">Binding affinities of the synthesized amino acids <b>1d</b>–<b>n</b> were determined at native AMPA, KA, and NMDA receptors (rat synaptosomes) and cloned rat homomeric subtypes GluK1–3, and results are summarized in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. The 3-chloro, 3-trifluoromethyl, 3-amino, and 3-cyano analogs, <b>1d</b>–<b>g</b>., respectively, all showed insignificant binding affinity for any of the iGluRs (IC<sub>50</sub> or <i>K</i><sub>i</sub> > 100 μM). Furthermore, 3-carbamido analog <b>1h</b> and 3-boronic acid analog <b>1i</b> did not display notable binding affinities for native iGluRs nor for homomeric GluK1–3 receptors (IC<sub>50</sub> or <i>K</i><sub>i</sub> > 100 μM). Finally, the 3,4-dihydroxy analog <b>1j</b> was a weak binder at the NMDA receptors (<i>K</i><sub>i</sub> = 35 μM). While these results were all together disappointing, the affinity profiles for the 4-substituted analogs <b>1k</b>–<b>m</b> were in contrast exciting. In comparison with the 4-hydroxy analog <b>1b</b>, the 4-fluoro analog <b>1k</b> displayed the first steps toward selectivity for the NMDA receptors by showing a lower affinity for native AMPA and KA receptors as well as for homomeric GluK1–3 receptors. This trend was boosted significantly for 4-chloro analog <b>1l</b>, which proved to be selective for native NMDA receptors with submicromolar binding affinity (<i>K</i><sub>i</sub> = 0.63 μM). Also for 4-bromo analog <b>1n</b>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> full selectivity for NMDA receptors was observed with binding affinity similar to <b>1l</b> (<i>K</i><sub>i</sub> = 0.62 μM). In contrast to this important finding, the binding affinity for native NMDA receptors dropped 30-fold for the 4-methyl analog <b>1m</b>.</div><div class="NLM_p">The cLogP(o/w) values of <b>1l</b> and <b>1n</b> were calculated at 1.9 and 2.1, respectively, placing both analogs in the recommended cLogP interval of −0.4 to 5.6 for good bioavailability.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Given that an aryl bromide is a less attractive functional group in compounds for biological administration compared to an aryl chloride, compound <b>1l</b> was selected for further functional studies at NMDA receptors.</div><div id="sec2-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Functional Characterization of <b>1l</b> at NMDA Receptor Subtypes</h3><div class="NLM_p">Compound <b>1l</b> was next evaluated in a functional assay at the four NMDA receptor subtypes, GluN1/GluN2A-D (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> and <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). At all four subtypes, <b>1l</b> was found to be a competitive antagonist with <i>K</i><sub>i</sub> values of 4.7, 10, 24, and 41 μM, respectively, and the selectivity profile of <b>1l</b> was similar to D-AP5 (<i>K</i><sub>i</sub> values of 0.39, 2.8, 5.9, and 21, respectively<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>).</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Concentration–inhibition data for <b>1l</b> at recombinant NMDA receptor subtypes GluN1/GluN2A-D. Responses were measured using two-electrode voltage-clamp electrophysiology and were activated by coapplication of 100 μM glycine and Glu to <i>Xenopus</i> oocytes expressing recombinant NMDA receptors subtypes. Ten micromolar Glu was used for GluN1/GluN2A, 3 μM Glu for GluN1/GluN2B and GluN1/GluN2C, and 1 μM Glu for GluN1/GluN2D receptors. Data are mean ± SD (error bars are mostly contained within the symbols). See <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> for IC<sub>50</sub> and estimated <i>K</i><sub>i</sub> values.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition of Recombinant NMDA Receptor Subtypes by <b>1l</b><a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i><sub>H</sub></th><th class="colsep0 rowsep0" align="center" char="±">estimated <i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="."><i>N</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GluN1/GluN2A</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 1</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GluN1/GluN2B</td><td class="colsep0 rowsep0" align="char" char="±">29 ± 1</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GluN1/GluN2C</td><td class="colsep0 rowsep0" align="char" char="±">110 ± 8</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char="±">24 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GluN1/GluN2D</td><td class="colsep0 rowsep0" align="char" char="±">170 ± 10</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 3</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values for inhibition of current responses activated by coapplication of 100 μM glycine and Glu to <i>Xenopus</i> oocytes expressing recombinant rat GluN1/GluN2A–D NMDA receptors. Responses were activated by Glu concentrations 2- to 3-fold higher than the EC<sub>50</sub> at the respective NMDA receptor subtypes; 10 μM Glu was used for GluN1/GluN2A, 3 μM Glu for GluN1/GluN2B and GluN1/GluN2C, and 1 μM Glu for GluN1/GluN2D receptors. <i>K</i><sub>i</sub> values were estimated using the Cheng–Prusoff relationship<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and previously determined Glu EC<sub>50</sub> values.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> IC<sub>50</sub> and <i>K</i><sub>i</sub> values are mean ± SEM, <i>n</i><sub>H</sub> is the Hill slope, and <i>N</i> is the number of oocytes.</p></div></div></div></div><div id="sec2-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetics of Compound <b>1l</b> in Mice</h3><div class="NLM_p">With the attractive pharmacological profile of <b>1l</b> in hand, we turned to determine its pharmacokinetics and brain permeation. The pharmacokinetic analysis was performed by 10 mg/kg i.p. injection at five time points between 10 and 240 min. The apparent pharmacokinetic parameters, area under the concentration–time curve from time zero to 240 min (AUC<sub>0–240 min</sub>), the maximum concentration after dosing (<i>C</i><sub>max</sub>), time to reach <i>C</i><sub>max</sub> (<i>t</i><sub>max</sub>), and elimination half-life (<i>t</i><sub>1/2β</sub>) in plasma, liver, and brain, calculated from the <i>in vivo</i> data are presented in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. The compound was absorbed from the injection site, and concentrations above the <i>K</i><sub>i</sub> value were detected from both plasma and liver. The <i>K</i><sub>p liver/plasma</sub> value was 0.19. Importantly, compound <b>1l</b> did not exhibit BBB permeation and was detected only at 30 and 60 min time points with concentrations of 0.3 and 0.1 nmol/g, respectively. We confirmed the poor BBB permeation using an <i>in situ</i> mouse brain perfusion technique. The brain concentration of compound <b>1l</b> following perfusion with 100 μM compound was below the detection limit of our analytical method (5 pmol/g). Moreover, there were no observable changes in the behavior of the mice after <b>1l</b> injection. This supports our findings from the <i>in vivo</i> pharmacokinetic experiments that <b>1l</b> is a fully peripherally restricted NMDA receptor antagonist suitable for affecting peripheral tumors. In addition to hepatocellular carcinoma, NMDA receptor expression has been reported to be elevated in colon, prostate, and breast cancers compared to healthy tissues.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Moreover, the lack of pharmacological effect in the CNS provides the possibility to utilize the compound as a research tool for investigating the role of peripheral NMDA receptors in other diseases and/or conditions such as chronic pain.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Parameters of Compound <b>1l</b> in Plasma, Liver, and Brain Calculated from <i>in Vivo</i> Data after a Single Dose of 10 mg/kg i.p. in Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">plasma</th><th class="colsep0 rowsep0" align="center">liver</th><th class="colsep0 rowsep0" align="center">brain</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–240 min)</sub> (nmol/g·min)</td><td class="colsep0 rowsep0" align="left">3020</td><td class="colsep0 rowsep0" align="left">575</td><td class="colsep0 rowsep0" align="left">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (nmol/g)</td><td class="colsep0 rowsep0" align="left">43.4</td><td class="colsep0 rowsep0" align="left">8.7</td><td class="colsep0 rowsep0" align="left">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (min)</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2β</sub> (min)</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div></div></div><div id="sec2-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Ability of Compound <b>1l</b> To Inhibit NMDA Receptor Expressed in Murine HCC Cells</h3><div class="NLM_p">With compound <b>1l</b> in hand, we proceeded to studies of its <i>in vitro</i> efficacy in mice. First, we confirmed the expression of the GluN1 NMDA receptor subunit in the murine HCC cell line by Western immunoblotting (data not shown). In order to assess the function of NMDA receptors in the murine HCC cell culture we used calcium imaging (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). To compare the abilities of <b>1l</b> and D-AP5 to inhibit NMDA receptor activation, we measured the intracellular Ca<sup>2+</sup> transients induced by 150 μM NMDA alone and in the presence of the compound <b>1l</b> (25 and 40 μM) or D-AP5 (20 μM). Both compounds were able to inhibit NMDA receptor activation significantly in the murine HCC cells suggesting their ability to antagonize the lipid signaling pathway in cancer cells.</div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ca<sup>2+</sup> transients via NMDA receptors in murine HCC cells. (A) Ca<sup>2+</sup> transients in HCC cells activated by NMDA applications (15 s) with and without NMDA receptor antagonists (<b>1l</b> and D-AP5). (B) Histogram showing percentage of induced Ca<sup>2+</sup> transients in a response to NMDA application and absence of the activation while applied together with <b>1l</b> at 25 or 41 μM concentration and D-AP5 at 20 μM concentration. Quantitative data were expressed as mean ± SEM (<i>n</i> = 5). The statistical significance was assessed with the Student-paired <i>t</i> test or Mann–Whitney <i>t</i> test for nonparametric data. Statistically significant differences were set at *<i>P</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Ability of Compound <b>1l</b> To Decrease PGE<sub>2</sub> Concentration in Murine HCC Cells</h3><div class="NLM_p">The ability of compound <b>1l</b> to decrease the extracellular PGE<sub>2</sub> concentration in murine HCC cells was investigated by incubating the cells in 24-well plates for 24 h with 100 μM <b>1l</b>. In addition, the PGE<sub>2</sub> concentration was measured from HCC cells with lipopolysaccharide (LPS) induced inflammation using the same compound <b>1l</b> concentration and incubation time (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Compound <b>1l</b> significantly decreased the PGE<sub>2</sub> concentration in both the presence and absence of LPS, confirming that the compound is able to interfere with the synthesis of PGE<sub>2</sub>. This inhibition of PGE<sub>2</sub> production will reduce the proinflammatory lipid signaling pathway in HCC cells, which has been suggested to downregulate ABC transporters in cancer cells.<a onclick="showRef(event, 'ref12 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref12 ref14 ref15 ref16">(12, 14-16)</a></div><figure id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of compound <b>1l</b> and D-AP5 on PGE<sub>2</sub> levels in HCC cells. Compounds <b>1l</b> and D-AP5 at 10 μM and compound <b>1l</b> at 100 μM reduced the concentration of PGE<sub>2</sub> after 24 h incubation to 68 ± 5%, 58 ± 6%, and 48 ± 6%, respectively. The addition of LPS (2.5 μg/mL) increased the PGE<sub>2</sub> concentration to 162 ± 7%, and the addition of compounds <b>1l</b> and D-AP5 at 10 μM as well as compound <b>1l</b> at 100 μM prevented the effect of LPS, reducing the PGE<sub>2</sub> concentrations to 127 ± 4%, 110 ± 7%, and 96 ± 17%, respectively. The data is presented as mean ± SEM, <i>n</i> = 3. The statistical significance of differences in PGE<sub>2</sub> concentrations between treatments was determined using one-way ANOVA and Tukey’s test (*<i>P</i> < 0.05, **<i>P</i> < 0.01).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Effect of the Compound <b>1l</b> on Transporter Expression in Mouse HCC Cells</h3><div class="NLM_p">Expression levels of Abcb1, Abcg2, Abcc2, and Abcc4 as well as Slc7a5 and Slc2a1 in HCC cells were determined by selected/multiple reaction monitoring (SRM/MRM) analysis in liquid chromatography–tandem mass spectrometry (LC–MS/MS),<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> following administration of 10 μM <b>1l</b> and compared to control. Compound <b>1l</b> reduced the expression levels of Abcb1 and Abcg2 transporters in the crude membrane fraction by 39% and 34%, respectively (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Abcc4 protein expression was reduced by 14%, but the reduction was not statistically significant, and Abcc2 protein expression was below the lower limit of quantification. Interestingly, the expression of Slc2a1 and Slc7a5 transporter proteins was decreased by 42% and 24%, respectively. However, the difference in the case of Slc7a5 was not statistically significant. In all, these findings evidence that NMDA receptor antagonism results in downregulation of ABC transporter expression in HCC cells. In addition, the expression of the two investigated nutrient transporters was reduced. In order to further study the significance of the transporter downregulation, we investigated the cell accumulation of transporter probes and sorafenib.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. ABC Transporter Expression Levels in Mouse HCC Cell Crude Membrane Fraction Measured by SMR/MRM Analysis</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char="±">protein expression level (fmol/μg of total protein)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">Abcb1 (Pgp)</th><th class="colsep0 rowsep0" align="center" char="±">Abcg2 (Bcrp)</th><th class="colsep0 rowsep0" align="center">Abcc2 (Mrp2)</th><th class="colsep0 rowsep0" align="center" char="±">Abcc4 (Mrp4)</th><th class="colsep0 rowsep0" align="center" char="±">Slc2a1 (Glut1)</th><th class="colsep0 rowsep0" align="center" char="±">Slc7a5 (Lat1)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">control</td><td class="colsep0 rowsep0" align="char" char="±">0.64 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">1.88 ± 0.04</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">0.31 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">22.7 ± 0.84</td><td class="colsep0 rowsep0" align="char" char="±">7.55 ± 0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 μM <b>1l</b></td><td class="colsep0 rowsep0" align="char" char="±">0.39 ± 0.06*<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">1.24 ± 0.13**</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">0.27 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">13.2 ± 0.53***</td><td class="colsep0 rowsep0" align="char" char="±">5.72 ± 1.61</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">below the lower limit of quantification. The statistical difference between compound <b>1l</b>-treated cells and the control cells was determined using unpaired two-tailed <i>t</i> test (*<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001). Data are presented as mean ± SEM (<i>n</i> = 4).</p></div></div></div></div><div id="sec2-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Ability of NMDA Receptor Antagonist <b>1l</b> To Alter the Cell Accumulation of Transporter Probes and Sorafenib</h3><div class="NLM_p">To investigate the ability of compound <b>1l</b> to reverse ABC transporter mediated MDR and decrease the uptake of essential nutrients in murine HCC cells, we determined the intracellular accumulation of known ABC transporter substrates: Abcb1 probe [<sup>3</sup>H]-digoxin,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Abcc1–5 probe fluorescein,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Abcb1 and Abcg2 substrate sorafenib (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>) as well as Slc7a5 substrate [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine and Slc2a1 substrate [<sup>14</sup>C]-<span class="smallcaps smallerCapital">d</span>-glucose (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a> The cells were incubated with or without 10 μM of compound <b>1l</b> in the growth medium for 24 h. Accumulation of the efflux probes in the cells was significantly increased after incubating the cells with compound <b>1l</b>. In addition, the cell uptake of [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine was reduced significantly. Therefore, the data provides evidence that the reduced transporter expression levels are significant enough to lead to reduced transporter activity. The risk of compound <b>1l</b> to interfere with transporter function was minimized by washing the cells before uptake experiments. Thus, the increased cell accumulation of transporter probes is not likely due to compound <b>1l</b> acting as a transporter inhibitor, but as a modulator of transporter expression.</div><figure id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound <b>1l</b> on cell accumulation of efflux probes [<sup>3</sup>H]-digoxin, fluorescein, and sorafenib. The incubation of the HCC cells with 10 μM compound <b>1l</b> increased the cell accumulation of (A) [<sup>3</sup>H]-digoxin, (B) fluorescein, and (C) sorafenib to 149% ± 10%, 201% ± 9%, and 152% ± 11%, respectively. The analyte concentrations are normalized by the amount of protein in each sample. The statistical difference between compound <b>1l</b>-treated cell and the control cells was determined using unpaired two-tailed <i>t</i> test (**<i>P</i> < 0.01, ***<i>P</i> < 0.001). Data are presented as mean ± SEM (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>1l</b> on cell accumulation of Slc2a1 and Slc7a5 transporter substrates [<sup>14</sup>C]-<span class="smallcaps smallerCapital">d</span>-glucose and [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine. The incubation of the HCC cells with 10 μM compound <b>1l</b> reduced the cell accumulation of (A) [<sup>14</sup>C]-<span class="smallcaps smallerCapital">d</span>-glucose and (B) [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine to 84% ± 8% and 81% ± 6%, respectively. The analyte concentrations are normalized by the amount of protein in each sample. The statistical difference between compound <b>1l</b>-treated cell and the control cells was determined using unpaired two-tailed <i>t</i> test (*<i>P</i> < 0.05). Data are presented as mean ± SEM (<i>n</i> = 4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Effect of Compound <b>1l</b> on Sorafenib Cytotoxicity in Mouse HCC Cells</h3><div class="NLM_p">The half maximal inhibitory concentration (IC<sub>50</sub>) value of sorafenib on HCC cell viability was investigated at 72 h using concentration range from 0.1 to 200 μM (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A). The effect of <b>1l</b> on HCC cell proliferation and the possible potentiating effect on sorafenib cytotoxicity were evaluated by incubating the HCC cells for 72 h at different sorafenib concentrations with and without a 100 μM concentration of <b>1l</b> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B). Interestingly, <b>1l</b> significantly augmented the efficacy of sorafenib at 1, 2.5, and 5 μM concentrations. At 10 μM sorafenib concentration, NMDA receptor antagonist <b>1l</b> also augmented sorafenib efficacy, although the effect was less pronounced. On its own the NMDA antagonist <b>1l</b> was only able to reduce HCC cell proliferation slightly. In addition, D-AP5 had a potentiating effect on sorafenib cytotoxicity at all sorafenib concentrations investigated (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>C). Previously it was shown that at above 100 μM concentrations a noncompetitive NMDA receptor antagonist has antiproliferative effects on HCC cells affecting the FOXO/TXNIP pathway. Therefore, the antiproliferative effect of <b>1l</b> alone is likely mediated via the same pathway. However, as sorafenib exerts its effect through the RAF/MEK/ERK pathway,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> the potentiating effect of <b>1l</b> is more likely mediated through the lipid signaling pathway and downregulation of efflux transporter expression.</div><figure id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Concentration-dependent antiproliferative efficacy of sorafenib in HCC cells after 72 h. IC<sub>50</sub> value was 7.4 ± 1.7 μM. Ability of compound <b>1l</b> to potentiate the cytotoxic efficacy of sorafenib in mouse HCC cells. (B) Potentiating effect of compound <b>1l</b> on sorafenib antiproliferative efficacy in murine HCC cells. Compared to sorafenib effect alone, the cell viability was further reduced in the presence of 100 μM compound <b>1l</b> from 88 ± 3% to 33 ± 3%, 82 ± 3% to 30 ± 2%, 72 ± 1% to 35 ± 2%, and 31 ± 2% to 24 ± 1%, at 1, 2.5, 5, and 10 μM sorafenib, respectively. Compound <b>1l</b> at 100 μM without sorafenib was able to reduce the cell viability to 84 ± 2%. (C) Potentiating effect of D-AP5 on sorafenib antiproliferative efficacy in murine HCC cells. The cell viability was reduced to 70 ± 3%, 63 ± 1%, 44 ± 1%, and 16 ± 1%, in combination of 100 μM D-AP5 and 1, 2.5, 5, and 10 μM sorafenib, respectively. D-AP5 at 100 μM without sorafenib was able to reduce the cell viability to 79 ± 2%. The remaining viability is presented as mean ± SEM (<i>n</i> = 3–6). The statistical difference between groups were determined by one-way ANOVA followed by Tukey’s multiple comparison test (*<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from the broad-acting iGluR antagonist <b>1a</b>, we have developed a potent and selective competitive NMDA receptor antagonist, compound <b>1l</b>, whose action is restricted to peripheral tissues and which displays good drug-like properties. Application of <b>1l</b> to murine HCC cells reduced the intracellular concentration of PGE<sub>2</sub> and thereby interfered with the proinflammatory lipid signaling pathway resulting in downregulation of MDR transporters. It was subsequently shown that <b>1l</b> augments cell accumulation of MDR transporter substrates and that cell accumulation of the HCC anticancer agent and ABC transporter substrate sorafenib was significantly increased leading to augmented cytotoxic efficacy. Another important finding was the significant downregulation of nutrient transporters, which are essential for the rapid growth of cancer cells. In summary, this proof-of-concept study demonstrates that competitive NMDA receptor antagonists represent a novel and promising strategy to reverse MDR in peripheral solid tumors, such as HCC.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p">All reagents were obtained from commercial suppliers and used without further purification. Dry solvents were obtained differently. THF was distilled over sodium/benzophenone. Et<sub>2</sub>O was dried over neatly cut sodium. All solvents were tested for water content using a Carl Fisher apparatus. Water- or air sensitive reactions were conducted in flame-dried glassware under nitrogen with syringe-septum cap technique. Purification by dry column vacuum chromatography (DCVC) was performed with silica gel size 25–40 μm (Merck, Silica gel 60). For TLC, Merck TLC Silica gel F254 plates were used with appropriate spray reagents: KMnO<sub>4</sub> or molybdenum blue. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were obtained on a Varian Mercury Plus (300 MHz) and a Varian Gemini 2000 instrument (75 MHz), respectively, unless otherwise noted. Dioxane was used as internal reference for NMR spectra run in D<sub>2</sub>O. Preparative HPLC was performed using either a Spectraseries UV100 detector with a JASCO 880-PU HPLC pump and an XTerraPrep MS C18 (10 μm, 10 × 300 mm) column or an Agilent Prep HPLC system, equipped with a 1100 series pump, a 1200 series multiple wavelength detector, and a Zorbax 300 SB-C18 (21.2 × 250 mm, 7 μm) column. LC–MS was performed using an Agilent 1200 HPLC system coupled to an Agilent 6400 triple quadrupole mass spectrometer equipped with an electrospray ionization source. A Zorbax Eclipse XDB-C18 (4.6 × 50 mm) column and gradients of 10% aqueous acetonitrile + 0.05% formic acid (buffer A) and 90% aqueous acetonitrile + 0.046% formic acid (buffer B) were employed. Optical rotation was measured using a PerkinElmer 241 spectrometer, with a Na lamp at 589 nm. Melting points were measured using an automated melting point apparatus, MPA100 OptiMelt (SRS), and are uncorrected. Compounds were dried either under high vacuum or freeze-dried using a Holm and Halby, Heto LyoPro 6000 freeze drier. Compounds for pharmacological characterization were all with a purity of >95%, determined by HPLC (254 nM).</div><div id="sec4-1-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (2<i>S</i>,3<i>R</i>)-2-Carboxy-3-(3-chlorophenyl)pyrrolidin-1-ium Chloride (<b>1d</b>)</h4><div class="NLM_p last">Acid <b>7d</b> (120 mg, 0.37 mmol, 1.0 equiv) was dissolved in a 1:1 mixture of TFA/DCM (7.2 mL). The reaction mixture was allowed to stir for 1 h at rt, then evaporated to dryness under reduced pressure. The solid was dissolved in 1 M HCl (2 mL) and evaporated to dryness (3×) to give the crude product, which was recrystallized from MeOH/CHCl<sub>3</sub> to afford the title compound as white needles (17 mg, 18%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 9.64 (br s, 1H), 7.27–7.22 (m, 3H), 7.15–7.13 (m, 1H), 4.40 (d, <i>J</i> = 5.5 Hz, 0.4H), 4.25 (d, <i>J</i> = 6.5 Hz, 0.6H), 3.79–3.44 (m, 3H), 2.38–2.28 (m, 1H), 2.06–1.96 (m, 1H), 1.49 (s, 4H), 1.42 (s, 5H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 177.6, 175.7, 155.2, 153.7, 142.9, 142.4, 134.6, 130.1, 127.5, 127.4, 127.1, 125.2, 81.2, 80.1, 65.4, 64.9, 49.4, 47.5, 46.1, 45.9, 32.7, 32.2, 28.3, 28.2. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>11</sub>H<sub>13</sub>ClNO<sub>2</sub> [M + H]<sup>+</sup> 226.1, found 226.1. Mp: decomposition.</div></div><div id="sec4-1-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (2<i>S</i>,3<i>R</i>)-2-Carboxy-3-(3-(trifluoromethyl)phenyl)pyrrolidin-1-ium Chloride (<b>1e</b>)</h4><div class="NLM_p last">Compound <b>7e</b> (135 mg) was dissolved in a 1:1 mixture TFA/DCM (7.0 mL). The reaction mixture was allowed to stir for 1 h at rt, then the solvent was evaporated under reduced pressure. The crude was dissolved in HCl 1 M (30 mL), and the solvent was evaporated to afford the corresponding HCl salt (63 mg) as a white solid. The compound was recrystallized from MeOH/CHCl<sub>3</sub> to afford the title compound as a white powder (51 mg, 46%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 9.64 (br s, 1H), 7.27–7.22 (m, 3H), 7.15–7.13 (m, 1H), 4.40 (d, <i>J</i> = 5.5 Hz, 0.4H), 4.25 (d, <i>J</i> = 6.5 Hz, 0.6H), 3.79–3.44 (m, 3H), 2.38–2.28 (m, 1H), 2.06–1.96 (m, 1H), 1.49 (s, 4H), 1.42 (s, 5H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 177.6, 175.7, 155.2, 153.7, 142.9, 142.4, 134.6, 130.1, 127.5, 127.4, 127.1, 125.2, 81.2, 80.1, 65.4, 64.9, 49.4, 47.5, 46.1, 45.9, 32.7, 32.2, 28.3, 28.2. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>NO<sub>2</sub> [M + H]<sup>+</sup> 295.06, found 295.1. [α]<sub>25</sub><sup>D</sup> +58.9 (<i>c</i> =  0.38, MeOH). Mp: 180.7–182.5 °C.</div></div><div id="sec4-1-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (2<i>S</i>,3<i>R</i>)-3-(3-Aminophenyl)pyrrolidine-2-carboxylic Acid Dihydrochloride (<b>1f</b>)</h4><div class="NLM_p last">Acid <b>7f</b> (41 mg, 0.101 mmol, 1 equiv) was dissolved in a 1:1 mixture TFA/DCM (2.0 mL). The reaction mixture was allowed to stir for 1.5 h at rt, then the solvent was evaporated under reduced pressure. The oily residue was dissolved in 1 M HCl (10 mL), and the solvent was evaporated (3×) to give the crude product, which was recrystallized from MeOH/CHCl<sub>3</sub> to afford the title compound as a white solid (22 mg, 78%). <sup>1</sup>H NMR (MeOD) δ 7.58–7.31 (m, 3H), 7.31 (d, <i>J</i> = 7.2 Hz, 1H), 4.45 (d, <i>J</i> = 9.1 Hz, 1H), 3.77–3.58 (m, 2H), 3.57–3.42 (m, 1H), 2.66–2.49 (m, 1H), 2.36–2.17 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 168.5, 144.4, 140.6, 131.18, 131.17, 124.8, 118.6, 66.7, 49.6, 46.8, 34.4. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>11</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 207.1, found 207.1. [α]<sub>25</sub><sup>D</sup> +62.7° (<i>c</i> = 0.22, MeOH). Mp: decomposition.</div></div><div id="sec4-1-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (2<i>S</i>,3<i>R</i>)-3-(3-Cyanophenyl)pyrrolidine-2-carboxylic Acid Hydrochloride (<b>1g</b>)</h4><div class="NLM_p last">Acid <b>7g</b> (65 mg, 0.205 mmol, 1 equiv) was dissolved in a 1:1 mixture of TFA/DCM (2.0 mL). The reaction mixture was allowed to stir for 3 h at rt, then the solvent was evaporated under reduced pressure. The oily residue was dissolved in HCl 1 M (10 mL) and evaporated to dryness (3×) to afford the title compound as a white solid (42 mg, 81%). <sup>1</sup>H NMR (D<sub>2</sub>O) δ 7.82 (t, <i>J</i> = 1.6 Hz, 1H), 7.78–7.70 (m, 2H), 7.59 (t, <i>J</i> = 7.8 Hz, 1H), 4.44 (d, <i>J</i> = 9.9 Hz, 1H), 3.80–3.68 (m, 2H), 3.57 (ddd, <i>J</i> = 11.8, 10.3, 6.9 Hz, 1H), 2.61 (dtd, <i>J</i> = 10.5, 7.1, 3.3 Hz, 1H), 2.35–2.22 (m, 1H). <sup>13</sup>C NMR (D<sub>2</sub>O + dioxane) δ 171.4, 140.3, 133.4, 132.5, 132.1, 130.5, 120.0, 112.3, 65.41, 48.0, 46.4, 33.4. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>12</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 217.10, found 217.0. Mp: 210.8–212.9 °C.</div></div><div id="sec4-1-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (2<i>S</i>,3<i>R</i>)-3-(3-Carbamoylphenyl)-2-carboxypyrrolidin-1-ium Chloride (<b>1h</b>)</h4><div class="NLM_p last">H<sub>2</sub>O<sub>2</sub> (4.23 mmol, 0.43 mL of 30% solution in H<sub>2</sub>O, 6 equiv) was added dropwise to a solution of <b>7g</b> (223 mg, 0.71 mmol, 1.0 equiv) and K<sub>2</sub>CO<sub>3</sub> (390 mg, 2.82 mmol, 4 equiv) in EtOH/H<sub>2</sub>O (1:1, 4.86 mL). The reaction mixture was stirred at rt for 70 min, then slowly acidified with 1 M HCl. The aqueous phase was extracted with EtOAc (3 × 10 mL) and the combined organic layers washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to give a pale yellow solid. The crude was dissolved in DCM (5.8 mL), and TFA (5.8 mL) was added. The reaction mixture was stirred for 2 h at rt. The solvent was evaporated, and the oily residue was dissolved in 1 M HCl and evaporated to dryness (3 × 10 mL). The crude pink solid was recrystallized from H<sub>2</sub>O/acetone to afford the title compound as a white solid (95 mg, 59% over two steps). <sup>1</sup>H NMR (D<sub>2</sub>O) δ 7.85 (d, <i>J</i> = 1.6 Hz, 1H), 7.83–7.77 (m, 1H), 7.70–7.65 (m, 1H), 7.59 (t, <i>J</i> = 7.7 Hz, 1H), 4.38 (d, <i>J</i> = 9.7 Hz, 1H), 3.77–3.67 (m, 2H), 3.64–3.52 (m, 1H), 2.61 (dtd, <i>J</i> = 13.9, 7.1, 3.4 Hz, 1H), 2.39–2.25 (m, 1H). <sup>13</sup>C NMR (D<sub>2</sub>O) δ 173.4, 172.3, 139.9, 134.1, 132.2, 130.1, 127.4, 127.2, 66.1, 48.7, 46.3, 33.7. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>12</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 235.1, found 235.1. Mp: decomposition.</div></div><div id="sec4-1-6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (2<i>S</i>,3<i>R</i>)-3-(3-Boronophenyl)pyrrolidine-2-carboxylic Acid Hydrochloride (<b>1i</b>)</h4><div class="NLM_p last">To a solution of <b>7i</b> (50 mg, 0.120 mmol, 1.0 equiv) in acetone (9.4 mL) was added 0.1 M NH<sub>4</sub>OAc (27.7 mg, 0.36 mmol, 3.0 equiv, in H<sub>2</sub>O) and NaIO<sub>4</sub> (76.8 mg, 0.36 mmol, 3 equiv). The reaction mixture was stirred for 48 h at rt. Acetone was removed under reduced pressure, and the aqueous layer was diluted with 2 M NaOH (4 mL) and washed with EtOAC. The aqueous phase was then acidified with 1 M HCl until pH ≈ 3 and extracted with EtOAc (4 × 5 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to dryness. The crude product was dissolved in DCM (1.0 mL) and TFA (1.0 mL), and the reaction mixture stirred for 2.5 h at rt. The solvents were evaporated, and the oily residue was dissolved in 1 M HCl and evaporated to dryness (3 × 10 mL) to give an off-white solid, which was recrystallized from H<sub>2</sub>O/acetone to give the title compound as an off-white solid (13 mg, 43% over two steps). <sup>1</sup>H NMR (D<sub>2</sub>O) δ 7.80–7.72 (m, 2H), 7.58–7.46 (m, 2H), 4.41 (d, <i>J</i> = 9.8 Hz, 1H), 3.75–3.65 (m, 2H), 3.56 (ddd, <i>J</i> = 11.7, 10.3, 6.9 Hz, 1H), 2.57 (dtd, <i>J</i> = 13.9, 7.1, 3.4 Hz, 1H), 2.38–2.20 (m, 1H). <sup>13</sup>C NMR (D<sub>2</sub>O + dioxane) δ 171.4, 137.9, 133.1, 132.6, 130.1, 128.7, 65.2, 48.2, 45.8, 33.1. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>11</sub>H<sub>15</sub>BNO<sub>4</sub> [M + H]<sup>+</sup> 236.1, found 236.1. Mp: decomposition.</div></div><div id="sec4-1-7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (2<i>S</i>,3<i>R</i>)-3-(3,4-Dihydroxyphenyl)pyrrolidine-2-carboxylic Acid (<b>1j</b>)</h4><div class="NLM_p last">In a flame-dried flask a solution of <b>7j</b> (70 mg, 0.21 mmol, 1.0 equiv) in dry DCM (3 mL) was cooled to 0 °C. A 1 M solution of BBr<sub>3</sub> (in DCM) (0.53 mL, 0.522 mmol, 2.5 equiv) was added dropwise, and the reaction mixture was allowed to stir 3 h at rt. The reaction mixture was quenched with H<sub>2</sub>O (1 mL), and the solvent evaporated. The crude product was purified by preparative HPLC and then recrystallized from MeOH to afford the title compound as a white solid (3.8 mg, 8% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.89–6.94 (m, 2H), 6.79–6.86 (m, 1H), 4.02 (d, <i>J</i> = 9.03 Hz, 1H), 3.54–3.62 (m, 1H), 3.36–3.51 (m, 2H), 2.43 (dtd, <i>J</i> = 3.64, 6.73, 13.52 Hz, 1H), 2.09–2.23 (m, 1H). MS (<i>m</i>/<i>z</i>) calcd. for C<sub>11</sub>H<sub>13</sub>NO<sub>4</sub> [M + H]<sup>+</sup> 224.09, found 224.1.</div></div><div id="sec4-1-8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (2<i>S</i>,3<i>R</i>)-2-Carboxy-3-(3-carboxy-4-fluorophenyl)pyrrolidin-1-ium Chloride (<b>1k</b>)</h4><div class="NLM_p last">Acid <b>7k</b> (85 mg, 0.24 mmol, 1 equiv) was dissolved in a 1:1 mixture TFA/DCM (4.66 mL). The reaction mixture was allowed to stir for 2 h at rt, then the solvent was evaporated under reduced pressure. The oily residue was dissolved in HCl 1 M (10 mL), and the solvent was evaporated (3×) to afford the title compound as a white solid (42 mg, 60%). <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 7.97 (dd, <i>J</i> = 6.9, 2.6 Hz, 1H), 7.69 (ddd, <i>J</i> = 8.6, 4.6, 2.5 Hz, 1H), 7.31 (dd, <i>J</i> = 11.0, 8.6 Hz, 1H), 4.36 (d, <i>J</i> = 9.7 Hz, 1H), 3.77–3.66 (m, 2H), 3.57 (ddd, <i>J</i> = 11.8, 10.2, 6.9 Hz, 1H), 2.59 (dtd, <i>J</i> = 13.9, 7.0, 3.3 Hz, 1H), 2.29 (dtd, <i>J</i> = 13.4, 10.4, 8.2 Hz, 1H). <sup>13</sup>C NMR (D<sub>2</sub>O) δ 172.0, 168.4, 162.5, 160.8, 135.34, 135.31, 135.2, 135.1, 131.5, 119.2, 119.1, 118.2, 118.1, 67.2, 65.9, 47.8, 46.3, 33.5. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>12</sub>H<sub>13</sub>FNO<sub>4</sub> [M + H]<sup>+</sup> 254.1, found 254.1. Mp: 196.8 → dec.</div></div><div id="sec4-1-9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (2<i>S</i>,3<i>R</i>)-3-(3-Carboxy-4-chlorophenyl)pyrrolidine-2-carboxylic Acid Hydrochloride (<b>1l</b>)</h4><div class="NLM_p last">Diacid <b>7l</b> (190 mg, 0.514 mmol, 1 equiv) was dissolved in a 1:1 mixture TFA/DCM (10 mL). The reaction mixture was allowed to stir for 2 h at rt, then the solvent was evaporated under reduced pressure. The oily residue was dissolved in 1 M HCl (10 mL), and the solvent was evaporated (3 times) to afford the corresponding HCl salt (135 mg). The crude product was recrystallized from H<sub>2</sub>O/acetone to afford the title compound as an off-white solid (89 mg, 56%). <sup>1</sup>H NMR (D<sub>2</sub>O) δ 7.85 (d, <i>J</i> = 1.8 Hz, 1H), 7.68–7.49 (m, 2H), 4.37 (d, <i>J</i> = 9.7 Hz, 1H), 3.71 (ddd, <i>J</i> = 11.8, 9.2, 5.1 Hz, 2H), 3.62–3.52 (m, 1H), 2.60 (dtd, <i>J</i> = 13.9, 7.1, 3.4 Hz, 1H), 2.35–2.23 (m, 1H). <sup>13</sup>C NMR (D<sub>2</sub>O) δ 171.9, 170.7, 138.3, 132.6, 131.9, 131.8, 131.7, 130.3, 65.7, 47.8, 46.2, 33.4. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>12</sub>H<sub>13</sub>ClNO<sub>4</sub> [M + H]<sup>+</sup> 270.0, found 270.0. Mp 239.4–241.3 °C.</div></div><div id="sec4-1-10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (2<i>S</i>,3<i>R</i>)-3-(3-Carboxy-4-methylphenyl)pyrrolidine-2-carboxylic Acid Hydrochloride (<b>1m</b>)</h4><div class="NLM_p last">A solution of NaIO<sub>4</sub> (638 mg, 2.98 mmol, 8.2 equiv) and RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O (4.5 mg, 0.022 mmol, 0.06 equiv) in H<sub>2</sub>O (4.5 mL) was added to a solution of <b>6m</b> (117 mg, 0.36 mmol) in MeCN/EtOAc (1:1, 5.2 mL) cooled to 0 °C. The reaction mixture was stirred for 30 min and then filtered through Celite, and the filter cake was washed with EtOAc. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated to give the corresponding diacid, which was used without further purification. The diacid <b>7m</b> was dissolved in a 1:1 mixture of TFA/DCM (6.0 mL), the reaction mixture was allowed to stir for 2.5 h at rt, and the solvent was evaporated under reduced pressure. The oily residue was dissolved in 1 M HCl (10 mL) and evaporated to dryness (3×). The crude product was purified by preparative HPLC (0 to 40% B in A) and then evaporated with 1 M HCl (3 × 1 mL) to afford the title compound, as a white solid (21 mg, 20% over two steps). <sup>1</sup>H NMR (600 MHz, D<sub>2</sub>O) δ 7.78 (d, <i>J</i> = 2.0 Hz, 1H), 7.45 (dd, <i>J</i> = 7.9, 2.1 Hz, 1H), 7.29 (d, <i>J</i> = 7.9 Hz, 1H), 4.39 (d, <i>J</i> = 9.8 Hz, 1H), 3.69–3.61 (m, 2H), 3.51 (ddd, <i>J</i> = 11.7, 10.2, 6.9 Hz, 1H), 2.50 (dtd, <i>J</i> = 10.5, 7.1, 3.2 Hz, 1H), 2.44 (s, 3H), 2.25–2.17 (m, 1H). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O) δ 171.54, 170.63, 139.15, 135.72, 132.31, 131.28, 130.16, 129.04, 64.56, 47.25, 45.81, 32.82, 20.04. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>13</sub>H<sub>16</sub>NO<sub>4</sub> [M + H]<sup>+</sup> 250.3, found 250.3. Mp: decomposition.</div></div><div id="sec4-1-11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (2<i>S</i>,3<i>R</i>)-3-(3-Carboxy-4-bromophenyl)pyrrolidine-2-carboxylic Acid Hydrochloride (<b>1n</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (600 MHz, D<sub>2</sub>O) δ 7.67 (d, <i>J</i> = 8.3 Hz, 1H), 7.63 (d, <i>J</i> = 2.3 Hz 1H), 7.36 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 4.18 (d, <i>J</i> = 9.4 Hz, 1H), 3.61–3.54 (m, 1H), 3.48–3.43 (m, 1H), 2.51–2.46 (m, 1H), 2.21–2.14 (m, 1H). <sup>13</sup>C NMR (600 MHz, D<sub>2</sub>O) δ 171.9, 171.6, 138.6, 134.8, 134.2, 131.4, 128.8, 118.4, 65.6, 47.5, 45.6, 32.8. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>12</sub>H<sub>12</sub>BrNO<sub>4</sub> [M + H]<sup>+</sup> 312.9 and 314.9, found 313.9 and 315.9. Mp: 250.1–257.3 °C.</div></div><div id="sec4-1-12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 5-Bromo-2-methylbenzyl)oxy)(<i>tert</i>-butyl)dimethylsilane (<b>3m</b>)</h4><div class="NLM_p last">To a flame-dried round-bottom flask was charged with 5-bromo-2-methylphenyl)methanol<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (4.34 g, 21.6 mmol), anhydrous DMF (50 mL), imidazole (4.41 g, 64.8 mmol), TBSCl (6.51 g, 43.2 mmol), and DMAP (264 mg, 2.16 mmol). The reaction mixture was stirred for 16 h at rt and subsequently diluted with EtOAc. The resulting mixture was washed twice with 1 M HCl, twice with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The crude product was purified by consecutive flash chromatography (heptane/EtOAc, 2:1 and 5:1) to provide title compound as a clear oil (4.63 g, 68%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.56 (d, <i>J</i> = 2.0 Hz, 1H), 7.27 (dd, <i>J</i> = 8.0, 2.2 Hz, 1H), 6.98 (d, <i>J</i> = 8.0 Hz, 1H), 4.65 (s, 2H), 2.19 (s, 3H), 0.95 (s, 9H), 0.11 (s, 6H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 141.60, 133.72, 131.50, 129.77, 129.30, 119.78, 62.76, 26.09, 18.56, 18.16, −5.17. <i>R</i><sub>f</sub> 0.84 (heptane/EtOAc, 1:1).</div></div><div id="sec4-1-13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>tert</i>-Butyldimethyl((2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)silane (<b>3n</b>)</h4><div class="NLM_p last">A dry, Ar-filled 20 mL vial was charged with bromine <b>3m</b> (419 mg, 1.33 mmol), (Bpin)<sub>2</sub> (354 mg, 1.40 mmol), KOAc (394 mg, 4.06 mmol), and (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub> (46.9 mg, 66.5 μmol). The vial was then evacuated and backfilled with Ar, followed by addition of degassed dioxane (13.2 mL). The vial was capped with a screw cap and stirred for 16 h at 100 °C. The reaction mixture was then diluted with EtOAc and washed three times with H<sub>2</sub>O. The organic partition was washed with brine, dried over MgSO<sub>4</sub>, filtered through Celite, and evaporated. The crude product was purified by DCVC (heptane/EtOAc, 10:1) to yield the title compound (407 mg, contains 5 mol % PPh<sub>3</sub>), which was used without further purification. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.76 (s, 1H), 7.62 (dd, <i>J</i> = 7.4, 1.0 Hz, 1H), 7.15 (d, <i>J</i> = 7.5 Hz, 1H), 4.70 (s, 2H), 2.34 (s, 3H), 1.33 (s, 12H), 0.93 (s, 9H), 0.09 (s, 6H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 139.94, 138.40, 134.16, 134.03, 129.75, 83.71, 64.14, 26.11, 25.01, 19.19, 18.57, −5.11. <i>R</i><sub>f</sub> 0.54 (heptane/EtOAc, 10:1).</div></div><div id="sec4-1-14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 2-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-3-(3-(ethoxycarbonyl)phenyl)-5-oxopyrrolidine-1-carboxylate (<b>4a</b>)</h4><div class="NLM_p last">[Rh(cod)Cl]<sub>2</sub> (37.6 mg, 0.076 mmol, 0.05 equiv), (<i>S</i>)-<i>tert</i>-butyl 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate (<b>2</b>) (500 mg, 1.53 mmol, 1.0 equiv) and (3-(ethoxycarbonyl)phenyl)boronic acid (<b>3a</b>, 474 mg, 2.44 mmol, 1.6 equiv) were placed in a 50 mL flask, which was evacuated and backfilled with N<sub>2</sub>. Degassed dioxane (13.0 mL) was added, and to the stirred clear solution, 1 M NaOH (2.44 mL, 1.6 equiv, degassed water) was added dropwise. The reaction mixture was stirred at rt for 4.5 h. The reaction mixture was diluted with H<sub>2</sub>O, and the aqueous phase was extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over MgSO<sub>4</sub>, and concentrated to give 743 mg. The crude product was purified by flash chromatography (heptanes/EtOAc, 9:1) to afford the title compound as an off-white solid (382 mg, 52%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.95 (dt, <i>J</i> = 7.4, 1.6 Hz, 1H), 7.87 (s, 1H), 7.39 (tt, <i>J</i> = 4.6, 3.3 Hz, 2H), 4.38 (q, <i>J</i> = 7.1 Hz, 2H), 4.09 (dt, <i>J</i> = 4.0, 2.1 Hz, 1H), 4.01 (dd, <i>J</i> = 10.6, 3.9 Hz, 1H), 3.82 (dd, <i>J</i> = 10.5, 2.2 Hz, 1H), 3.54 (dt, <i>J</i> = 9.6, 2.4 Hz, 1H), 3.17 (dd, <i>J</i> = 17.9, 9.6 Hz, 1H), 2.53 (dd, <i>J</i> = 17.9, 2.8 Hz, 1H), 1.53 (s, 9H), 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 0.91 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 173.7, 166.4, 150.0, 144.6, 131.4, 130.6, 129.4, 128.5, 128.0, 83.3, 66.6, 63.7, 61.3, 40.1, 38.8, 28.2, 26.0, 18.3, 14.5, −5.3. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>25</sub>H<sub>39</sub>NO<sub>6</sub>Si [M + H]<sup>+</sup> 478.2, found 378.2 [(M + H)-Boc]<sup>+</sup>. <i>R</i><sub>f</sub> 0.25 (heptanes/EtOAc, 8:2).</div></div><div id="sec4-1-15" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 3-(3-Bromophenyl)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidine-1-carboxylate (<b>4b</b>)</h4><div class="NLM_p last">To a solution at rt of (<i>S</i>)-<i>tert</i>-butyl 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate (<b>2</b>) (1.0 g, 3.05 mmol, 1.0 equiv) and (3-bromophenyl)boronic acid (<b>3b</b>, 981 mg, 4.89 mmol, 1.6 equiv) in degassed THF (26.3 mL) under nitrogen was added [Rh(cod)Cl]<sub>2</sub> (75.3 mg, 0.153 mmol, 0.05 equiv). A 1 M NaOH (4.9 mL, 1.6 equiv) solution was then added dropwise, and the reaction mixture stirred at rt for 4 h. The reaction mixture was diluted with H<sub>2</sub>O, and the aqueous phase was extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over MgSO<sub>4</sub>, and concentrated to give 1.56 g. The crude product was purified by flash chromatography (heptanes/EtOAc, 9:1) to afford the title compound as a white solid (803 mg, 54%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.40 (ddd, <i>J</i> = 7.9, 1.9, 1.0 Hz, 1H), 7.34 (t, <i>J</i> = 1.8 Hz, 1H), 7.21 (t, <i>J</i> = 7.8 Hz, 1H), 7.14–7.09 (m, 1H), 4.06 (dt, <i>J</i> = 3.9, 2.0 Hz, 1H), 3.99 (dd, <i>J</i> = 10.5, 3.9 Hz, 1H), 3.80 (dd, <i>J</i> = 10.5, 2.2 Hz, 1H), 3.42 (dt, <i>J</i> = 9.6, 2.2 Hz, 1H), 3.14 (dd, <i>J</i> = 17.9, 9.6 Hz, 1H), 2.50 (dd, <i>J</i> = 17.9, 2.6 Hz, 1H), 1.53 (s, 9H), 0.91 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 400 MHz) δ 173.6, 150.0, 146.6, 130.8, 130.5, 129.9, 125.0, 123.2, 83.4, 66.6, 63.8, 39.94, 38.7, 28.2, 26.0, 18.3, −5.3, −5.4. <i>R</i><sub>f</sub> 0.21 (heptanes/EtOAc, 9:1).</div></div><div id="sec4-1-16" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3-(3-chlorophenyl)-5-oxopyrrolidine-1-carboxylate (<b>4d</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-<i>tert</i>-butyl 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate (<b>2</b>) (500 mg, 1.53 mmol, 1.0 equiv) and (3-chlorophenyl)boronic acid (<b>3d</b>, 382 mg, 2.44 mmol, 1.6 equiv) in THF/H<sub>2</sub>O (9:1, 15 mL) under nitrogen at rt was added [Rh(cod)Cl]<sub>2</sub> (37.6 mg, 0.076 mmol, 0.05 equiv). Then, 1 M NaOH (2.5 mL, 1.6 equiv) was added dropwise, and the reaction mixture was stirred at rt for 4.5 h. The reaction mixture was diluted with H<sub>2</sub>O, and the aqueous phase was extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over MgSO<sub>4</sub>, and concentrated to give 690 mg. The crude product was purified by flash chromatography (heptanes/EtOAc, 4:1) to afford the title compound as a white solid (387 mg, 58%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.55–7.38 (m, 4H, Ar–H), 4.09 (m, 1H, CH–N), 4.01 (m, 1H), 3.83 (dd, <i>J</i> = 10.5, 2.3 Hz, 1H), 3.54 (dt, <i>J</i> = 9.5, 2.3 Hz, 1H), 3.20 (dd, <i>J</i> = 17.9, 9.7 Hz, 1H), 2.53 (dd, <i>J</i> = 17.8, 2.5 Hz, 1H), 1.54 (s, 9H), 0.92 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 173.3, 149.8, 145.1, 131.3 (q, <i>J</i> = 32 Hz, <u class="uu">C</u>–CF<sub>3</sub>), 129.7, 129.4, 124.0 (q, <i>J</i> = 3.7 Hz, C–Ar), 123.9 (q, <i>J</i> = 270 Hz, CF<sub>3</sub>), 123.6 (q, <i>J</i> = 3.7, C–Ar), 83.3, 66.3, 63.3, 39.8, 38.7, 28.0, 25.8, 18.1, −5.5, −5.6. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>22</sub>H<sub>35</sub>ClNO<sub>4</sub>Si [M + H]<sup>+</sup> 440.2, found 340.1 [(M + H)-Boc]<sup>+</sup>. [α]<sub>25</sub><sup>D</sup> −26.5 (<i>c</i> = 0.27, MeOH). Mp: 71.4–73.9 °C. <i>R</i><sub>f</sub> 0.29 (heptanes/EtOAc, 9:1).</div></div><div id="sec4-1-17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 2-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-5-oxo-3-(3-(trifluoromethyl)phenyl)pyrrolidine-1-carboxylate (<b>4e</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-<i>tert</i>-butyl 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate (<b>2</b>) (1.0 g, 3.053 mmol, 1 equiv) and commercially available (3-(trifluormomethyl)phenyl)boronic acid (<b>3e</b>, 928 mg, 4.89 mmol, 1.6 equiv) in THF/H<sub>2</sub>O (9:1, 30.0 mL) under nitrogen at rt was added [Rh(cod)Cl]<sub>2</sub> (75.3 mg, 0.153 mmol, 0.05 equiv). Then, 1 M NaOH (5.0 mL, 1.6 equiv) was added dropwise, and the reaction mixture was stirred at rt for 4 h. The reaction mixture was diluted with H<sub>2</sub>O, and the aqueous phase was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (1 × 30 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptanes/EtOAc, 9:1) to afford the title compound as a white solid (727 mg, 56%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.55–7.38 (m, 4H), 4.09 (m, 1H), 4.01 (m, 1H), 3.83 (dd, <i>J</i> = 10.5, 2.3 Hz, 1H), 3.54 (dt, <i>J</i> = 9.5, 2.3 Hz, 1H), 3.20 (dd, <i>J</i> = 17.9, 9.7 Hz, 1H), 2.53 (dd, <i>J</i> = 17.8, 2.5 Hz, 1H), 1.54 (s, 9H), 0.92 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 173.3, 149.8, 145.1, 131.3 (q, <i>J</i> = 32 Hz), 129.7, 129.4, 124.0 (q, <i>J</i> = 3.7 Hz), 123.9 (q, <i>J</i> = 270 Hz), 123.6 (q, <i>J</i> = 3.7 Hz), 83.3, 66.3, 63.3, 39.8, 38.7, 28.0, 25.8, 18.1, −5.5, −5.6. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>23</sub>H<sub>35</sub>F<sub>3</sub>NO<sub>4</sub>Si [M + H]<sup>+</sup> 474.2, found 374.1 [(M + H)-Boc]<sup>+</sup>. [α]<sub>25</sub><sup>D</sup> −26.4 (<i>c</i> = 0.32, MeOH). Mp: 95.3–96.9 °C. <i>R</i><sub>f</sub> 0.29 (heptanes/EtOAc, 9:1).</div></div><div id="sec4-1-18" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 3-(3-((<i>tert</i>-Butoxycarbonyl)amino)phenyl)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidine-1-carboxylate (<b>4f</b>)</h4><div class="NLM_p last">[Rh(cod)Cl]<sub>2</sub> (37.6 mg, 0.076 mmol, 0.05 equiv), (S)-<i>tert</i>-butyl 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate (500 mg, 1.53 mmol, 1.0 equiv), and 3-(<i>tert</i>-butoxycarbonylamino)boronic acid (<b>3f</b>, 579 mg, 2.44 mmol, 1.6 equiv) were placed in a 50 mL flask, which was evacuated and backfilled with N<sub>2</sub>. Degassed dioxane (13.0 mL) was added followed by dropwise addition of 1 M NaOH (2.44 mL, 1.6 equiv, degassed water). The reaction mixture was stirred at rt for 3.5 h. The reaction mixture was diluted with H<sub>2</sub>O, and the aqueous phase was extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over MgSO<sub>4</sub>, and concentrated to give 743 mg. The crude product was purified by flash chromatography (heptanes/EtOAc, 9:1) to afford the title compound as a pale yellow oil (471 mg, 59% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.19–7.30 (m, 3H), 6.82–6.90 (m, 1H), 6.49 (s, 1H), 4.07–4.12 (m, 1H), 4.02 (dd, <i>J</i> = 3.51, 10.54 Hz, 1H), 3.80 (dd, <i>J</i> = 1.88, 10.67 Hz, 1H), 3.43 (td, <i>J</i> = 1.88, 9.54 Hz, 1H), 3.15 (dd, <i>J</i> = 9.54, 17.82 Hz, 1H), 2.50 (dd, <i>J</i> = 2.26, 17.82 Hz, 1H), 1.52 (s, 9H), 0.91 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 174.1, 152.6, 149.9, 145.4, 138.9, 129.7, 120.7, 117.2, 116.6, 83.0, 80.7, 66.6, 63.8, 40.2, 38.9, 28.3, 28.1, 25.8, 18.2, −5.5. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>27</sub>H<sub>45</sub>N<sub>2</sub>O<sub>6</sub>Si [M + H]<sup>+</sup> 521.3, found 365.2 [(M + H)-Boc-<i>t</i>-Bu]. [α]<sub>25</sub><sup>D</sup> −19.8 (<i>c</i> = 0.55, MeOH). <i>R</i><sub>f</sub> 0.28 (heptanes/EtOAc, 8:2).</div></div><div id="sec4-1-19" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 3-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidine-1-carboxylate (<b>4j</b>)</h4><div class="NLM_p last">[Rh(cod)Cl]<sub>2</sub> (112.9 mg, 0.229 mmol, 0.05 equiv) was added to a solution of (<i>S</i>)-<i>tert</i>-butyl 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate (<b>2</b>) (1.50 g, 4.58 mmol, 1.0 equiv) and benzo[<i>d</i>][1,3]dioxol-5-ylboronic acid (1.22 g, 7.33 mmol, 1.6 equiv) in THF (39.0 mL) under nitrogen at rt. Aqueous 1 M NaOH (7.5 mL, 1.6 equiv) was then added dropwise, and the reaction mixture was stirred at rt for 4 h. The reaction mixture was diluted with H<sub>2</sub>O, and the aqueous phase was extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (1 × 50 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptanes/EtOAc, 9:1) to afford the title compound as a white solid (1.38 g, 67%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.75 (d, <i>J</i> = 8.0 Hz, 1H), 6.68 (d, <i>J</i> 1.8 Hz, 1H), 6.64 (dd, <i>J</i> = 8.0, 1.8 Hz, 1H), 5.95 (s, 2H), 4.03 (m, 1H), 3.98 (m, 1H), 3.78 (dd, <i>J</i> = 10.4, 2.1 Hz, 1H), 3.37 (dt, <i>J</i> = 9.5, 2.3 Hz, 1H), 3.12 (dd, <i>J</i> = 17.8, 9.5 Hz, 1H), 2.47 (dd, <i>J</i> = 17.8, 2.8 Hz, 1H), 1.53 (s, 9H), 0.91 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 173.9, 149.8, 148.2, 146.6, 138.1, 119.3, 108.5, 106.7, 101.1, 83.0, 66.9, 63.5, 40.2, 38.5, 28.1, 25.8, 18.2, −5.5. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>23</sub>H<sub>36</sub>NO<sub>6</sub>Si [M + H]<sup>+</sup> 450.2, found 350.1 [(M + H)-Boc]<sup>+</sup>. [α]<sub>25</sub><sup>D</sup> −25.6 (<i>c</i> = 0.42, MeOH). Mp: 106.6–107.6 °C. <i>R</i><sub>f</sub> 0.36 (heptanes/EtOAc, 8:2).</div></div><div id="sec4-1-20" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 2-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-3-(3-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-fluorophenyl)-5-oxopyrrolidine-1-carboxylate (<b>4k</b>)</h4><div class="NLM_p last">A flamed-dry round-bottomed flask was charged with a solution of <i>tert</i>-BuLi in pentane (8.98 mL, 15.265 mmol, 5.0 equiv) and cooled to −78 °C. A solution of bromine <b>3k</b> (2.44 g, 7.634 mmol, 2.5 equiv) in dry Et<sub>2</sub>O (25 mL) was added dropwise, and the clear, yellow solution was stirred at −78 °C for 10 min. A suspension of CuCN in dry Et<sub>2</sub>O (2.5 mL) was added portion-wise at −78 °C. The resulting suspension was stirred at −78 °C for 5 min and then at −42 °C for 10 min (clear solution), after which it was recooled to −78 °C. Enone <b>2</b> was dissolved in dry Et<sub>2</sub>O (3.0 mL) and added dropwise to the cuprate mixture at −78 °C, which resulted in a color change to bright dark red. The temperature was raised to −42 °C, and the reaction mixture was stirred at this temperature for 1 h. The brown solution was quenched by addition of a freshly prepared sat. NaHCO<sub>3</sub> (5 mL), allowed to warm up to rt, and then transferred to a separating funnel with water (15 mL) and EtOAc (15 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (2 × 15 mL). The combined organic layers were washed with brine (1 × 15 mL), dried over anhydrous MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i> to dryness. The crude product was purified by column chromatography (heptanes/EtOAc, 9:1) to afford the title compound as a pale yellow oil (793 mg, 1.40 mmol, 46% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.30 (dd, <i>J</i> = 6.8, 2.3 Hz, 1H), 7.04 (ddd, <i>J</i> = 7.5, 4.9, 2.5 Hz, 1H), 6.95 (dd, <i>J</i> = 9.6, 8.5 Hz, 1H), 4.77 (s, 2H), 4.04 (dd, <i>J</i> = 3.9, 2.0 Hz, 1H), 3.99 (dd, <i>J</i> = 10.4, 4.0 Hz, 1H), 3.79 (dd, <i>J</i> = 10.4, 2.1 Hz, 1H), 3.45 (dt, <i>J</i> = 9.6, 2.3 Hz, 1H), 3.13 (dd, <i>J</i> = 17.9, 9.6 Hz, 1H), 2.49 (dd, <i>J</i> = 17.9, 2.7 Hz, 1H), 1.52 (s, 9H), 0.94 (s, 9H), 0.91 (s, 9H), 0.11 (s, 3H), 0.11 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 173.9, 159.8, 158.1, 150.0, 140.12, 140.10, 129.2, 129.1, 126.64, 126.61, 126.25, 126.19, 115.6, 115.4, 83.2, 66. 9, 63.7, 59.1, 59.0, 40.3, 38.3, 28.2, 26.1, 26.0, 18.6, 18.3, −5.17, −5.20, −5.3. <i>R</i><sub>f</sub> 0.32 (heptanes/EtOAc, 9:1).</div></div><div id="sec4-1-21" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 2-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-3-(3-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-chlorophenyl)-5-oxopyrrolidine-1-carboxylate (<b>4l</b>)</h4><div class="NLM_p last">A flamed-dry round-bottomed flask was charged with a solution of <i>tert</i>-BuLi in pentane (8.98 mL, 15.265 mmol, 5.0 equiv) and cooled to −78 °C. A solution of <b>3l</b> (2.56 g, 7.63 mmol, 2.5 equiv) in dry Et<sub>2</sub>O (25 mL) was added dropwise, and the clear, yellow/orange solution was stirred at −78 °C for 10 min. A suspension of CuCN in dry Et<sub>2</sub>O (2.4 mL) was added portion-wise at −78 °C. The resulting suspension was stirred at −78 °C for 5 min and then at −42 °C for 10 min (clear solution), after which it was recooled to −78 °C. Enone <b>2</b> was dissolved in dry Et<sub>2</sub>O (3.0 mL) and added dropwise to the cuprate mixture at −78 °C, which resulted in a color change to bright dark red. The temperature was raised to −42 °C, and the reaction mixture was stirred at this temperature for 1 h. The brown solution was quenched by addition of a freshly prepared sat. NaHCO<sub>3</sub> (5 mL), allowed to warm up to rt, and then transferred to a separating funnel with water (15 mL) and EtOAc (15 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (2 × 15 mL). The combined organic layers were washed with brine (1 × 15 mL), dried over anhydrous MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i> to dryness. The crude product was purified by column chromatography (heptanes/EtOAc, 9:1) to afford the title compound as a low-melting white solid (1.31 g, 73%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.39 (d, <i>J</i> = 2.3 Hz, 1H), 7.26 (d, <i>J</i> = 8.2 Hz, 1H), 7.01 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 4.77 (s, 2H), 4.04 (dt, <i>J</i> = 3.9, 2.0 Hz, 1H), 4.00 (dd, <i>J</i> = 10.4, 3.9 Hz, 1H), 3.78 (dd, <i>J</i> = 10.4, 2.0 Hz, 1H), 3.45 (dt, <i>J</i> = 9.6, 2.3 Hz, 1H), 3.14 (dd, <i>J</i> = 17.9, 9.6 Hz, 1H), 2.50 (dd, <i>J</i> = 17.9, 2.8 Hz, 1H), 1.52 (s, 9H), 0.96 (s, 9H), 0.90 (s, 9H), 0.13 (s, 3H), 0.13 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 173.7, 150.0, 143.1, 139.6, 130.2, 129.6, 125.9, 125.8, 83.2, 66.7, 63.7, 62.4, 40.1, 38. 6, 28.2, 26.1, 26.0, 18.6, 18.4, −5.1, −5.2, −5.34, −5.35. <i>R</i><sub>f</sub> 0.47 (heptanes/EtOAc, 8:2).</div></div><div id="sec4-1-22" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>tert</i>-Butyl (2<i>S</i>,3<i>R</i>)-2-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-3-(3-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-methylphenyl)-5-oxopyrrolidine-1-carboxylate (<b>4m</b>)</h4><div class="NLM_p last">[Rh(cod)Cl]<sub>2</sub> (23.2 mg, 0.047 mmol, 0.05 equiv), (<i>S</i>)-<i>tert</i>-butyl 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate (<b>2</b>) (300 mg, 0.92 mmol), <i>tert</i>-butyldimethyl((2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)silane (<b>3n</b>) (532 mg, 1.47 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (477 mg, 1.46 mmol) were placed in a 25 mL flask, which was evacuated and backfilled with Ar. Degassed, anhydrous THF (8.9 mL) was added, followed by addition of degassed H<sub>2</sub>O (21 μL, 1.1 mmol). The reaction mixture was stirred at rt for 24 h. The reaction mixture was diluted with H<sub>2</sub>O, and the aqueous phase was extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptane:EtOAc, 10:1 to 5:2) to afford the title compound as a pale yellow oil (211 mg, 41% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.24 (d, <i>J</i> = 1.4 Hz, 1H), 7.09 (d, <i>J</i> = 7.8 Hz, 1H), 7.00 (dd, <i>J</i> = 7.7, 2.0 Hz, 1H), 4.68 (s, 2H), 4.11–4.05 (m, 1H), 4.01 (dd, <i>J</i> = 10.5, 3.8 Hz, 1H), 3.79 (dd, <i>J</i> = 10.5, 2.0 Hz, 1H), 3.46–3.41 (m, 1H), 3.13 (dd, <i>J</i> = 17.9, 9.6 Hz, 1H), 2.53 (dd, <i>J</i> = 17.8, 2.8 Hz, 1H), 2.25 (s, 3H), 1.52 (s, 9H), 0.94 (s, 9H), 0.91 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.29, 150.02, 141.83, 139.94, 134.14, 130.65, 124.93, 124.83, 82.97, 67.01, 63.70, 63.41, 40.18, 38.57, 28.19, 26.08, 25.97, 18.52, 18.32, 18.26, −5.14, −5.15, −5.38, −5.40. <i>R</i><sub>f</sub> 0.43 (heptanes/EtOAc, 5:1).</div></div><div id="sec4-1-23" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 3-(3-Chlorophenyl)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>6d</b>)</h4><div class="NLM_p">In a flame-dried flask a solution of <b>4d</b> (368 mg, 0.84 mmol, 1.0 equiv) in dry THF (2.2 mL) was cooled to −78 °C. LiBEtH<sub>3</sub> 1 M (1.0 mL, 1.00 mmol, 1.2 equiv) was added via syringe dropwise, and the reaction mixture was stirred for 1 h, quenched with NaHCO<sub>3</sub> sat. sol. (3 mL), and warmed to rt. The aqueous phase was extracted with EtOAc (3 × 5 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to give the corresponding hemiaminal <b>5d</b> as a colorless oil, which was used in the next step without further purification.</div><div class="NLM_p last">In a flame-dried flask a solution of the crude hemiaminal <b>5d</b> (0.84 mmol, 1.0 equiv) in dry DCM (2.6 mL) was cooled to −78 °C. HSiEt<sub>3</sub> (0.27 mL, 1.670 mmol, 2 equiv) and BF<sub>3</sub>·Et<sub>2</sub>O (0.23 mL, 1.837 mmol, 2.2 equiv) were added sequentially via syringe, and the reaction mixture stirred for 6 h. The reaction mixture was quenched with sat. NaHCO<sub>3</sub> (4 mL) and warmed to rt. The mixture was diluted with DCM, and the organic phase was separated, washed with sat. NH<sub>4</sub>Cl (5 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptanes/EtOAc, 2:1) to afford the title compounds as a colorless gummy oil (154 mg, 59% over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.31–7.26 (m, 3H, Ar–H), 7.16–7.14 (m, 1H, Ar–H), 3.94 (m, 1H, CH–N), 3.78 (m, 1H), 3.67 (m, 1H), 3.40 (m, 1H), 3.05 (broad s, 1H), 2.20 (m, 1H), 1.97 (m, 1H), 1.54 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 156.5, 143.0, 134.5, 130.0, 127.6, 127.2, 125.7, 80.5, 66.7, 65.5, 47.2, 46.8, 32.6, 28.4. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>16</sub>H<sub>23</sub>ClNO<sub>3</sub> [M – H]<sup>+</sup> 312.14, found 212.1 [(M + H)-Boc]<sup>+</sup>. [α]<sub>25</sub><sup>D</sup> −13.1 (<i>c</i> = 0.92, MeOH). <i>R</i><sub>f</sub> 0.49 (heptanes/EtOAc, 1:1 + 1% AcOH).</div></div><div id="sec4-1-24" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 2-(Hydroxymethyl)-5-oxo-3-(3-(trifluoromethyl)phenyl)pyrrolidine-1-carboxylate (<b>6e</b>)</h4><div class="NLM_p">In a flame-dried flask a solution of <b>4e</b> (500 mg, 1.06 mmol, 1.0 equiv) in dry THF (2.8 mL) was cooled to −78 °C. LiBEtH<sub>3</sub> 1 M (solution in THF) (1.27 mL, 1.27 mmol, 1.2 equiv) was added via syringe dropwise, and the reaction mixture was stirred for 40 min, quenched with NaHCO<sub>3</sub> sat. sol. (3 mL), and warmed to rt. The aqueous phase was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to give the corresponding hemiaminal <b>5e</b> as a colorless oil, which was used in the next step without further purification.</div><div class="NLM_p last">In a flame-dried flask, a solution of the crude hemiaminal <b>5e</b> (1.06 mmol, 1 equiv) in dry DCM (3.3 mL) was cooled to −78 °C. HSiEt<sub>3</sub> (0.34 mL, 2.11 mmol, 2 equiv) and BF<sub>3</sub>·Et<sub>2</sub>O (0.29 mL, 2.315 mmol, 2.2 equiv) were sequentially added via syringe, and the reaction mixture was stirred for 6 h. After the complete consumption of the substrate, the reaction was quenched with sat. NaHCO<sub>3</sub> (4 mL) and warmed to rt. The mixture was diluted with DCM, and the organic phase was separated, washed with sat. NH<sub>4</sub>Cl (5 mL), dried over MgSO<sub>4</sub>, and concentrated to give 371 mg (crude). The crude was purified by flash chromatography (heptanes/EtOAc, 2:1) to afford the title compound as a colorless gummy oil (286 mg, 78% yield over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) 7.49–7.39 (m, 4H), 4.94 (br s, 1H, OH), 3.92 (br s, 1H), 3.75–3.58 (m, 3H), 3.35 (ddd, <i>J</i> = 11.2, 8.9, 6.8, 1H), 3.04 (m, 1H), 2.18 (br s, 1H), 1.99–1.89 (m, 1H), 1.46 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 156.3, (154.3), (143.9), 142.1, 130.9 (q, <i>J</i> = 31.5 Hz, <u class="uu">C</u>–CF<sub>3</sub>), 130.8, 129.1, 124.1, 123.9 (q, <i>J</i> = 272.2 Hz, CF<sub>3</sub>), 123.8, 80.4, (80.1), 66.6, (65.6), 65.0, (62.5), 47.1, 46.7, (46.2), (32.6), 31.7. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>23</sub>F<sub>3</sub>NO<sub>3</sub> [M + H]<sup>+</sup> 346.2, found 246.1 [(M + H)-Boc]<sup>+</sup>. [α]<sub>25</sub><sup>D</sup> −10.3 (<i>c</i> = 0.43, MeOH). <i>R</i><sub>f</sub> 0.23 (heptanes/EtOAc, 2:1).</div></div><div id="sec4-1-25" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 3-(3-((<i>tert</i>-Butoxycarbonyl)amino)phenyl)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>6f</b>)</h4><div class="NLM_p">In a flame-dried flask a solution of <b>4f</b> (371 mg, 0.71 mmol, 1.0 equiv) in dry THF (1.86 mL) was cooled to −78 °C. LiBEtH<sub>3</sub> 1 M (solution in THF) (1.7 mL, 1.72 mmol, 2.4 equiv) was added via syringe dropwise, and the reaction mixture was stirred for 1 h, quenched with sat. NaHCO<sub>3</sub> (3 mL), and warmed to rt. The aqueous phase was extracted with EtOAc (3 × 5 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to give the corresponding hemiaminal <b>4f</b> as a colorless oil, which was used in the next step without further purification.</div><div class="NLM_p last">In a flame-dried flask a solution of the crude hemiaminal <b>4f</b> (0.714 mmol, 1 equiv) in dry DCM (2.2 mL) was cooled to −78 °C. HSiEt<sub>3</sub> (0.23 mL, 1.43 mmol, 2.0 equiv) and BF<sub>3</sub>·Et<sub>2</sub>O (0.27 mL, 2.14 mmol, 3.0 equiv) were sequentially added via syringe, and the reaction mixture was stirred for 5 h. After the complete consumption of the substrate, the reaction was quenched with NaHCO<sub>3</sub> sat. sol. (4 mL) and warmed to rt. The mixture was diluted with DCM, and the organic phase was separated, washed with sat. NH<sub>4</sub>Cl (5 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptanes/EtOAc, 2:1) to afford the title compound as a colorless oil (110 mg, 31% over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.39 (s, 1H), 7.21 (t, <i>J</i> = 7.8 Hz, 1H), 7.12 (d, <i>J</i> = 8.1 Hz, 1H), 6.89 (d, <i>J</i> = 7.6 Hz, 1H), 6.57 (s, 1H), 3.90 (d, <i>J</i> = 6.8 Hz, 1H), 3.79–3.68 (m, 2H), 3.60 (dd, <i>J</i> = 11.5, 6.7 Hz, 1H), 3.39–3.27 (m, 1H), 2.92 (s, 1H), 2.14 (dtd, <i>J</i> = 9.1, 6.5, 2.8 Hz, 1H), 1.96 (dtd, <i>J</i> = 12.4, 10.1, 8.1 Hz, 1H), 1.51 (s, 9H), 1.49 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 152.8, 141.1 (b), 139.0, 129.4, 122.3, 117.7, 117.4, 80.7, 80.6, 67.0, 48.0, 47.2, 32.9, 28.6, 28.5. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>21</sub>H<sub>32</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup> 392.23, found 293.1 [(M-Boc) + H]<sup>+</sup>. [α]<sub>25</sub><sup>D</sup> −8.6 (<i>c</i> = 0.31, MeOH). <i>R</i><sub>f</sub> 0.16 (heptanes/EtOAc, 2:1).</div></div><div id="sec4-1-26" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 3-(3-Cyanophenyl)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>6g</b>)</h4><div class="NLM_p last">Under nitrogen atmosphere, TBAF (1.74 mmol, 3 equiv, 1.74 mL of 1 M solution in THF) was added to a solution of <b>8g</b> (242 mg, 0.581 mmol, 1 equiv) in dry THF (5.6 mL). The reaction mixture was stirred at rt for 2 h, then diluted with water (10 mL) and sat. NaHCO<sub>3</sub> (10 mL). The aqueous layer was extracted with EtOAc (2 × 10 mL), and the combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by column chromatography (heptanes/EtOAc, 1:1) to give the title compound as a pale yellow oil (202 mg, 63% yield over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.51–7.34 (m, 4H), 4.78 (br s, 1H), 3.86 (br s, 1H), 3.73–3.54 (m, 3H), 3.33 (ddd, <i>J</i> = 11.1, 8.8, 6.8 Hz, 1H), 3.01 (bs, 1H), 2.17 (m, 1H), 1.95–1.81 (m, 1H), 1.43 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 156.2, 154.2, 144.6, 142.9, 132.0, 131.1, 130.7, 129.6, 118.6, 112.7, 80.6, 80.3, 66.5, 65.5, 64.9, 62.4, 46.9, 46.8, 46.3, 32.5, 31.7, 28.4. <i>R</i><sub>f</sub> 0.21 (heptanes/EtOAc, 1:1).</div></div><div id="sec4-1-27" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 2-(Hydroxymethyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine-1-carboxylate (<b>6i</b>)</h4><div class="NLM_p last">Under nitrogen atmosphere, TBAF (1.311 mmol, 3 equiv, 1.31 mL of 1 M solution in THF), was added to a solution of <b>9</b> (226 mg, 0.437 mmol, 1 equiv) in dry THF (5.3 mL). The reaction mixture was stirred at rt for 2.5 h, then was diluted with sat. NaHCO<sub>3</sub> (10 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by column chromatography (heptanes/EtOAc, 2:1) to give the title compound as a colorless oil (106 mg, 63%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.72–7.63 (m, 2H), 7.32–7.29 (m, 2H), 3.96 (bs, 1H), 3.72 (m, 2H), 3.59 (dd, <i>J</i> = 11.5, 6.7 Hz, 1H), 3.33 (td, <i>J</i> = 10.5, 6.5 Hz, 1H), 2.89 (bs, 1H), 2.10 (bs, 1H), 2.04–1.89 (m, 1H), 1.48 (s, 9H), 1.33 (s, 12H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 156.9, 139.9, 133.9, 133.7, 130.7, 129.6, 128.2, 83.9, 80.5, 67.1, 66.0, 48.0, 47.2, 33.1, 28.5, 24.9. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 302.17, found 203.1 [(M + H)-Boc]<sup>+</sup>. <i>R</i><sub>f</sub> 0.17 (heptanes/EtOAc, 2:1).</div></div><div id="sec4-1-28" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 3-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-2-(hydroxymethyl)-5-oxopyrrolidine-1-carboxylate (<b>6j</b>)</h4><div class="NLM_p">In a flame-dried flask a solution of <b>4j</b> (687 mg, 1.53 mmol, 1.0 equiv) in dry THF (4 mL) was cooled to −78 °C. LiBEtH<sub>3</sub> 1 M (THF solution) (1.83 mL, 1.834 mmol, 1.2 equiv) was added via syringe dropwise, and the reaction mixture was stirred for 45 min, quenched with NaHCO<sub>3</sub> sat. sol. (4 mL), and warmed to rt. The aqueous phase was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to give the corresponding hemiaminal <b>5j</b> as a colorless oil, which was used in the next step without further purification.</div><div class="NLM_p last">In a flame-dried flask a solution of the crude hemiaminal (1.53 mmol, 1 equiv) in dry DCM (4.8 mL) was cooled to −78 °C. HSiEt<sub>3</sub> (0.49 mL, 3.06 mmol, 2 equiv) and BF<sub>3</sub>·Et<sub>2</sub>O (0.42 mL, 3.37 mmol, 2.2 equiv) were added sequentially via syringe, and the reaction mixture was stirred for 6 h. The reaction was quenched with sat. NaHCO<sub>3</sub> (4 mL) and warmed to rt. The mixture was diluted with DCM, and the organic phase was separated, washed with sat. NH<sub>4</sub>Cl (5 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptanes/EtOAc, 2:1) to afford the title compound as a pale yellow oil (334 mg, 69% yield over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.69–6.64 (m, <i>J</i> = 4.7, 3.2 Hz, 2H), 6.61 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 5.85 (s, 2H), 3.82–3.58 (m, 3H), 3.53 (dd, <i>J</i> = 11.4, 6.0 Hz, 1H), 3.26 (ddd, <i>J</i> = 11.0, 9.4, 6.7 Hz, 1H), 2.88–2.73 (m, 1H), 2.05 (br s, 1H), 1.89–1.72 (m, 1H), 1.42 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 156.4, 154.4, 147.9, 146.4, 136.7, 134.7, 120.7, 120.4, 108.2, 107.5, 100. 9, 80.3, 80.0, 66.9, 66.0, 65.2, 62.4, 47.3, 46.8, 46.4, 32.8, 32.0, 28.3. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>24</sub>NO<sub>5</sub> [M + H]<sup>+</sup> 322.16, found 222.1 [(M + H)-Boc]<sup>+</sup>. [α]<sub>25</sub><sup>D</sup> −18.3 (<i>c</i> = 1.2, MeOH). <i>R</i><sub>f</sub> 0.38 (heptanes/EtOAc, 2:1).</div></div><div id="sec4-1-29" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (2S,3<i>R</i>)-<i>tert</i>-Butyl 3-(4-Fluoro-3-(hydroxymethyl)phenyl)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>6k</b>)</h4><div class="NLM_p">In a flame-dried flask a solution of <b>4k</b> (793 mg, 1.40 mmol, 1.0 equiv) in dry THF (4.3 mL) was cooled to −78 °C. LiBEtH<sub>3</sub> 1 M (1.68 mL, 1.675 mmol, 1.2 equiv) was added via syringe dropwise, and the reaction mixture was stirred for 1 h, then quenched with sat. NaHCO<sub>3</sub> (5 mL). The aqueous phase was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to give the corresponding hemiaminal <b>5k</b> as a colorless oil, which was used in the next step without further purification.</div><div class="NLM_p last">In a flame-dried flask a solution of the crude hemiaminal (1.40 mmol, 1.0 equiv) in dry DCM (4.43 mL) was cooled to −78 °C. HSiEt<sub>3</sub> (0.44 mL, 2.79 mmol, 2 equiv) and BF<sub>3</sub>·Et<sub>2</sub>O (0.38 mL, 3.07 mmol, 2.2 equiv) were added sequentially via syringe, and the reaction mixture stirred for 5 h at −78 °C. The reaction mixture was quenched with sat. NaHCO<sub>3</sub> (5 mL), warmed to rt, and diluted with DCM. The organic phase was separated, washed with sat. NH<sub>4</sub>Cl (5 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude was dissolved in dry THF under N<sub>2</sub> atmosphere at rt, and 1 M TBAF (THF solution) (1.02 mL, 1.02 mmol, 3 equiv) was added dropwise. The reaction mixture was allowed to stir overnight, quenched with sat. NaHCO<sub>3</sub> (5 mL), and portioned between EtOAc (10 mL) and H<sub>2</sub>O (10 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (2 × 10 mL). The combined organic layers were washed with brine (1 × 10 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptanes/EtOAc, 2:3) to afford the title compound as a colorless oil (92 mg, 20% over three steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.35–7.26 (m, 1H), 7.08 (ddd, <i>J</i> = 7.7, 5.0, 2.4 Hz, 1H), 6.95 (dd, <i>J</i> = 9.7, 8.4 Hz, 1H), 5.13 (br s, 1H), 4.68 (s, 2H), 3.95–3.53 (m, 4H), 3.31 (td, <i>J</i> = 10.4, 6.4 Hz, 1H), 2.90 (br s, 1H), 2.22–2.05 (m, 1H), 1.89 (ddd, <i>J</i> = 12.6, 10.5, 8.2 Hz, 1H), 1.47 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 600 MHz) δ 160.3, 158.6, 156.8, 154.7, 138.3, 136.6, 128.6, 128.5, 128.13, 128.10, 115.5, 115.4, 80.7, 67.1, 66.1, 65.6, 62.8, 58.94, 58.91, 47.2, 47.1, 46.7, 46.5, 33.0, 32.3, 28.5. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>25</sub>FNO<sub>4</sub> [M + H]<sup>+</sup> 326.2, found 226.1 [(M-Boc) + H]<sup>+</sup>. <i>R</i><sub>f</sub> 0.18 (heptanes/EtOAc, 1:1).</div></div><div id="sec4-1-30" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 3-(4-Chloro-3-(hydroxymethyl)phenyl)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>6l</b>)</h4><div class="NLM_p">In a flame-dried flask a solution of <b>4l</b> (1.31 g, 2.24 mmol, 1 equiv) in dry THF (6.85 mL) was cooled to −78 °C. LiBEtH<sub>3</sub> 1 M (2.69 mL, 2.69 mmol, 1.2 equiv) was added via syringe dropwise, and the reaction mixture was stirred for 1 h, quenched with sat. NaHCO<sub>3</sub> (6 mL), and warmed to rt. The aqueous phase was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to give the corresponding hemiaminal <b>5l</b> as a colorless oil, which was used in the next step without further purification.</div><div class="NLM_p last">In a flame-dried flask a solution of the crude hemiaminal <b>5l</b> (2.24 mmol, 1 equiv) in dry DCM (7.1 mL) was cooled to −78 °C. HSiEt<sub>3</sub> (0.71 mL, 4.476 mmol, 2 equiv) and BF<sub>3</sub>·Et<sub>2</sub>O (0.62 mL, 4.94 mmol, 2.2 equiv) were sequentially added via syringe, and the reaction mixture was stirred for 5 h at −78 °C. After the complete consumption of the substrate, the reaction was quenched with sat. NaHCO<sub>3</sub> (4 mL) and warmed to rt. The mixture was diluted with DCM, and the organic phase was separated, washed with sat. NH<sub>4</sub>Cl (5 mL), dried over MgSO<sub>4</sub>, and concentrated to give 1.12 g. The crude product was dissolved in dry THF under N<sub>2</sub> atmosphere at rt, and 1 M TBAF–THF solution (6.7 mL, 6.71 mmol, 3 equiv) was added dropwise. After 2 h, the reaction mixture was quenched with sat. NaHCO<sub>3</sub> (5 mL), EtOAc (10 mL), and H<sub>2</sub>O (10 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (2 × 10 mL). The combined organic layers were washed with brine (1 × 10 mL), dried over MgSO<sub>4</sub>, and concentrated to dryness. The crude product was purified by flash chromatography (heptanes/EtOAc, 2:1 → 3:2) to afford the title compounds as a colorless oil (370 mg, 49% over three steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.37 (d, <i>J</i> = 1.9 Hz, 1H), 7.25 (d, <i>J</i> = 8.2 Hz, 1H), 7.04 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 4.69 (s, 2H), 4.00–3.48 (m, 6H), 3.41–3.24 (m, 1H), 2.92 (s, 1H), 2.12 (dtd, <i>J</i> = 9.4, 6.4, 2.9 Hz, 1H), 1.89 (dq, <i>J</i> = 12.3, 9.7 Hz, 1H), 1.47 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 156.7, 139.9, 139.0, 130.9, 129.5, 127.5, 127.5, 80.7, 66.8, 65.5, 62.3, 47.2, 47.0, 32.8, 28.5. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>25</sub>ClNO<sub>4</sub> [M + H]<sup>+</sup> 342.1, found 242.1 [(M-Boc) + H]<sup>+</sup>. <i>R</i><sub>f</sub> 0.25 (heptanes/EtOAc, 6:4).</div></div><div id="sec4-1-31" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>tert</i>-Butyl (2<i>S</i>,3<i>R</i>)-2-(Hydroxymethyl)-3-(3-(hydroxymethyl)-4-methylphenyl)pyrrolidine-1-carboxylate (<b>6m</b>)</h4><div class="NLM_p last">Compound <b>4m</b> (211 mg, 0.037 mmol) was dissolved in dry THF (3.1 mL), and dimethylsulfide borane complex (0.11 mL, 10.5 M in THF) was added dropwise. The reaction mixture was refluxed for 2.5 h, after which it was allowed to cool down to rt and diluted with Et<sub>2</sub>O, quenched with sat. NH<sub>4</sub>Cl, and the organic portion separated. The organic partition was washed with brine, dried over MgSO<sub>4</sub>, filtered through Celite, and concentrated <i>in vacuo</i>. The crude product was dissolved in THF (4.7 mL) and treated with TBAF (1 M, 2.24 mL) at rt for 23 h. The mixture was diluted with EtOAc and washed consecutively with NH<sub>4</sub>Cl (1 M), H<sub>2</sub>O, and brine, and dried over MgSO<sub>4</sub>. The solution was concentrated under reduced pressure and purified by flash column chromatography (heptanes/EtOAc, 10:1 → EtOAc) to provide the title compound as a colorless syrup (117 mg, 97%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (two rotamers) 7.25 (s, 1H), 7.11–7.07 (m, 1H), 7.06–7.01 (m, 1H), 4.68–4.50 (m, 2H), 3.99–3.84 (m, 1H), 3.72 (m, 2H), 3.65–3.55 (m, 1H), 3.38–3.26 (m, 1H), 2.87 (m, 1H), 2.30–2.25 (m, 3H), 2.15–2.05 (m, 1H), 2.00–1.86 (m, 1H), 1.49 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 156.93, 139.42, 130.66, 128.87, 126.69, 126.45, 114.21, 80.66, 67.02, 65.78, 63.11, 47.56, 47.22, 33.00, 28.57, 18.27. <i>R</i><sub>f</sub> 0.05 (heptanes/EtOAc, 10:1).</div></div><div id="sec4-1-32" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (2<i>S</i>,3<i>R</i>)-1-(<i>tert</i>-Butoxycarbonyl)-3-(3-chlorophenyl)pyrrolidine-2-carboxylic Acid (<b>7d</b>)</h4><div class="NLM_p last">A solution of NaIO<sub>4</sub> (434 mg, 2.03 mmol, 4.1 equiv) and RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O (3.1 mg, 0.015 mmol, 0.03 equiv) in H<sub>2</sub>O (6.2 mL) was added to a solution of <b>6d</b> (154 mg, 0.494 mmol, 1 equiv) in MeCN/EtOAc (1:1, 7.0 mL) cooled to 0 °C. The reaction mixture was stirred for 30 min, then filtered through Celite, and the filter cake was washed with EtOAc. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptanes/EtOAc, 1:1 + 1% AcOH) to afford the title compound as an off-white solid (138 mg, 86%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 9.64 (br s, 1H), 7.27–7.22 (m, 3H), 7.15–7.13 (m, 1H), 4.40 (d, <i>J</i> = 5.5 Hz, 0.4H), 4.25 (d, <i>J</i> = 6.5 Hz, 0.6H), 3.79–3.44 (m, 3H), 2.38–2.28 (m, 1H), 2.06–1.96 (m, 1H), 1.49 (s, 4H), 1.42 (s, 5H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 177.6, 175.7, 155.2, 153.7, 142.9, 142.4, 134.6, 130.1, 127.5, 127.4, 127.1, 125.2, 81.2, 80.1, 65.4, 64.9, 49.4, 47.5, 46.1, 45.9, 32.7, 32.2, 28.3, 28.2. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>16</sub>H<sub>21</sub>ClNO<sub>4</sub> [M + H]<sup>+</sup> 326.12, found 226.0 [(M + H)-Boc]<sup>+</sup>. [α]<sub>25</sub><sup>D</sup> +40.5 (<i>c</i> = 0.55, MeOH). <i>R</i><sub>f</sub> 0.27 (heptanes/EtOAc, 1:1 + 1% AcOH). Mp: decomposition.</div></div><div id="sec4-1-33" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (2<i>S</i>,3<i>R</i>)-1-(<i>tert</i>-Butoxycarbonyl)-3-(3-(trifluoromethyl)phenyl)pyrrolidine-2-carboxylic Acid (<b>7e</b>)</h4><div class="NLM_p last">A solution of NaIO<sub>4</sub> (380.6 mg, 1.78 mmol, 4.1 equiv) and RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O (2.7 mg, 0.013 mmol, 0.03 equiv) in H<sub>2</sub>O (5.45 mL) was added to a solution of <b>6e</b> in MeCN/EtOAc (1:1, 6.2 mL) cooled to 0 °C. The reaction mixture was stirred for 30 min, then was filtered through Celite, and the filter cake was washed with EtOAc. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated to give the title compound as a colorless sticky oil (95 mg, 61%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 9.26 (br s, 1H), 7.55–7.44 (m, 4H), 4.43 (d, <i>J</i> = 5.8 Hz, 0.4H), 4.27 (d, <i>J</i> = 6.5 Hz, 0.6H), 3.81–3.52 (m, 3H), 2.42–2.31 (m, 1H), 2.10–1.99 (m, 1H), 1.50 (s, 4H), 1.42 (s, 5H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 177.4, 175.4, 155.3 153.7, 141.8, 141.3, 131.1 (q, <i>J</i> = 33.0 Hz, <u class="uu">C</u>-CF<sub>3</sub>), 130.4, 130.3, 129.4, 129.3, 124.2, 124.1, 123.9 (q, <i>J</i> = 272.2 Hz, CF<sub>3</sub>), 123.8, 123.7, 81.3, 81.1, 65.4, 65.0, 49.5, 47.6, 46.1, 45.9, 32.8, 32.3, 28.3, 28.1. [α]<sub>25</sub><sup>D</sup> + 27.9 (<i>c</i> = 0.64, MeOH). <i>R</i><sub>f</sub> 0.26 (heptanes/EtOAc, 1:1 + 1% AcOH).</div></div><div id="sec4-1-34" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (2<i>S</i>,3<i>R</i>)-1-(<i>tert</i>-Butoxycarbonyl)-3-(3-((<i>tert</i>-butoxycarbonyl)amino)phenyl)pyrrolidine-2-carboxylic Acid (<b>7f</b>)</h4><div class="NLM_p last">A solution of NaIO<sub>4</sub> (179 mg, 0.836 mmol, 4.1 equiv) and RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O (1.27 mg, 0.006 mmol, 0.03 equiv) in H<sub>2</sub>O (2.55 mL) was added to a solution of <b>6f</b> (80 mg, 0.204 mmol, 1 equiv) in MeCN/EtOAc (1:1, 2.9 mL) cooled to 0 °C. The reaction mixture was stirred for 30 min, then filtered through filter paper, and the filter cake was washed with EtOAc. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated to give 128 mg. The crude product was purified by flash chromatography (heptanes/EtOAc, 1:1 + 1% AcOH) to afford the title compound as a colorless oil (41 mg, 49% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 10.51 (s, 1H), 7.30 (bs, 1H), 7.25–7.16 (m, 2H), 6.94–6.89 (m, 1H), 6.73 (bs, 1H), 4.41 (d, <i>J</i> = 5.4 Hz, 0.4H), 4.25 (d, <i>J</i> = 6.5 Hz, 0.6H), 3.85–3.35 (m, 3H), 2.42–2.18 (m, 1H), 2.07–1.96 (m, 1H), 1.51 (s, 9H), 1.49 (s, 4H), 1.41 (s, 5H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 178.1, 177.1, 175.8, 155.6, 153.9, 142.0, 141.5, 139.0, 138.9, 129.5, 121.7, 117.7, 117.4, 81.3, 80.9, 65.7, 65.3, 60.6, 50.0, 47.8, 46.4, 46.1, 32.9, 32.5, 28.5, 28.5, 28.4. [α]<sub>25</sub><sup>D</sup> +48.4 (<i>c</i> = 0.28, MeOH). <i>R</i><sub>f</sub> 0.21 (heptanes/EtOAc, 1:1 + 1% AcOH).</div></div><div id="sec4-1-35" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (2<i>S</i>,3<i>R</i>)-1-(<i>tert</i>-Butoxycarbonyl)-3-(3-cyanophenyl)pyrrolidine-2-carboxylic Acid (<b>7g</b>)</h4><div class="NLM_p last">A solution of NaIO<sub>4</sub> (435 mg, 2.03 mmol, 4.1 equiv) and RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O (3.09 mg, 0.015 mmol, 0.03 equiv) in H<sub>2</sub>O (6.19 mL) was added to a solution of <b>6g</b> (150 mg, 0.496 mmol, 1 equiv) in MeCN/EtOAc (1:1, 7.04 mL) cooled to 0 °C. The reaction mixture was stirred for 1 h, then filtered through filter paper, and the filter cake was washed with EtOAc. The aqueous layer was extracted with EtOAc (3 × 5 mL), and the combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptanes/EtOAc, 1:2 + 1% AcOH) to afford the title compound as a white solid (119 mg, 76%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 10.56 (bs, 1H), 7.66–7.37 (m, 4H), 4.37 (d, <i>J</i> = 5.6 Hz, 0.5H), 4.23 (d, <i>J</i> = 6.6 Hz, 0.5H), 3.83–3.40 (m, 3H), 2.36 (dt, <i>J</i> = 11.9, 6.5 Hz, 1H), 2.01 (dq, <i>J</i> = 12.7, 7.9 Hz, 1H), 1.48 (s, 4H), 1.41 (s, 5H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 177.3, 175.3, 155.4, 153.7, 142.5, 142.1, 131.8, 131. 7, 131.2, 131.1, 130.8, 130.7, 129.9, 118.6, 113.1, 81.7, 81.3, 65.4, 65.1, 49.3, 47.4, 46.2, 46.0, 32.7, 32.3, 28.5, 28.3. MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 317.15, found 217.1 [(M + H)-Boc]<sup>+</sup>. Mp: 141.4–143.1 °C. <i>R</i><sub><i>f</i></sub> 0.26 (heptanes/EtOAc, 1:2 + 1% AcOH).</div></div><div id="sec4-1-36" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (2<i>S</i>,3<i>R</i>)-1-(<i>tert</i>-Butoxycarbonyl)-3-(3-carbamoylphenyl)pyrrolidine-2-carboxylic Acid (<b>7h</b>)</h4><div class="NLM_p last">H<sub>2</sub>O<sub>2</sub> 30% (w/w) in H<sub>2</sub>O (0.089 mL, 0.870 mmol, 6 equiv) was added dropwise to a solution of <b>7g</b> (46 mg, 0.145 mmol, 1 equiv) and K<sub>2</sub>CO<sub>3</sub> (80 mg, 0.58 mmol, 4 equiv) in EtOH/H<sub>2</sub>O (1:1, 1 mL). The reaction mixture was stirred for 3 h at rt, then cautiously acidified with HCl 1 M (until pH ≈ 3) and extracted with EtOAc (3 × 5 mL). The combined organic layers were washed with brine (1 × 15 mL), dried over MgSO<sub>4</sub>, and concentrated to give the title compound (32 mg, 66%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 8.61 (br s, 1H), 7.87–7.61 (m, 2H), 7.48–7.30 (m, 2H), 7.12–6.72 (m, 2H), 4.50 (d, <i>J</i> = 6.6 Hz, 0.5H), 4.21 (d, <i>J</i> = 7.3 Hz, 0.5H), 3.83–3.40 (m, 3H), 2.44–2.17 (m, 1H), 2.12–1.94 (m, 1H), 1.47 (s, 5H), 1.40 (s, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 176.4, 175.0, 171.0, 170.9, 155.4, 154.0, 141.2, 141.1, 133.6, 133.3, 131.2, 130.7, 129.3, 129.2, 127.3, 126.8, 126.6, 126.5, 81.3, 81.0, 66.1, 65.3, 50.1, 48.5, 46.7, 46.2, 33.4, 32.4, 28.6, 28.4. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>23</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup> 335.16, found 235.1 [(M + H)-Boc]<sup>+</sup>. Mp: 136.9–139.4 °C. <i>R</i><sub>f</sub> 0.13 (heptanes/EtOAc, 1:3 + 1% AcOH).</div></div><div id="sec4-1-37" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (2<i>S</i>,3<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine-2-carboxylic Acid (<b>7i</b>)</h4><div class="NLM_p last">A solution of NaIO<sub>4</sub> (231 mg, 1.08 mmol, 4.1 equiv) and RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O (1.63 mg, 0.008 mmol, 0.03 equiv) in H<sub>2</sub>O (3.27 mL) was added to a solution of <b>6i</b> (106 mg, 0.263 mmol, 1.0 equiv) in MeCN/EtOAc (1:1, 3.7 mL) cooled to 0 °C. The reaction mixture was stirred for 30 min, then filtered through filter paper, and the filter cake was washed with EtOAc. The aqueous layer was extracted with EtOAc (3 × 5 mL), and the combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and concentrated to afford the title compound as an off-white solid (72 mg, 66%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 7.77–7.65 (m, 2H), 7.35–7.32 (m, 2H), 4.46 (d, <i>J</i> = 5.6 Hz, 0.4H), 4.30 (d, <i>J</i> = 6.7 Hz, 0.6H), 3.85–3.42 (m, 3H), 2.43–2.23 (m, 1H), 2.07 (dt, <i>J</i> = 16.9, 8.1 Hz, 1H), 1.50 (s, 4H), 1.42 (s, 5H), 1.34 (s, 12H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 178.1, 175.5, 155.7, 153.8, 140.2, 139.76, 134.0, 133.8, 133.3, 133.3, 130.2, 129.6, 128.3, 84.0, 81.3, 80.8, 65.8, 65.3, 50.1, 47.8, 46.4, 46.2, 33.3, 32.8, 28.5, 28.4, 25.0. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>22</sub>H<sub>33</sub>BNO<sub>6</sub> [M + H]<sup>+</sup> 418.2, found 318.1 [(M + H)-Boc]<sup>+</sup>. Mp: decomposition. <i>R</i><sub><i>f</i></sub> 0.40 (heptanes/EtOAc, 1:2 + 1% AcOH).</div></div><div id="sec4-1-38" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (2<i>S</i>,3<i>R</i>)-3-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-1-(<i>tert</i>-butoxycarbonyl)-5-oxopyrrolidine-2-carboxylic Acid (<b>7j</b>)</h4><div class="NLM_p">IBX (340 mg, 1.21 mmol, 2 equiv) was added to a solution of <b>6j</b> (195.0 mg, 0.607 mmol, 1 equiv) in DMSO (2.4 mL) at rt. The reaction mixture was allowed to stir until the total consumption of the starting material (3.5 h), then was quenched with sat. NaHCO<sub>3</sub> (3 mL). The aqueous phase was extracted with EtOAc (3 × 5 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude aldehyde (colorless oil) was used in the next step without further purification.</div><div class="NLM_p last">The crude aldehyde (0.607 mmol, 1 equiv), NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O (284 mg, 1.82 mmol, 3 equiv), and 2-methyl-2-butene (0.32 mL, 3.04 mmol, 5 equiv) were dissolved in <i>tert</i>-BuOH/H<sub>2</sub>O (3:1, 3 mL). NaClO<sub>2</sub> was then added, and the reaction mixture was stirred for 1.5 h at rt. After the complete consumption of the starting material, the reaction was quenched with pH 7 phosphate buffer (3 mL), and the aqueous phase was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (heptanes/EtOAc, 2:1 + 1% AcOH) to afford the title compound as an off-white solid (135 mg, 66% over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 7.93 (br s, 1H), 6.72 (m, 3H), 5.94 (s, 2H), 4.33 (d, <i>J</i> = 5.3 Hz, 0.4H), 4.18 (d, <i>J</i> = 6.6 Hz, 0.6H), 3.80–3.36 (m, 3H), 2.33–2.22 (m, 1H), 2.07–1.88 (m, 1H), 1.50 (s, 4H), 1.42 (s, 5H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 178.2, 175.1, 155.9, 153. 8, 148.2, 146.9, 146.80, 134.8, 134.3, 120.4, 120.3, 108.5, 107.4, 101.2, 81.6, 80.9, 66.0, 65.6, 49.9, 47.4, 46.4, 46.1, 33.1, 32.7, 28.5, 28.4. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>22</sub>NO<sub>6</sub> [M + H]<sup>+</sup> 336.1, found 236.1 [(M + H)-Boc]<sup>+</sup>. [α]<sub>25</sub><sup>D</sup> +43.8 (<i>c</i> = 1.0, MeOH). Mp: 129.5–131.7. <i>R</i><sub>f</sub> 0.32 (heptanes/EtOAc, 1:1 + 1% AcOH).</div></div><div id="sec4-1-39" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (2<i>S</i>,3<i>R</i>)-1-(<i>tert</i>-Butoxycarbonyl)-3-(3-carboxy-4-fluorophenyl)pyrrolidine-2-carboxylic Acid (<b>7k</b>)</h4><div class="NLM_p last">A solution of NaIO<sub>4</sub> (496 mg, 2.32 mmol, 8.2 equiv) and RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O (3.5 mg, 0.017 mmol, 0.06 equiv) in H<sub>2</sub>O (3.51 mL) was added to a solution of <b>6k</b> (92 mg, 0.283 mmol, 1 equiv) in MeCN/EtOAc (1:1, 3.98 mL) cooled to 0 °C. The reaction mixture was stirred for 2 h, then was filtered through filter paper, and the filter cake was washed with EtOAc. The aqueous layer was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to give 93 mg. The crude was purified by column chromatography (eluent: hept/EtOAc 1/3 + 1% AcOH) to afford the title compound as white needles (89 mg, 89% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ (two rotamers) 7.91 (dd, <i>J</i> = 6.8, 2.5 Hz, 1H), 7.49 (ddd, <i>J</i> = 8.6, 4.4, 2.5 Hz, 1H), 7.15 (dt, <i>J</i> = 14.4, 7.2 Hz, 1H), 4.39 (d, <i>J</i> = 6.4 Hz, 0.5H), 4.22 (d, <i>J</i> = 7.3 Hz, 0.5H), 3.88–3.45 (m, 3H), 2.33 (dt, <i>J</i> = 12.4, 6.1 Hz, 1H), 2.10–1.99 (m, 1H), 1.51 (s, 5H), 1.43 (s, 4H). <sup>13</sup>C NMR (MeOD) δ (two rotamers) 177.9, 176.4, 174.4, 168.4, 168.3, 162.7, 162.6, 161.0, 160.9, 156.2, 153.7, 136.7, 136.2, 134.53, 134.47, 134.0, 133.9, 131.8, 131.4, 118.0, 117.90, 117.86, 117.7, 82.2, 81.3, 65.8, 65. 6, 49.3, 46.8, 46.6, 46.2, 33.0, 32.7, 28.5, 28.4, 20.7. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>21</sub>FNO<sub>6</sub> [M + H]<sup>+</sup> 354.1, found 254.1 [(M + H)-Boc]<sup>+</sup>. Mp: 168.5–170.6 °C. <i>R</i><sub>f</sub> 0.16 (heptanes/EtOAc, 3:1 + 1% AcOH).</div></div><div id="sec4-1-40" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (2<i>S</i>,3<i>R</i>)-1-(<i>tert</i>-Butoxycarbonyl)-3-(3-carboxy-4-chlorophenyl)pyrrolidine-2-carboxylic Acid (<b>7l</b>)</h4><div class="NLM_p last">A solution of NaIO<sub>4</sub> (164 mg, 7.68 mmol, 8.2 equiv) and RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O (11.6 mg, 0.056 mmol, 0.06 equiv) in H<sub>2</sub>O (11.6 mL) was added to a solution of <b>6l</b> (320 mg, 0.936 mmol, 1 equiv) in MeCN/EtOAc (1:1, 13.2 mL) cooled to 0 °C. The reaction mixture was stirred for 2 h, then was filtered through filter paper, and the filter cake was washed with EtOAc. The aqueous layer was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by column chromatography (heptanes/EtOAc, 1:3 + 1% AcOH) to afford the title compound as a white solid (205 mg, 51% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (two rotamers) 7.88 (d, <i>J</i> = 2.1 Hz, 1H), 7.46 (dd, <i>J</i> = 8.1, 4.4 Hz, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 1H), 6.91 (br s, 2H), 4.40 (d, <i>J</i> = 6.2 Hz, 0.5H), 4.24 (d, <i>J</i> = 7.2 Hz, 0.5H), 3.85–3.48 (m, 3H), 2.41–2.30 (m, 1H), 2.03 (dt, <i>J</i> = 9.1, 8.6 Hz, 1H), 1.51 (s, 5H), 1.44 (s, 4H). <sup>13</sup>C NMR (MeOD) δ (two rotamers) 175.7, 175.3, 169.0, 168.9, 156.0, 155.6, 141.7, 141.2, 132.93, 132.87, 132.80, 132.76, 132.7, 132.31, 132.27, 132.2, 131.1, 130.9, 82.0, 81.6, 67.2, 66.6, 50.5, 47.3, 47.1, 33.8, 33.2, 28.7, 28.5. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>17</sub>H<sub>21</sub>ClNO<sub>6</sub> [M + H]<sup>+</sup> 370.1, found 270.0 [(M + H)-Boc]<sup>+</sup>. Mp: 184.2–185.6 °C. <i>R</i><sub>f</sub> 0.26 (heptanes/EtOAc, 3:1 + 1% AcOH).</div></div><div id="sec4-1-41" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 3-(3-Bromophenyl)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carboxylate (<b>8b</b>)</h4><div class="NLM_p">In a flame-dried flask a solution of <b>4b</b> (803 mg, 1.66 mmol, 1 equiv) in dry THF (5.1 mL) was cooled to −78 °C. LiBEtH<sub>3</sub> 1 M (THF solution) (1.99 mL, 1.99 mmol, 1.2 equiv) was added via syringe dropwise, and the reaction mixture was stirred for 1 h, quenched with sat. NaHCO<sub>3</sub> (3 mL), and warmed to rt. The aqueous phase was extracted with EtOAc (3 × 5 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated to give the corresponding hemiaminal <b>5b</b>, which was used in the next step without further purification.</div><div class="NLM_p">In a flame-dried flask a solution of the crude hemiaminal <b>5b</b> (1.66 mmol, 1 equiv) in dry DCM (5.3 mL) was cooled to −78 °C. HSiEt<sub>3</sub> (0.53 mL, 3.31 mmol, 2 equiv) and BF<sub>3</sub>·Et<sub>2</sub>O (0.46 mL, 3.65 mmol, 2.2 equiv) were added sequentially via syringe, and the reaction mixture stirred for 4.5 h. The reaction was quenched with sat. NaHCO<sub>3</sub> (4 mL) and warmed to rt. The mixture was diluted with DCM, and the organic phase was separated, washed with sat. NH<sub>4</sub>Cl (5 mL), dried over MgSO<sub>4</sub>, and concentrated to dryness to give crude alcohol <b>6b</b>.</div><div class="NLM_p last">TBSCl (300 mg, 1.99 mmol, 1.2 equiv) was added to a solution of the crude alcohol <b>6b</b> (1.66 mmol, 1 equiv) and imidazole (282 mg, 4.14 mmol, 2.5 equiv) in dry DMF (11.7 mL) under nitrogen at rt. The reaction mixture was stirred overnight, then poured into H<sub>2</sub>O. The aqueous layer was extracted with Et<sub>2</sub>O (3 × 10 mL), and the collective organic layers were washed with 1 M HCl (10 mL) and brine (10 mL), dried over MgSO<sub>4</sub> and concentrated to give 839 mg (crude). The crude product was purified by flash chromatography (heptanes/EtOAc, 9:1) to afford the title compound as a colorless oil (572 mg, 73% over three steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.39–7.32 (m, 2H), 7.16 (dd, <i>J</i> = 16.8, 9.0 Hz, 2H), 4.03–3.27 (m, 6H), 2.35–2.19 (m, 1H), 1.96–1.80 (m, 1H), 1.48 (s, 9H), 0.89 (s, 9H), 0.04 (s, 3H), 0.04 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.3, 146.6, 146.2, 130.7, 130.6, 130.6, 130.3, 129.7, 126.1, 126.0, 122.8, 79.8, 79.4, 65.5, 65.4, 63.2, 61.8, 47.0, 46.6, 46.4, 45.5, 32.8, 31.7, 28.7, 26.0, 18.3, −5.3. <i>R</i><sub>f</sub> 0.27 (heptanes/EtOAc, 9:1).</div></div><div id="sec4-1-42" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 2-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-3-(3-cyanophenyl)pyrrolidine-1-carboxylate (<b>8g</b>)</h4><div class="NLM_p last">Aryl bromide <b>8b</b> (500 mg, 1.06 mmol, 1 equiv), Zn(CN)<sub>2</sub> (75 mg, 0.64 mmol, 0.6 equiv), Zn powder (8.3 mg, 0.127 mmol, 0.12 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (48.6 mg, 0.053 mmol, 0.05 equiv), and dppf (58.9 mg, 0.106 mmol, 0.1 equiv) were placed in a 10 mL oven-dried flask, which was evacuated and backfilled with N<sub>2</sub>. Dry dimethylacetamide (2.1 mL) was added, and the reaction mixture was stirred at 120 °C for 75 min, then cooled to rt and diluted with EtOAc (5 mL). The organic phase was washed with sat. NaHCO<sub>3</sub>, brine, dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by column chromatography (heptanes/EtOAc, 95:5) to give the title compound a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.53–7.35 (m, 4H), 3.99–3.58 (m, 4H), 3.57–3.49 (m, 1H), 3.42–3.29 (m, 1H), 2.30 (dtd, <i>J</i> = 12.8, 7.3, 5.6 Hz, 1H), 1.87 (dq, <i>J</i> = 14.3, 7.2 Hz, 1H), 1.47 (s, 9H), 0.86 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.1, 145.5, 145.3, 131.9, 131.7, 131.0, 130.2, 129.5, 118.8, 112.7, 79.9, 79.5, 65.2, 63.2, 61.8, 46.7, 46.6, 46.1, 45.4, 32.5, 31.6, 28.6, 25.8, 18.2, −5.4. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>18</sub>H<sub>29</sub>N<sub>2</sub>OSi [(M + H)-Boc]<sup>+</sup> 317.2, found 317.2. <i>R</i><sub>f</sub> 0.59 (heptanes/EtOAc, 2:1)</div></div><div id="sec4-1-43" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (2<i>S</i>,3<i>R</i>)-<i>tert</i>-Butyl 2-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine-1-carboxylate (<b>8i</b>)</h4><div class="NLM_p last">(BPin)<sub>2</sub> (380 mg, 1.50 mmol, 1.1 equiv), PdCl<sub>2</sub>(dppf) (49.7 mg, 0.068 mmol, 0.05 equiv), and KOAc (400 mg, 4.08 mmol, 3.0 equiv) were placed in an oven-dried flask, which was evacuated and backfilled with nitrogen. A solution of aryl bromide <b>8</b> (640 mg, 1.36 mmol, 1.0 equiv) in dry DMF (8.2 mL) was added via syringe, and the reaction mixture was stirred at 80 °C for 5 h. The reaction mixture was cooled to rt and diluted with H<sub>2</sub>O (10 mL). The aqueous layer was extracted with Et<sub>2</sub>O (3 × 10 mL), and the combined organic layers were washed with HCl 1 M (1 × 10 mL), brine (1 × 10 mL), dried over MgSO<sub>4</sub>, and concentrated. The crude product was purified by column chromatography (heptanes/EtOAc, 95:5) to give the title compound as a colorless oil (431 mg, 61%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.71–7.64 (m, 2H), 7.36–7.27 (m, 2H), 4.10–3.49 (m, 5H), 3.43–3.23 (m, 1H), 2.31–2.19 (m, 1H), 1.99–1.88 (m, 1H), 1.49 (s, 9H), 1.34 (s, 12H), 0.89 (s, 9H), 0.04 (s, 6H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (two rotamers) 154.4, 154.3, 143.2, 142.7, 133.9, 133.7, 133.0, 130.5, 130.3, 129.4 (bs), 128.2, 83.9, 79.5, 79.1, 65.5, 65.4, 63.0, 61.5, 47.2, 46.7, 46.5, 45.7, 33.0, 31.8, 28.7, 26.0, 25.0, 25.0, 18.3, −5.3. LC–MS (<i>m</i>/<i>z</i>) calcd. for C<sub>28</sub>H<sub>49</sub>BNO<sub>5</sub>Si [M + H]<sup>+</sup> 518.3, found 336.2 [(M + H)-Boc-Pin]<sup>+</sup>. <i>R</i><sub>f</sub> 0.16 (heptanes/EtOAc, 95:5).</div></div></div><div id="sec4-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Pharmacological Studies</h3><div class="NLM_p last">All reagents and solvents were commercial and of high purity analytical grade or ultragradient HPLC-grade purchased from Sigma, (St. Louis, MO, USA), J.T. Baker (Denventer, The Netherlands), Merck (Darmstadt, Germany), or Riedel-de Haën (Seelze, Germany). Water was purified using a Milli-Q Gradient system (Millipore, Milford, MA, USA). LPS from <i>Escherichia coli</i> 055:B5 and fluorescein were purchased from Sigma (St. Louis, MO, USA). [<sup>3</sup>H]-digoxin, 250 μCi (9.25 MBq), and Emulsifier safe liquid scintillation cocktail were purchased from PerkinElmer (Boston, MA, USA). Prostaglandin E2 was purchased from Biotechne Ltd. (Abingdon, UK) and sorafenib from Cayman Chemical (Ann Arbor, MI, USA).</div></div><div id="sec4-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Liquid Chromatographic and Mass Spectrometric (LC–MS/MS) Analyses</h3><div class="NLM_p last">An Agilent 1200 Series Rapid Resolution LC System was used together with a Poroshell 120 EC-C-18 column (50 mm × 2.1 mm, 2.7 μm) for liquid chromatography prior to MS analysis of compound <b>1l</b>, sorafenib, and PGE<sub>2</sub> with Agilent 6410 triple quadrupole mass spectrometer equipped with an electrospray ionization source (Agilent Technologies Inc., Wilmington, DE). The high-performance liquid chromatography eluents were water (A) containing 0.1% (v/v) formic acid and acetonitrile (B). For the compound <b>1l</b>, a gradient elution with 5–60% B was applied over 1–3 min, followed by 1 min of isocratic elution with 60% B and 3 min column equilibration, giving a total time of 7 min/injection. For sorafenib, a gradient elution with 20–90% B was applied over 1–4 min, followed by 1 min of isocratic elution with 90% B and 3 min column equilibration, giving a total time of 8 min/injection. For PGE<sub>2</sub> an isocratic method with 10% B was used. For all compounds the eluent flow rate was 0.2 mL/min, the column temperature was 40 °C, and injection volume was 5 μL. The following mass spectrometry conditions were used for the compound <b>1l</b>, sorafenib, and PGE<sub>2</sub>. Electrospray ionization: positive ion mode for compound <b>1l</b>, sorafenib and negative ion mode for PGE<sub>2</sub>; drying gas (nitrogen) temperature, 300 °C; drying gas flow rate, 8 L/min; nebulizer pressure, 20 psi; and capillary voltage, 3500 V. Analyte detection was performed using multiple reaction monitoring, the transitions being 270.1 → 114.5 and 236.1 → 190 for compound <b>1l</b> and <b>1a</b> (internal standard), respectively. The transitions for sorafenib and the used internal standard, diclofenac, were 465.1 → 252.2 and 296.1 → 250, respectively. The transition for PGE<sub>2</sub> was 315.4 → 314.5. Fragmentor voltages used for compound <b>1l</b>, <b>1a</b>, sorafenib, diclofenac, and PGE<sub>2</sub> were 60, 140, 140, 100, and 180 V, and the collision energies were 40, 16, 30, 10, and 6 V, respectively. Agilent MassHunter Workstation Acquisition software (Data Acquisition for Triple Quadrupole Mass Spectometer, version B.03.01) was used for data acquisition, and Quantitative Analysis (B.04.00) software was used for the data processing and analysis. The compound <b>1l</b> lower limit of quantification for the brain, liver, and plasma samples were 0.02 nmol/g, 0.02 nmol/g, and 0.5 μM respectively. The lower limit of quantification for sorafenib and PGE<sub>2</sub> in cell samples was 1 nM. Linearity of the calibration curves was evaluated by a quadratic regression analysis. The method was also selective, accurate, and precise over the calibration range. Within-run accuracy and precision were calculated from the results of the quality control samples at the three concentrations. The accuracies and precisions for quality control concentrations of 20% were considered to be acceptable.</div></div><div id="sec4-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Preparation of Crude Membrane Fractions of Mouse HCC Cells</h3><div class="NLM_p last">Mouse <i>Nras</i> driven <i>p</i>53<sup>–/–</sup> HCC cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with <span class="smallcaps smallerCapital">l</span>-glutamine (2 mM), heat-inactivated fetal bovine serum (10%), penicillin (50 U/mL), and streptomycin (50 μg/mL). The cells were incubated for 48 h with or without 10 μM of compound <b>1l</b>, washed three times with HBSS, followed by centrifugation of the cells into a pellet and rapid freezing in liquid nitrogen. ProteoExtract Subcellular Proteome Extraction Kit (Merck KGaA, Darmstadt, Germany) was used for the isolation of crude membrane fraction from the cell pellets following the manufacturer’s instructions. The protein concentrations in the crude membrane fractions were determined as mean of three samples by Bio-Rad Protein Assay (EnVision, PerkinElmer, Inc., Waltham, MA, USA), and aliquots containing 50 μg of total protein were taken for further sample preparation.</div></div><div id="sec4-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Protein Quantification by Multiplexed Selected/Multiple Reaction Monitoring by LC–MS/MS</h3><div class="NLM_p">The protein expressions of the investigated transporters were simultaneously determined by means of multiplexed multiple reaction monitoring analysis. The aliquots containing 50 μg of protein from the crude membrane fractions were solubilized in 500 mM Tris–HCl (pH 8.5), 7 M guanidine hydrochloride, and 10 mM EDTA, and the proteins were <i>S</i>-carbamoylmethylated with iodoacetamide following dithiothreitol treatment. The alkylated proteins were precipitated using methanol and chloroform. The precipitates were dissolved in 6 M urea in 100 mM Tris–HCl (pH 8.5), diluted five-fold with 100 mM Tris–HCl (pH 8.5), spiked with internal standard peptides, and treated with Protease-Max surfactant (Promega, Madison, WI, USA). The dilutions were treated with lysyl endopeptidase (Lys-C: Wako Pure Chemical Industries, Osaka, Japan) at rt for 3 h, after which tosylphenylalanyl chloromethyl ketone-treated trypsin (Promega, Madison, WI, USA) at an enzyme/substrate ratio of 1:100 was added into the samples and incubated at 37 °C for 16 h. The tryptic digests were mixed formic acid and then centrifuged at 4 °C and 14 000<i>g</i> for 5 min. The supernatant was mixed with water prior to LC–MS/MS analysis.</div><div class="NLM_p">LC–MS/MS analysis was performed by coupling an Agilent 1290 Infinity LC (Agilent Technologies, Waldbronn, Germany) instrumentation to an Agilent 6495 Triple Quadrupole Mass Spectrometer with an electrospray ionization (ESI) source (Agilent Technologies, Palo Alto, CA, USA) using multiple reaction monitoring (MRM). The following conditions were applied: positive ionization mode, the drying gas (nitrogen) was maintained at 210 °C, drying gas flow rate was 16 L/min, nebulizer gas pressure was 45 psi, sheath gas temperature 300 °C, sheath gas flow 11 L/min, fragmentor voltage was 380 V, and the mass-spectrometer (MS) capillary voltage was 3.0 kV. The following ion funnel parameters were used for both positive and negative ionization: high-pressure ion funnel RF voltage 200 V, and low-pressure ion funnel RF voltage 100 V. An injection volume of 15 μL was used, and analytes were separated by AdvanceBio Peptide Map 2.1 × 250 mm, 2.7 μm. Mobile phases A and B, respectively, consisted of 0.1% formic acid in milli-Q water and acetonitrile. The gradient sequence was as follows: flow rate of 0.30 mL/min, 50 min of total run time, 97:3 to 60:40 (A:B) during 40 min after injection, 5:95 at 44 min, 97:3 at 45 min, and constant 97:3 for 5 min. The eluted peptides were selectively and simultaneously analyzed by SRM/MRM mode with LC–MS/MS. For each target protein, one unique peptide was chosen according to previously published work.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> These peptides were monitored with two or three different SRM/MRM transition sets (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>) derived from one set of stable isotope-labeled peptides purchased from JPT Peptide Technologies GmbH (Berlin, Germany) and unlabeled peptides.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Probe Peptides and MRM Transitions for the LC–MS/MS Analysis of Investigated Transporters</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">MRM transitions (<i>m</i>/<i>z</i>)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">transporter</th><th class="colsep0 rowsep0" align="center">St/Is</th><th class="colsep0 rowsep0" align="center">probe peptide sequence</th><th class="colsep0 rowsep0" align="center">Q1</th><th class="colsep0 rowsep0" align="center">Q3.1</th><th class="colsep0 rowsep0" align="center">Q3.2</th><th class="colsep0 rowsep0" align="center">Q3.3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">Abcb1</td><td class="colsep0 rowsep0" align="left">St</td><td class="colsep0 rowsep0" align="left">NTTGALTTR</td><td class="colsep0 rowsep0" align="left">467.8</td><td class="colsep0 rowsep0" align="left">618.4</td><td class="colsep0 rowsep0" align="left">719.4</td><td class="colsep0 rowsep0" align="left">516.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Is</td><td class="colsep0 rowsep0" align="left">NTTGALTTR<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">472.6</td><td class="colsep0 rowsep0" align="left">628.4</td><td class="colsep0 rowsep0" align="left">729.4</td><td class="colsep0 rowsep0" align="left">571.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">Abcg2</td><td class="colsep0 rowsep0" align="left">St</td><td class="colsep0 rowsep0" align="left">SSLLDVLAAR</td><td class="colsep0 rowsep0" align="left">522.8</td><td class="colsep0 rowsep0" align="left">757.5</td><td class="colsep0 rowsep0" align="left">644.3</td><td class="colsep0 rowsep0" align="left">529.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Is</td><td class="colsep0 rowsep0" align="left">SSLLDVLAAR<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">527.8</td><td class="colsep0 rowsep0" align="left">767.5</td><td class="colsep0 rowsep0" align="left">654.4</td><td class="colsep0 rowsep0" align="left">539.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">Abcc2</td><td class="colsep0 rowsep0" align="left">St</td><td class="colsep0 rowsep0" align="left">LTIIPQDPILFSGNLR</td><td class="colsep0 rowsep0" align="left">899.0</td><td class="colsep0 rowsep0" align="left">1356.7</td><td class="colsep0 rowsep0" align="left">678.9</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Is</td><td class="colsep0 rowsep0" align="left">LTIIPQDPILFSGNLR<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">904.0</td><td class="colsep0 rowsep0" align="left">1366.7</td><td class="colsep0 rowsep0" align="left">683.9</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">Abcc4</td><td class="colsep0 rowsep0" align="left">St</td><td class="colsep0 rowsep0" align="left">APVLFFDR</td><td class="colsep0 rowsep0" align="left">482.8</td><td class="colsep0 rowsep0" align="left">796.4</td><td class="colsep0 rowsep0" align="left">697.4</td><td class="colsep0 rowsep0" align="left">584.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Is</td><td class="colsep0 rowsep0" align="left">APVLFFDR<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">487.8</td><td class="colsep0 rowsep0" align="left">806.4</td><td class="colsep0 rowsep0" align="left">707.4</td><td class="colsep0 rowsep0" align="left">594.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">Slc7a5</td><td class="colsep0 rowsep0" align="left">St</td><td class="colsep0 rowsep0" align="left">VQDAFAAAK</td><td class="colsep0 rowsep0" align="left">460.8</td><td class="colsep0 rowsep0" align="left">693.4</td><td class="colsep0 rowsep0" align="left">578.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Is</td><td class="colsep0 rowsep0" align="left">VQDAFAAAK<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">464.8</td><td class="colsep0 rowsep0" align="left">701.4</td><td class="colsep0 rowsep0" align="left">586.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">Slc2a1</td><td class="colsep0 rowsep0" align="left">St</td><td class="colsep0 rowsep0" align="left">TFDEIASGFR</td><td class="colsep0 rowsep0" align="left">571.8</td><td class="colsep0 rowsep0" align="left">894.4</td><td class="colsep0 rowsep0" align="left">537.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Is</td><td class="colsep0 rowsep0" align="left">TFDEIASGFR<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">576.8</td><td class="colsep0 rowsep0" align="left">904.4</td><td class="colsep0 rowsep0" align="left">547.3</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Denotes <sup>13</sup>C-labeled arginine and lysine.</p></div></div></div></div><div id="sec4-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Ability of Compound <b>1l</b> To Alter the Cell Accumulation of Transporter Probes and Sorafenib</h3><div class="NLM_p last">The ability of compound <b>1l</b> to increase the cell accumulation of Abcb1 probe [<sup>3</sup>H]-digoxin, Abcc1–5 probe fluorescein, and Abcb1 and Abcg2 substrate sorafenib as well as to decrease cell accumulation of Slc7a5 probe [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine and Slc2a1 probe [<sup>14</sup>C]-<span class="smallcaps smallerCapital">d</span>-glucose was determined in mouse <i>Nras</i> driven <i>p</i>53<sup>–/–</sup> HCC cells. The cells were cultured in DMEM supplemented with <span class="smallcaps smallerCapital">l</span>-glutamine (2 mM), heat-inactivated fetal bovine serum (10%), penicillin (50 U/mL), and streptomycin (50 μg/mL). HCC cells were seeded at the density of 1 × 10<sup>5</sup> cells/well onto 24-well plates. After seeding, the cells were incubated for 24 h with or without 10 μM of compound <b>1l</b>. In order to ensure that compound <b>1l</b> does not inhibit the function of the efflux transporters, the incubation medium was removed and the cells were carefully washed three times with prewarmed Hank’s balance salt solution (HBSS) containing 125 mM choline chloride, 4.8 mM KCl, 1.2 mM MgSO<sub>4</sub>, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 1.3 mM CaCl<sub>2</sub>, 5.6 mM glucose, 100 μM leucine, and 25 mM HEPES (pH 7.4), after which a transporter probe, [<sup>3</sup>H]-digoxin, [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine, [<sup>14</sup>C]-<span class="smallcaps smallerCapital">d</span>-glucose, 20 μM fluorescein, or 10 μM sorafenib, was added in prewarmed HBSS buffer (250 μL) on the top of the cell layer and incubating at 37 °C for 30 min for [<sup>3</sup>H]-digoxin, fluorescein and sorafenib or 5 min for [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine and [<sup>14</sup>C]-<span class="smallcaps smallerCapital">d</span>-glucose. Subsequently, the cells were washed three times with ice-cold HBSS and lysed with 500 μL of 0.1 M NaOH. The protein concentrations in each well were determined by Bio-Rad Protein Assay (EnVision, PerkinElmer, Inc., Waltham, MA, USA). The lysate from the [<sup>3</sup>H]-digoxin, [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine, and [<sup>14</sup>C]-<span class="smallcaps smallerCapital">d</span>-glucose samples was mixed with 3.5 mL of emulsifier safe liquid scintillation cocktail. The radioactivity was measured by liquid scintillation counting (Wallac 1450 MicroBeta; Wallac Oy, Finland). The fluorescein samples were measured using fluorescein detector (EnVision, PerkinElmer, Inc., Waltham, MA, USA), and the sorafenib concentrations were determined by the LC–MS/MS.</div></div><div id="sec4-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Live Imaging of Murine HCC Cell Culture</h3><div class="NLM_p last">The cells were loaded with the Ca<sup>2+</sup> sensitive fluorescent dye Fluo-4-AM (5 μM) for 45 min followed by a 20 min washout in the BSS containing the following (in millimolar): 2.5 KCl, 152 NaCl, 10 glucose, 2 CaCl<sub>2</sub>, and 10 HEPES at pH 7.4. Fluorescence was visualized using the imaging setup (TILL Photonics GmbH) consisting of a monochromatic light source and a CCD camera (SensiCam). Cells loaded with Fluo-4 were imaged with an excitation light of 495 nm (exposure time 100 ms, binning 2). Chemicals were applied using a fast perfusion system (Rapid Solution Changer RSC-200, BioLogic Science). Data were analyzed offline using the TILL Photonics and Origin 8 software.</div></div><div id="sec4-8" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Ability of <b>1l</b> To Decrease PGE<sub>2</sub> Concentration in the Cells</h3><div class="NLM_p last">The ability of compound <b>1l</b> to decrease PGE<sub>2</sub> synthesis was studied in HCC cells with and without LPS-induced inflammation. The LPS concentration in the growth medium was 2.5 μg/mL. The cells were incubated 24 h with or without 100 μM compound <b>1l</b>. Subsequently, the cells were washed three times with ice-cold HBSS, and then lysed with 500 μL of acetonitrile on ice. The PGE<sub>2</sub> concentrations from the cell lysates were determined by the LC–MS/MS.</div></div><div id="sec4-9" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Antiproliferative Activity <i>in Vitro</i></h3><div class="NLM_p last">The mouse HCC cells were seeded at the density of 2 × 10<sup>4</sup> cells/well onto collagen-coated 96-well plates, and the cells were used for the experiments 1 day after seeding. A concentration of 1, 2.5, 5, and 10 μM sorafenib, 100 μM compound <b>1l</b>, and the combination of all the mentioned sorafenib concentrations with 100 μM compound <b>1l</b> were added into the growth medium and incubated for 3 days. Each day the medium was changed, and after the 72 h incubation, the cell viability was determined by resazurin cell proliferation kit (Sigma, St. Louis, MO, USA), which is directly proportional to aerobic respiration and cellular metabolism of cells. The samples were measured fluorometrically by monitoring the increase in fluorescence at a wavelength of 590 nm using an excitation wavelength of 560 nm (EnVision, PerkinElmer, Inc., Waltham, MA, USA). The cell death was confirmed in the decrease of cell amount by visualizing the wells with microscopy.</div></div><div id="sec4-10" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Animals</h3><div class="NLM_p last">Adult male mice weighing 25 ± 5 g were supplied by the National Laboratory Animal Centre (Kuopio, Finland). Mice were housed in stainless steel cages on a 12 h light (07:00–19:00) and 12 h dark (19:00–07:00) cycle at an ambient temperature of 22 ± 1 °C with a relative humidity of 50–60%. All experiments were carried out during the light phase. Tap water and food pellets (Lactamin R36; Lactamin AB, Södertälje, Sweden) were available ad libitum. All procedures with the animals were performed according to European Community Guidelines and Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85–23, revised in 1985). The procedures were reviewed and approved by the Finnish National Animal Experiment Board.</div></div><div id="sec4-11" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> <i>In Situ</i> Mouse Brain Perfusion</h3><div class="NLM_p last">Mice were anesthetized with intraperitoneal (i.p.) injections of ketamine (120 mg/kg) and xylazine (8 mg/mL), and their right carotid artery system was exposed. The right external carotid artery was ligated, and the right common carotid artery was cannulated with a catheter filled with 100 IU/mL heparin. The perfusions were performed at 37 °C with a flow rate of 2.5 mL/min for 60 s followed by the washing of the capillaries for 2 s with 4 °C drug-free perfusion buffer. The method is described in more detail by Gynther et al.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div><div id="sec4-12" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> <i>In Vivo</i> Pharmacokinetics of Compound <b>1l</b></h3><div class="NLM_p last">A 5.0 mM concentration of compound <b>1l</b> was dissolved in a vehicle containing 0.9% (w/v) NaCl in water. A dose of 10 mg/kg of compound <b>1l</b> was administered as a bolus injection (i.p.) to mice. The mice were sacrificed by decapitation at selected time points between (10–240 min), and plasma, brain, and liver were collected for analysis.</div></div><div id="sec4-13" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Plasma and Tissue Sample Preparation</h3><div class="NLM_p last">Plasma samples were prepared by precipitating 100 μL of plasma with 200 μL of acetonitrile containing the internal standard (<b>1a</b>). Samples were vortexed and centrifuged for 10 min at 14 000<i>g</i> at 4 °C. Then 100 μL of supernatant was mixed with 100 μL of ultrapure water prior to LC–MS/MS analysis. Tissue samples were weighed and homogenized with ultrapure water (1:3). An aliquot of 100 μL was taken, and the analyte was isolated from the samples by protein precipitation with 300 μL of acetonitrile containing the internal standard. Samples were vortexed and centrifuged for 10 min at 14 000<i>g</i> at 4 °C. Then 200 μL of supernatant was mixed with 100 μL of ultrapure water prior to LC–MS/MS analysis.</div></div><div id="sec4-14" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Two-Electrode Voltage-Clamp Electrophysiology</h3><div class="NLM_p last">Rat cDNAs encoding GluN1–1a (Genbank accession number <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=U11418">U11418</a> and <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=U08261">U08261</a>; hereafter GluN1), GluN2A (<a href="https://www.ncbi.nlm.nih.gov/gquery?Term=D13211">D13211</a>), GluN2B (<a href="https://www.ncbi.nlm.nih.gov/gquery?Term=U11419">U11419</a>), GluN2C (<a href="https://www.ncbi.nlm.nih.gov/gquery?Term=M91563">M91563</a>), and GluN2D (<a href="https://www.ncbi.nlm.nih.gov/gquery?Term=L31611">L31611</a>) were generously provided by Dr. S. Heinemann (Salk Institute, La Jolla, CA), Dr. S. Nakanishi (Osaka Bioscience Institute, Osaka, Japan), and Dr. P. Seeburg (University of Heidelberg). The cDNA encoding rat GluN2B was modified without changing the amino acid sequence to remove a T7 RNA polymerase termination site located in the C-terminal domain.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> For expression in <i>Xenopus laevis</i> oocytes, cDNAs were linearized using restriction enzymes and used as templates to synthesize cRNA using the mMessage mMachine kit (Ambion, Life Technologies, Paisley, UK). <i>Xenopus</i> oocytes were obtained from Rob Weymouth (<i>Xenopus</i> 1, Dexter, MI) and prepared as previously described.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The oocytes were injected with cRNAs encoding GluN1 and GluN2 in a 1:2 ratio and maintained at 18 °C in Barth’s solution containing 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO<sub>3</sub>, 0.82 mM MgSO<sub>4</sub>, 0.33 mM Ca(NO<sub>3</sub>)<sub>2</sub>, 0.91 mM CaCl<sub>2</sub>, 10 mM HEPES (pH 7.5 with NaOH) supplemented with 100 IU/mL penicillin, 100 μg/mL streptomycin, and 50 μg/mL gentamycin (Invitrogen, Life Technologies, Paisley, UK). Two-electrode voltage-clamp recordings were performed on <i>Xenopus</i> oocytes at rt 2–6 days postinjection with the extracellular recording solution comprising 90 mM NaCl, 1 mM KCl, 10 mM HEPES, 0.5 mM BaCl<sub>2</sub>, and 0.01 mM EDTA (pH 7.4 with NaOH) at a holding potential of −40 mV essentially as previously described.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> NMDA receptor ligands were dissolved in extracellular recording solution and applied to the oocyte by gravity-driven perfusion.</div></div><div id="sec4-15" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Data Analysis</h3><div class="NLM_p last">All statistical analyses were performed using GraphPad Prism v. 5.03 software (GraphPad Software, San Diego, CA, USA). Statistical differences between groups were tested using two-tailed <i>t</i> test (<a class="ref internalNav" href="#fig1" aria-label="Figures 1">Figures 1</a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Concentration–inhibition data were measured using two-electrode voltage-clamp electrophysiology fitted to the Hill equation to obtain IC<sub>50</sub> values for individual oocytes as previously described.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The sorafenib IC<sub>50</sub> value for cytotoxicity in murine HCC cells was calculated by nonlinear regression analysis and presented as the mean ± SEM. The pharmacokinetic parameters, AUC<sub>0–240 min</sub>, <i>C</i><sub>max</sub>, <i>t</i><sub>max</sub>, and <i>t</i><sub>1/2β</sub> in plasma, brain, and liver, were obtained from the pharmacokinetic data.</div></div><div id="sec4-16" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Radioligand Binding</h3><div class="NLM_p last">Ligand affinities at native AMPA, KA, and NMDA receptors (rat brain synaptosomes) were determined using [<sup>3</sup>H]AMPA, [<sup>3</sup>H]KA, and [<sup>3</sup>H]CGP-39653, respectively, as previously described.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Ligand affinities at recombinant homomeric rat GluK1–3 were determined using [<sup>3</sup>H]KA as the radioligand as previously detailed (Sagot et al. and Alcaide et al.).<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> Data were analyzed using GraphPad Prism 7 (GraphPad Software, San Diego, CA) to determine ligand IC<sub>50</sub> and <i>K</i><sub>i</sub> values.</div></div><div id="sec4-17" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> In Silico Studies</h3><div class="NLM_p last">Calculation of LogP(o/w) and total polar surface area (TPSA) was done in MOE version 2016.08.02 released by Chemcomp corporation.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="NOTES-d53e6813-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01624">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01624" class="ext-link">10.1021/acs.jmedchem.7b01624</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">SMILES (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01624/suppl_file/jm7b01624_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01624/suppl_file/jm7b01624_si_001.csv">jm7b01624_si_001.csv (1.11 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01624" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mikko Gynther</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#89e4e0e2e2e6a7eef0e7fde1ecfbc9fcecefa7efe0"><span class="__cf_email__" data-cfemail="adc0c4c6c6c283cad4c3d9c5c8dfedd8c8cb83cbc4">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lennart Bunch</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0180-4639" title="Orcid link">http://orcid.org/0000-0002-0180-4639</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7d11181f083d0e081319531608531916"><span class="__cf_email__" data-cfemail="dfb3babdaa9facaab1bbf1b4aaf1bbb4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ilaria Proietti Silvestri</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob C. Hansen</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kasper B. Hansen</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical and Pharmaceutical Sciences and Center for Biomolecular
Structure and Dynamics, University of Montana, Missoula, Montana 59812, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3303-4819" title="Orcid link">http://orcid.org/0000-0002-3303-4819</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tarja Malm</span> - <span class="hlFld-Affiliation affiliation">Department
of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211 Kuopio, Finland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yevheniia Ishchenko</span> - <span class="hlFld-Affiliation affiliation">Department
of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211 Kuopio, Finland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Younes Larsen</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liwei Han</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silke Kayser</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seppo Auriola</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aleksanteri Petsalo</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Birgitte Nielsen</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darryl S. Pickering</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8687-6094" title="Orcid link">http://orcid.org/0000-0001-8687-6094</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>These authors contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank the Lundbeck Foundation and the Danish Medical Research Council for financial support of the medicinal chemistry work reported herein. Emil Aaltonen Foundation and The Finnish Cultural Foundation are acknowledged for the funding regarding the pharmacokinetic analysis, transporter expression modulation, and cytotoxicity studies. Finally, the National Institutes of Health (P20GM103546 and R01NS097536) is acknowledged for financial support in regards to the functional characterization of <b>1l</b> at NMDA receptors. Mrs. Sari Ukkonen is acknowledged for technical assistance. The murine hcc cells were a kind donation by Prof. Lars Zender, Tübingen University.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i86" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i86"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="DEF-LIST-d53e6832-autogenerated"><div id="ac_i87" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i87"> Abbreviations Used</h2><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">Abcb1</td><td class="NLM_def"><p class="first last">ATP-binding cassette subfamily B member 1</p></td></tr><tr><td class="NLM_term">Abcc</td><td class="NLM_def"><p class="first last">ATP-binding cassette subfamily C</p></td></tr><tr><td class="NLM_term">Abcg2</td><td class="NLM_def"><p class="first last">ATP-binding cassette subfamily G member 2</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the concentration curve</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">cPLA2</td><td class="NLM_def"><p class="first last">cytoplasmic phospholipase A2</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DCVC</td><td class="NLM_def"><p class="first last">dry collum vacuum chromatography</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethyl-4-aminopyridine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle medium</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylsulfonamide</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hank’s balance salt solution</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">IBX</td><td class="NLM_def"><p class="first last">2-iodoxybenzoic acid</p></td></tr><tr><td class="NLM_term">LC–MS/MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">MRM</td><td class="NLM_def"><p class="first last">multiple reaction monitoring</p></td></tr><tr><td class="NLM_term">PGE<sub>2</sub></td><td class="NLM_def"><p class="first last">prostaglandin E2</p></td></tr><tr><td class="NLM_term">SRM</td><td class="NLM_def"><p class="first last">selected reaction monitoring</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">TBSCl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl chloride</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time to reach the maximum concentration</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2β</sub></td><td class="NLM_def"><p class="first last">elimination half-life</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04153" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04153" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Holohan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span> </span><span class="NLM_article-title">Cancer Drug Resistance: An Evolving Paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+Drug+Resistance%3A+An+Evolving+Paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0lg7v1NLqgUegA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520Drug%2520Resistance%253A%2520An%2520Evolving%2520Paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Rudalska, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longerich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McJunkin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuestefeld, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, T.-W. T.-W. T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leibold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Thun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirmacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, K.-H. K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, N. P. N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, S. W. S. W. S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geffers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zender, L.</span><span> </span><span class="NLM_article-title">In Vivo RNAi Screening Identifies a Mechanism of Sorafenib Resistance in Liver Cancer</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span><span class="refDoi"> DOI: 10.1038/nm.3679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1038%2Fnm.3679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=25216638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOlt7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1138-1146&author=R.+Rudalskaauthor=D.+Dauchauthor=T.+Longerichauthor=K.+McJunkinauthor=T.+Wuestefeldauthor=T.-W.+T.-W.+T.-W.+Kangauthor=A.+Hohmeyerauthor=M.+Pesicauthor=J.+Leiboldauthor=A.+von+Thunauthor=P.+Schirmacherauthor=J.+Zuberauthor=K.-H.+K.-H.+Weissauthor=S.+Powersauthor=N.+P.+N.+P.+Malekauthor=M.+Eilersauthor=B.+Siposauthor=S.+W.+S.+W.+S.+W.+Loweauthor=R.+Geffersauthor=S.+Lauferauthor=L.+Zender&title=In+Vivo+RNAi+Screening+Identifies+a+Mechanism+of+Sorafenib+Resistance+in+Liver+Cancer&doi=10.1038%2Fnm.3679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer</span></div><div class="casAuthors">Rudalska, Ramona; Dauch, Daniel; Longerich, Thomas; McJunkin, Katherine; Wuestefeld, Torsten; Kang, Tae-Won; Hohmeyer, Anja; Pesic, Marina; Leibold, Josef; von Thun, Anne; Schirmacher, Peter; Zuber, Johannes; Weiss, Karl-Heinz; Powers, Scott; Malek, Nisar P.; Eilers, Martin; Sipos, Bence; Lowe, Scott W.; Geffers, Robert; Laufer, Stefan; Zender, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1138-1146</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In solid tumors, resistance to therapy inevitably develops upon treatment with cytotoxic drugs or molecularly targeted therapies.  Here, we describe a system that enables pooled shRNA screening directly in mouse hepatocellular carcinomas (HCC) in vivo to identify genes likely to be involved in therapy resistance.  Using a focused shRNA library targeting genes located within focal genomic amplifications of human HCC, we screened for genes whose inhibition increased the therapeutic efficacy of the multikinase inhibitor sorafenib.  Both shRNA-mediated and pharmacol. silencing of Mapk14 (p38α) were found to sensitize mouse HCC to sorafenib therapy and prolong survival by abrogating Mapk14-dependent activation of Mek-Erk and Atf2 signaling.  Elevated Mapk14-Atf2 signaling predicted poor response to sorafenib therapy in human HCC, and sorafenib resistance of p-Mapk14-expressing HCC cells could be reverted by silencing Mapk14.  Our results suggest that a combination of sorafenib and Mapk14 blockade is a promising approach to overcoming therapy resistance of human HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquN9Poy48vIbVg90H21EOLACvtfcHk0lg6cuW5WgvJCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOlt7rL&md5=a843ee6d8060b9dcd04083cf1991f97c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnm.3679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3679%26sid%3Dliteratum%253Aachs%26aulast%3DRudalska%26aufirst%3DR.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DLongerich%26aufirst%3DT.%26aulast%3DMcJunkin%26aufirst%3DK.%26aulast%3DWuestefeld%26aufirst%3DT.%26aulast%3DKang%26aufirst%3DT.-W.%2BT.-W.%2BT.-W.%26aulast%3DHohmeyer%26aufirst%3DA.%26aulast%3DPesic%26aufirst%3DM.%26aulast%3DLeibold%26aufirst%3DJ.%26aulast%3Dvon%2BThun%26aufirst%3DA.%26aulast%3DSchirmacher%26aufirst%3DP.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DK.-H.%2BK.-H.%26aulast%3DPowers%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DN.%2BP.%2BN.%2BP.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DSipos%26aufirst%3DB.%26aulast%3DLowe%26aufirst%3DS.%2BW.%2BS.%2BW.%2BS.%2BW.%26aulast%3DGeffers%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DZender%26aufirst%3DL.%26atitle%3DIn%2520Vivo%2520RNAi%2520Screening%2520Identifies%2520a%2520Mechanism%2520of%2520Sorafenib%2520Resistance%2520in%2520Liver%2520Cancer%26jtitle%3DNat.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D1138%26epage%3D1146%26doi%3D10.1038%2Fnm.3679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Szakács, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth-Genthe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Targeting Multidrug Resistance in Cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1038/nrd1984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1038%2Fnrd1984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=16518375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=219-234&author=G.+Szak%C3%A1csauthor=J.+K.+Patersonauthor=J.+A.+Ludwigauthor=C.+Booth-Gentheauthor=M.+M.+Gottesman&title=Targeting+Multidrug+Resistance+in+Cancer&doi=10.1038%2Fnrd1984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting multidrug resistance in cancer</span></div><div class="casAuthors">Szakacs, Gergely; Paterson, Jill K.; Ludwig, Joseph A.; Booth-Genthe, Catherine; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-234</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy.  In most cases, multiple drugs are used, as resistance to single agents occurs almost universally.  For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chem. structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years.  Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters.  We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7LUp3JikHr7Vg90H21EOLACvtfcHk0lg6cuW5WgvJCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D&md5=67ca376f65aa58a71288167f6815a896</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1984%26sid%3Dliteratum%253Aachs%26aulast%3DSzak%25C3%25A1cs%26aufirst%3DG.%26aulast%3DPaterson%26aufirst%3DJ.%2BK.%26aulast%3DLudwig%26aufirst%3DJ.%2BA.%26aulast%3DBooth-Genthe%26aufirst%3DC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DTargeting%2520Multidrug%2520Resistance%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D219%26epage%3D234%26doi%3D10.1038%2Fnrd1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Zhang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.-S.</span><span> </span><span class="NLM_article-title">Multidrug Resistance Proteins (MRPs) and Cancer Therapy</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">–</span> <span class="NLM_lpage">812</span><span class="refDoi"> DOI: 10.1208/s12248-015-9757-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1208%2Fs12248-015-9757-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=802-812&author=Y.-K.+Zhangauthor=Y.-J.+Wangauthor=P.+Guptaauthor=Z.-S.+Chen&title=Multidrug+Resistance+Proteins+%28MRPs%29+and+Cancer+Therapy&doi=10.1208%2Fs12248-015-9757-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1208%2Fs12248-015-9757-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-015-9757-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DZ.-S.%26atitle%3DMultidrug%2520Resistance%2520Proteins%2520%2528MRPs%2529%2520and%2520Cancer%2520Therapy%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26spage%3D802%26epage%3D812%26doi%3D10.1208%2Fs12248-015-9757-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Stacy, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span><span class="refDoi"> DOI: 10.1124/mol.113.088609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fmol.113.088609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24021215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=655-669&author=A.+E.+Stacyauthor=P.+J.+Janssonauthor=D.+R.+Richardson&title=Molecular+Pharmacology+of+ABCG2+and+Its+Role+in+Chemoresistance&doi=10.1124%2Fmol.113.088609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pharmacology of ABCG2 and its role in chemoresistance</span></div><div class="casAuthors">Stacy, Alexandra E.; Jansson, Patric J.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-669</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The ATP-binding cassette, subfamily G, isoform 2 protein (ABCG2) is an important member of the ABC transporter superfamily, which has been suggested to be involved in multidrug resistance (MDR) in cancer.  Its diverse range of substrates includes many common chemotherapeutics such as imatinib, doxorubicin, and mitoxantrone.  Physiol., ABCG2 is highly expressed in areas such as the blood-brain barrier and gastrointestinal tract, where it is thought to play a role in protection against xenobiotic exposure.  High ABCG2 expression has also been found in a variety of solid tumors and in hematol. malignancies and has been correlated with poorer clin. outcomes.  Furthermore, ABCG2 expression is a characteristic feature of cancer stem cells, which are able to self-renew and differentiate.  These cancer stem cells have been postulated to play an important role in MDR, where their inherent ABCG2 expression may allow them to survive chemotherapy and repopulate the tumor after exposure to chemotherapeutics.  This observation raises the exciting possibility that by inhibiting ABCG2, cancer stem cells and other cancers may be targeted and eradicated, at which point conventional chemotherapeutics would be sufficient to eliminate the remaining tumor cells.  Inhibitors of ABCG2, such as tyrosine kinase inhibitors, phosphodiesterase-5 inhibitors, and the fumitremorgin-type indolyl diketopiperazine, Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester], could potentially be used for this purpose.  However, these agents are still awaiting comprehensive clin. assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplO8F0Ak6Zp7Vg90H21EOLACvtfcHk0lhZ8qVbBkUkJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLjP&md5=d619971aca497b3b66e70c3c5bcca0bb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.088609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.088609%26sid%3Dliteratum%253Aachs%26aulast%3DStacy%26aufirst%3DA.%2BE.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DMolecular%2520Pharmacology%2520of%2520ABCG2%2520and%2520Its%2520Role%2520in%2520Chemoresistance%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D655%26epage%3D669%26doi%3D10.1124%2Fmol.113.088609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gillet, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efferth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remacle, J.</span><span> </span><span class="NLM_article-title">Chemotherapy-Induced Resistance by ATP-Binding Cassette Transporter Genes</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1775</span><span class="NLM_x">, </span> <span class="NLM_fpage">237</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1016/j.bbcan.2007.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.bbcan.2007.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=17572300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFKmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1775&publication_year=2007&pages=237-262&author=J.-P.+Gilletauthor=T.+Efferthauthor=J.+Remacle&title=Chemotherapy-Induced+Resistance+by+ATP-Binding+Cassette+Transporter+Genes&doi=10.1016%2Fj.bbcan.2007.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy-induced resistance by ATP-binding cassette transporter genes</span></div><div class="casAuthors">Gillet, Jean-Pierre; Efferth, Thomas; Remacle, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1775</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-262</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A key issue in the treatment of many cancers is the development of resistance to chemotherapeutic drugs.  Resistance mechanisms are numerous and complex.  One of them is mediated by the overexpression of ATP-binding cassette (ABC) transporters able to efflux drugs out of the tumor cell.  The last two decades have seen notable growth of knowledge concerning the involvement of ABC transporters in resistance to chemotherapy.  This review emphasizes these transporters, their clin. relevance and the diagnostic methods and strategies to circumvent multidrug resistance (MDR) mediated by ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDLF7Lt3bkrVg90H21EOLACvtfcHk0lhaC3UZCSukgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFKmtLY%253D&md5=3c28f2eb4b0913b7893b011638143e88</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2007.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2007.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DGillet%26aufirst%3DJ.-P.%26aulast%3DEfferth%26aufirst%3DT.%26aulast%3DRemacle%26aufirst%3DJ.%26atitle%3DChemotherapy-Induced%2520Resistance%2520by%2520ATP-Binding%2520Cassette%2520Transporter%2520Genes%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2007%26volume%3D1775%26spage%3D237%26epage%3D262%26doi%3D10.1016%2Fj.bbcan.2007.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Wu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. S.</span><span> </span><span class="NLM_article-title">The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1996</span><span class="NLM_x">–</span> <span class="NLM_lpage">2011</span><span class="refDoi"> DOI: 10.1021/mp200261n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200261n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlert74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=1996-2011&author=C.+P.+Wuauthor=C.+H.+Hsiehauthor=Y.+S.+Wu&title=The+Emergence+of+Drug+Transporter-Mediated+Multidrug+Resistance+to+Cancer+Chemotherapy&doi=10.1021%2Fmp200261n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy</span></div><div class="casAuthors">Wu, Chung-Pu; Hsieh, Chia-Hung; Wu, Yu-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1996-2011</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Chemotherapy is currently one of the most effective ways to treat metastatic cancers.  However, of the various mechanisms that are involved in conferring resistance, upregulation of drug efflux ATP-binding cassette (ABC) transporters, such as P-glycoprotein (ABCB1), multidrug resistance protein 1 (ABCC1) and ABCG2, has become a major obstacle to cancer chemotherapy and seriously affects the clin. outcome.  To date, at least 15 ABC drug transporters have been identified and characterized to transport and confer resistance to practically the entire spectrum of cancer drugs, causing multidrug resistance (MDR) in cancers.  Unfortunately, despite decades of research, there is still no real soln. to MDR.  This review highlights some of the major findings, the roles and problems assocd. with MDR-linked ABC drug transporters in metastatic cancers and solid tumors, and the current strategies to improve the clin. outcome in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRXYw8gOc5m7Vg90H21EOLACvtfcHk0lhaC3UZCSukgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlert74%253D&md5=f28ff271be9eceb7cebbfe1cd3676c20</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fmp200261n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200261n%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DHsieh%26aufirst%3DC.%2BH.%26aulast%3DWu%26aufirst%3DY.%2BS.%26atitle%3DThe%2520Emergence%2520of%2520Drug%2520Transporter-Mediated%2520Multidrug%2520Resistance%2520to%2520Cancer%2520Chemotherapy%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2011%26volume%3D8%26spage%3D1996%26epage%3D2011%26doi%3D10.1021%2Fmp200261n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Rigalli, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciriaci, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceballos, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, S. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luquita, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mottino, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghanem, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catania, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, M. L.</span><span> </span><span class="NLM_article-title">Regulation of Multidrug Resistance Proteins by Genistein in a Hepatocarcinoma Cell Line: Impact on Sorafenib Cytotoxicity</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0119502</span><span class="refDoi"> DOI: 10.1371/journal.pone.0119502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1371%2Fjournal.pone.0119502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=25781341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0119502&author=J.+P.+Rigalliauthor=N.+Ciriaciauthor=A.+Ariasauthor=M.+P.+Ceballosauthor=S.+S.+M.+Villanuevaauthor=M.+G.+Luquitaauthor=A.+D.+Mottinoauthor=C.+I.+Ghanemauthor=V.+A.+Cataniaauthor=M.+L.+Ruiz&title=Regulation+of+Multidrug+Resistance+Proteins+by+Genistein+in+a+Hepatocarcinoma+Cell+Line%3A+Impact+on+Sorafenib+Cytotoxicity&doi=10.1371%2Fjournal.pone.0119502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity</span></div><div class="casAuthors">Rigalli, Juan Pablo; Ciriaci, Nadia; Arias, Agostina; Ceballos, Maria Paula; Villanueva, Silvina Stella Maris; Luquita, Marcelo Gabriel; Mottino, Aldo Domingo; Ghanem, Carolina Ines; Catania, Viviana Alicia; Ruiz, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0119502/1-e0119502/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide.  Sorafenib is the only drug available that improves the overall survival of HCC patients.  P-glycoprotein (P-gp), Multidrug resistance-assocd. proteins 2 and 3 (MRP2 and 3) and Breast cancer resistance protein (BCRP) are efflux pumps that play a key role in cancer chemoresistance.  Their modulation by dietary compds. may affect the intracellular accumulation and therapeutic efficacy of drugs that are substrates of these transporters.  Genistein (GNT) is a phytoestrogen abundant in soybean that exerts its genomic effects through Estrogen-Receptors and Pregnane-X-Receptor (PXR), which are involved in the regulation of the above-mentioned transporters.  We evaluated the effect of GNT on the expression and activity of P-gp, MRP2, MRP3 and BCRP in HCC-derived HepG2 cells.  GNT (at 1.0 and 10 μM) increased P-gp and MRP2 protein expression and activity, correlating well with an increased resistance to sorafenib cytotoxicity as detected by the methylthiazole tetrazolium (MTT) assay.  GNT induced P-gp and MRP2 mRNA expression at 10 but not at 1.0 μM concn. suggesting a different pattern of regulation depending on the concn.  Induction of both transporters by 1.0 μM GNT was prevented by cycloheximide, suggesting translational regulation.  Downregulation of expression of the miR-379 by GNT could be assocd. with translational regulation of MRP2.  Silencing of PXR abolished P-gp induction by GNT (at 1.0 and 10 μM) and MRP2 induction by GNT (only at 10 μM), suggesting partial mediation of GNT effects by PXR.  Taken together, the data suggest the possibility of nutrient-drug interactions leading to enhanced chemoresistance in HCC when GNT is ingested with soy rich diets or dietary supplements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHKBOckFJ4lrVg90H21EOLACvtfcHk0ljNcBIyOm6rzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSitb0%253D&md5=5f43b958387029d6c311c76aea700f0d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0119502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0119502%26sid%3Dliteratum%253Aachs%26aulast%3DRigalli%26aufirst%3DJ.%2BP.%26aulast%3DCiriaci%26aufirst%3DN.%26aulast%3DArias%26aufirst%3DA.%26aulast%3DCeballos%26aufirst%3DM.%2BP.%26aulast%3DVillanueva%26aufirst%3DS.%2BS.%2BM.%26aulast%3DLuquita%26aufirst%3DM.%2BG.%26aulast%3DMottino%26aufirst%3DA.%2BD.%26aulast%3DGhanem%26aufirst%3DC.%2BI.%26aulast%3DCatania%26aufirst%3DV.%2BA.%26aulast%3DRuiz%26aufirst%3DM.%2BL.%26atitle%3DRegulation%2520of%2520Multidrug%2520Resistance%2520Proteins%2520by%2520Genistein%2520in%2520a%2520Hepatocarcinoma%2520Cell%2520Line%253A%2520Impact%2520on%2520Sorafenib%2520Cytotoxicity%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0119502%26doi%3D10.1371%2Fjournal.pone.0119502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Huang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. J.</span><span> </span><span class="NLM_article-title">BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e83627</span><span class="refDoi"> DOI: 10.1371/journal.pone.0083627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1371%2Fjournal.pone.0083627" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e83627&author=W.+C.+Huangauthor=Y.+L.+Hsiehauthor=C.+M.+Hungauthor=P.+H.+Chienauthor=Y.+F.+Chienauthor=L.+C.+Chenauthor=C.+Y.+Tuauthor=C.+H.+Chenauthor=S.+C.+Hsuauthor=Y.+M.+Linauthor=Y.+J.+Chen&title=BCRP%2FABCG2+Inhibition+Sensitizes+Hepatocellular+Carcinoma+Cells+to+Sorafenib&doi=10.1371%2Fjournal.pone.0083627"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0083627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0083627%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DHsieh%26aufirst%3DY.%2BL.%26aulast%3DHung%26aufirst%3DC.%2BM.%26aulast%3DChien%26aufirst%3DP.%2BH.%26aulast%3DChien%26aufirst%3DY.%2BF.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DTu%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DHsu%26aufirst%3DS.%2BC.%26aulast%3DLin%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26atitle%3DBCRP%252FABCG2%2520Inhibition%2520Sensitizes%2520Hepatocellular%2520Carcinoma%2520Cells%2520to%2520Sorafenib%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De83627%26doi%3D10.1371%2Fjournal.pone.0083627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Gnoth, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radtke, M.</span><span> </span><span class="NLM_article-title">In Vitro to in Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1341</span><span class="NLM_x">–</span> <span class="NLM_lpage">1346</span><span class="refDoi"> DOI: 10.1124/dmd.110.032052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fdmd.110.032052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=20413726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWktrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1341-1346&author=M.+J.+Gnothauthor=S.+Sandmannauthor=K.+Engelauthor=M.+Radtke&title=In+Vitro+to+in+Vivo+Comparison+of+the+Substrate+Characteristics+of+Sorafenib+Tosylate+toward+P-Glycoprotein&doi=10.1124%2Fdmd.110.032052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro to in vivo comparison of the substrate characteristics of sorafenib toward P-glycoprotein</span></div><div class="casAuthors">Gnoth, M. J.; Sandmann, S.; Engel, K.; Radtke, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1341-1346</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sorafenib (Nexavar) is a novel oral Raf kinase and vascular endothelial growth factor receptor inhibitor.  Most anticancer drugs are substrates for ATP-binding cassette efflux pumps esp. for P-glycoprotein (P-gp).  To evaluate the influence of P-gp on the pharmacokinetics of sorafenib substrate properties for this transporter were investigated.  Therefore, permeability of sorafenib across Caco-2 and P-gp-overexpressing cells was detd.  To det. the in vivo relevance of these in vitro findings, pharmacokinetics of sorafenib in mdr1a/1b(-/-) and wild-type (WT) mice was studied.  Sorafenib is highly permeable and exhibits a slight efflux across Caco-2 cells.  In P-gp-overexpressing cells, a small concn.-dependent efflux was obsd., which was completely blocked by the addn. of ivermectin.  In mdr1a/1b(-/-) and WT mice, unchanged compd. represented by far the majority of radioactivity in plasma.  After i.v. and oral administration, brain/plasma concn. ratios in mdr1a/1b(-/-) mice were 1.3- to 1.5-fold higher than those in WT mice.  However, after i.v. or oral administration, plasma concns. were similar in both mouse strains.  In conclusion, sorafenib is highly permeable and a weak P-gp substrate in vitro.  These findings were confirmed by the small factor of 1.3 to 1.5 obsd. for the brain/plasma ratios in mdr1a/1b(-/-) vs. WT mice in vivo.  Based on these in vitro and in vivo results, it is unlikely that P-gp has a major effect on the plasma concns. of sorafenib in humans.  Because of the high permeability and low P-gp-mediated transport, sorafenib might be able to cross the blood-brain barrier and target tumors within the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj5f9alyzuZbVg90H21EOLACvtfcHk0ljNcBIyOm6rzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWktrjL&md5=571551e695e075bc679c1da7507e2def</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032052%26sid%3Dliteratum%253Aachs%26aulast%3DGnoth%26aufirst%3DM.%2BJ.%26aulast%3DSandmann%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DK.%26aulast%3DRadtke%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520to%2520in%2520Vivo%2520Comparison%2520of%2520the%2520Substrate%2520Characteristics%2520of%2520Sorafenib%2520Tosylate%2520toward%2520P-Glycoprotein%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1341%26epage%3D1346%26doi%3D10.1124%2Fdmd.110.032052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Callaghan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luk, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebawy, M.</span><span> </span><span class="NLM_article-title">Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">631</span><span class="refDoi"> DOI: 10.1124/dmd.113.056176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fdmd.113.056176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24492893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFGjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=623-631&author=R.+Callaghanauthor=F.+Lukauthor=M.+Bebawy&title=Inhibition+of+the+Multidrug+Resistance+P-Glycoprotein%3A+Time+for+a+Change+of+Strategy%3F&doi=10.1124%2Fdmd.113.056176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?</span></div><div class="casAuthors">Callaghan, Richard; Luk, Frederick; Bebawy, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-631, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  P-glycoprotein (P-gp) is a key player in the multidrug-resistant phenotype in cancer.  The protein confers resistance by mediating the ATP-dependent efflux of an astonishing array of anticancer drugs.  Its broad specificity has been the subject of numerous attempts to inhibit the protein and restore the efficacy of anticancer drugs.  The general strategy has been to develop compds. that either compete with anticancer drugs for transport or act as direct inhibitors of P-gp.  Despite considerable in vitro success, there are no compds. currently available to "block" P-gp-mediated resistance in the clinic.  The failure may be attributed to toxicity, adverse drug interaction, and numerous pharmacokinetic issues.  This review provides a description of several alternative approaches to overcome the activity of P-gp in drug-resistant cells.  These include 1) drugs that specifically target resistant cells, 2) novel nanotechnologies to provide high-dose, targeted delivery of anticancer drugs, 3) compds. that interfere with nongenomic transfer of resistance, and 4) approaches to reduce the expression of P-gp within tumors.  Such approaches have been developed through the pursuit of greater understanding of resistance mediators such as P-gp, and they show considerable potential for further application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepn0xRcaTyLVg90H21EOLACvtfcHk0lg-0NWNO3m9Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFGjsbk%253D&md5=89c38218dc0c75a76309295453a5bd5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.056176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.056176%26sid%3Dliteratum%253Aachs%26aulast%3DCallaghan%26aufirst%3DR.%26aulast%3DLuk%26aufirst%3DF.%26aulast%3DBebawy%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520the%2520Multidrug%2520Resistance%2520P-Glycoprotein%253A%2520Time%2520for%2520a%2520Change%2520of%2520Strategy%253F%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D623%26epage%3D631%26doi%3D10.1124%2Fdmd.113.056176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Fletcher, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, M. D.</span><span> </span><span class="NLM_article-title">ABC Transporters in Cancer: More than Just Drug Efflux Pumps</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1038/nrc2789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1038%2Fnrc2789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=20075923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=147-156&author=J.+I.+Fletcherauthor=M.+Haberauthor=M.+J.+Hendersonauthor=M.+D.+Norris&title=ABC+Transporters+in+Cancer%3A+More+than+Just+Drug+Efflux+Pumps&doi=10.1038%2Fnrc2789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters in cancer: more than just drug efflux pumps</span></div><div class="casAuthors">Fletcher, Jamie I.; Haber, Michelle; Henderson, Michelle J.; Norris, Murray D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Multidrug transporter proteins are best known for their contributions to chemoresistance through the efflux of anticancer drugs from cancer cells.  However, a considerable body of evidence also points to their importance in cancer extending beyond drug transport to fundamental roles in tumor biol.  Currently, much of the evidence for these addnl. roles is correlative and definitive studies are needed to confirm causality.  We propose that delineating the precise roles of these transporters in tumorigenesis and treatment response will be important for the development of more effective targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpquOxf0jnPG7Vg90H21EOLACvtfcHk0lg-0NWNO3m9Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGlsQ%253D%253D&md5=bb2ff0eae5cdcf8e7087f17f23ab5100</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrc2789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2789%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DJ.%2BI.%26aulast%3DHaber%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DNorris%26aufirst%3DM.%2BD.%26atitle%3DABC%2520Transporters%2520in%2520Cancer%253A%2520More%2520than%2520Just%2520Drug%2520Efflux%2520Pumps%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D147%26epage%3D156%26doi%3D10.1038%2Fnrc2789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Traynelis, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollmuth, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBain, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vance, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogden, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingledine, R.</span><span> </span><span class="NLM_article-title">Glutamate Receptor Ion Channels: Structure, Regulation, and Function</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.1124/pr.109.002451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fpr.109.002451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=20716669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=405-496&author=S.+F.+Traynelisauthor=L.+P.+Wollmuthauthor=C.+J.+McBainauthor=F.+S.+Mennitiauthor=K.+M.+Vanceauthor=K.+K.+Ogdenauthor=K.+B.+Hansenauthor=H.+Yuanauthor=S.+J.+Myersauthor=R.+Dingledine&title=Glutamate+Receptor+Ion+Channels%3A+Structure%2C+Regulation%2C+and+Function&doi=10.1124%2Fpr.109.002451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate receptor ion channels: structure, regulation, and function</span></div><div class="casAuthors">Traynelis, Stephen F.; Wollmuth, Lonnie P.; McBain, Chris J.; Menniti, Frank S.; Vance, Katie M.; Ogden, Kevin K.; Hansen, Kasper B.; Yuan, Hongjie; Myers, Scott J.; Dingledine, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-496</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The mammalian ionotropic glutamate receptor family encodes 18 gene products that coassemble to form ligand-gated ion channels contg. an agonist recognition site, a transmembrane ion permeation pathway, and gating elements that couple agonist-induced conformational changes to the opening or closing of the permeation pore.  Glutamate receptors mediate fast excitatory synaptic transmission in the central nervous system and are localized on neuronal and non-neuronal cells.  These receptors regulate a broad spectrum of processes in the brain, spinal cord, retina, and peripheral nervous system.  Glutamate receptors are postulated to play important roles in numerous neurol. diseases and have attracted intense scrutiny.  The description of glutamate receptor structure, including its transmembrane elements, reveals a complex assembly of multiple semiautonomous extracellular domains linked to a pore-forming element with striking resemblance to an inverted potassium channel.  In this review we discuss International Union of Basic and Clin. Pharmacol. glutamate receptor nomenclature, structure, assembly, accessory subunits, interacting proteins, gene expression and translation, post-translational modifications, agonist and antagonist pharmacol., allosteric modulation, mechanisms of gating and permeation, roles in normal physiol. function, as well as the potential therapeutic use of pharmacol. agents acting at glutamate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov0rj4nMr5ObVg90H21EOLACvtfcHk0lizs47hztarsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbJ&md5=5d0a7945b5ad99113adf9f6312bafe13</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fpr.109.002451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.109.002451%26sid%3Dliteratum%253Aachs%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26aulast%3DWollmuth%26aufirst%3DL.%2BP.%26aulast%3DMcBain%26aufirst%3DC.%2BJ.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DVance%26aufirst%3DK.%2BM.%26aulast%3DOgden%26aufirst%3DK.%2BK.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DMyers%26aufirst%3DS.%2BJ.%26aulast%3DDingledine%26aufirst%3DR.%26atitle%3DGlutamate%2520Receptor%2520Ion%2520Channels%253A%2520Structure%252C%2520Regulation%252C%2520and%2520Function%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D405%26epage%3D496%26doi%3D10.1124%2Fpr.109.002451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Qosa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotti, D.</span><span> </span><span class="NLM_article-title">Regulation of ABC Efflux Transporters at Blood-Brain Barrier in Health and Neurological Disorders</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1628</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span><span class="refDoi"> DOI: 10.1016/j.brainres.2015.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.brainres.2015.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=26187753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2hs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1628&publication_year=2015&pages=298-316&author=H.+Qosaauthor=D.+S.+Millerauthor=P.+Pasinelliauthor=D.+Trotti&title=Regulation+of+ABC+Efflux+Transporters+at+Blood-Brain+Barrier+in+Health+and+Neurological+Disorders&doi=10.1016%2Fj.brainres.2015.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders</span></div><div class="casAuthors">Qosa, Hisham; Miller, David S.; Pasinelli, Piera; Trotti, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1628</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">298-316</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The strength of the blood-brain barrier (BBB) in providing protection to the central nervous system from exposure to circulating chems. is maintained by tight junctions between endothelial cells and by a broad range of transporter proteins that regulate exchange between CNS and blood.  The most important transporters that restrict the permeability of large no. of toxins as well as therapeutic agents are the ABC transporters.  Among them, P-gp, BCRP, MRP1 and MRP2 are the utmost studied.  These efflux transporters are neuroprotective, limiting the brain entry of neurotoxins; however, they could also restrict the entry of many therapeutics and contribute to CNS pharmacoresistance.  Characterization of several regulatory pathways that govern expression and activity of ABC efflux transporters in the endothelium of brain capillaries have led to an emerging consensus that these processes are complex and contain several cellular and mol. elements.  Alterations in ABC efflux transporters expression and/or activity occur in several neurol. diseases.  Here, we review the signaling pathways that regulate expression and transport activity of P-gp, BCRP, MRP1 and MRP2 as well as how their expression/activity changes in neurol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDwi6W7psSR7Vg90H21EOLACvtfcHk0lizs47hztarsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2hs7vK&md5=3cb682ce23196b2f4bbb125ed5a4b094</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2015.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2015.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DQosa%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DD.%2BS.%26aulast%3DPasinelli%26aufirst%3DP.%26aulast%3DTrotti%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520ABC%2520Efflux%2520Transporters%2520at%2520Blood-Brain%2520Barrier%2520in%2520Health%2520and%2520Neurological%2520Disorders%26jtitle%3DBrain%2520Res.%26date%3D2015%26volume%3D1628%26spage%3D298%26epage%3D316%26doi%3D10.1016%2Fj.brainres.2015.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Leslie, C. C.</span><span> </span><span class="NLM_article-title">Properties and Regulation of Cytosolic Phospholipase A2</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">16709</span><span class="NLM_x">–</span> <span class="NLM_lpage">16712</span><span class="refDoi"> DOI: 10.1074/jbc.272.27.16709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1074%2Fjbc.272.27.16709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=9201969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADyaK2sXksVentb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=16709-16712&author=C.+C.+Leslie&title=Properties+and+Regulation+of+Cytosolic+Phospholipase+A2&doi=10.1074%2Fjbc.272.27.16709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Properties and regulation of cytosolic phospholipase A2</span></div><div class="casAuthors">Leslie, Christina C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">16709-16712</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review, with 77 refs., on the properties and regulation of phospholipase A2, which plays an important role in mediating arachidonic acid release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAy56BGk_IwbVg90H21EOLACvtfcHk0lizs47hztarsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksVentb8%253D&md5=f7c23ebb7d10d0d32d1404406fa86c01</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.27.16709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.27.16709%26sid%3Dliteratum%253Aachs%26aulast%3DLeslie%26aufirst%3DC.%2BC.%26atitle%3DProperties%2520and%2520Regulation%2520of%2520Cytosolic%2520Phospholipase%2520A2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D16709%26epage%3D16712%26doi%3D10.1074%2Fjbc.272.27.16709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Maeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omata, M.</span><span> </span><span class="NLM_article-title">Inflammation and Cancer: Role of Nuclear Factor-kappaB Activation</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">836</span><span class="NLM_x">–</span> <span class="NLM_lpage">842</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2008.00763.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1111%2Fj.1349-7006.2008.00763.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=18294278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslCrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=836-842&author=S.+Maedaauthor=M.+Omata&title=Inflammation+and+Cancer%3A+Role+of+Nuclear+Factor-kappaB+Activation&doi=10.1111%2Fj.1349-7006.2008.00763.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and cancer: role of nuclear factor-kappaB activation</span></div><div class="casAuthors">Maeda, Shin; Omata, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">836-842</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been thought that there is a strong relationship between inflammation and carcinogenesis so that the development of cancer occurs with chronic inflammation in many organs.  An in-depth understanding of the mechanism by which inflammation can lead to carcinogenesis may enable the development of drugs targeted at important mols., providing a powerful tool for preventing cancer development.  In this review, we focused on a signal transduction system, the nuclear factor-kappaB (NF-κB) pathway, which is thought to play a role in the process leading from inflammation to carcinogenesis, and may thus serve as a candidate for targeted intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8gz2S24BurVg90H21EOLACvtfcHk0lix2FxqDHdFJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslCrsLk%253D&md5=d4291bbff88fee41f1143146e309162f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00763.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00763.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DS.%26aulast%3DOmata%26aufirst%3DM.%26atitle%3DInflammation%2520and%2520Cancer%253A%2520Role%2520of%2520Nuclear%2520Factor-kappaB%2520Activation%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26spage%3D836%26epage%3D842%26doi%3D10.1111%2Fj.1349-7006.2008.00763.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sai, W.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, D.-F.</span><span> </span><span class="NLM_article-title">Chemosensitization of HepG2 Cells by Suppression of NF-kappaB/p65 Gene Transcription with Specific-siRNA</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">12814</span><span class="NLM_x">–</span> <span class="NLM_lpage">12821</span><span class="refDoi"> DOI: 10.3748/wjg.v21.i45.12814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.3748%2Fwjg.v21.i45.12814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=26668505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsFSjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=12814-12821&author=Y.+Shiauthor=S.-Y.+Wangauthor=M.+Yaoauthor=W.-L.+Saiauthor=W.+Wuauthor=J.-L.+Yangauthor=Y.+Caiauthor=W.-J.+Zhengauthor=D.-F.+Yao&title=Chemosensitization+of+HepG2+Cells+by+Suppression+of+NF-kappaB%2Fp65+Gene+Transcription+with+Specific-siRNA&doi=10.3748%2Fwjg.v21.i45.12814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA</span></div><div class="casAuthors">Shi, Yun; Wang, Si-Ye; Yao, Min; Sai, Wen-Li; Wu, Wei; Yang, Jun-Ling; Cai, Yin; Zheng, Wen-Jie; Yao, Deng-Fu</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">12814-12821</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">2219-2840</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Inc.</span>)
        </div><div class="casAbstract">AIM: To investigate small interfering RNA (siRNA)- mediated inhibition of nuclear factor-kappa B (NF-κB) activation and multidrug-resistant (MDR) phenotype formation in human HepG2 cells.  METHODS: Total RNA was extd. from human HepG2 or LO2 cells.  NF-κB/p65 mRNA was amplified by nested reverse transcription polymerase chain reaction and confirmed by sequencing.  NF-κB/p65 was analyzed by immunohistochem.  Specific-siRNA was transfected to HepG2 cells to knock down NF-κB/p65 expression.  The effects on cell proliferation, survival, and apoptosis were assessed, and the level of NF- κB/p65 or P-glycoprotein (P-gp) was quant. analyzed by ELISA.  RESULTS: HepG2 cells express NF-κB/p65 and express relatively less phosphorylated p65 (P-p65) and little P-gp.  After treatment of HepG2 cells with different doses of doxorubicin, the expression of NF-κB/p65, P-p65, and esp. P-gp were dose-dependently upregulated.  After HepG2 cells were transfected with NF-κB/p65 siRNA (100 nmol/L), the expression of NF-κB/p65, P-p65, and P-gp were downregulated significantly and dose-dependently.  The viability of HepG2 cells was decreased to 23% in the combination NF-κB/p65 siRNA (100 nmol/L) and doxorubicin (0.5 μmol/L) group and 47% in the doxorubicin (0.5 μmol/L) group (t = 7.043, P < 0.001).  CONCLUSION: Knockdown of NF-κB/p65 with siRNA is an effective strategy for inhibiting HepG2 cell growth by downregulating P-gp expression assocd. chemosensitization and apoptosis induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCkiloH4Noo7Vg90H21EOLACvtfcHk0lix2FxqDHdFJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsFSjt78%253D&md5=1ce3ecd247c03e61eb7b16a3cbc1ad1e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v21.i45.12814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v21.i45.12814%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DSai%26aufirst%3DW.-L.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.-L.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DW.-J.%26aulast%3DYao%26aufirst%3DD.-F.%26atitle%3DChemosensitization%2520of%2520HepG2%2520Cells%2520by%2520Suppression%2520of%2520NF-kappaB%252Fp65%2520Gene%2520Transcription%2520with%2520Specific-siRNA%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2015%26volume%3D21%26spage%3D12814%26epage%3D12821%26doi%3D10.3748%2Fwjg.v21.i45.12814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Deutsch, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burket, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, A. D.</span><span> </span><span class="NLM_article-title">NMDA Receptors on the Surface of Cancer Cells: Target for Chemotherapy?</span> <span class="citation_source-journal">Biomed. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.1016/j.biopha.2014.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.biopha.2014.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24751001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmslaiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2014&pages=493-496&author=S.+I.+Deutschauthor=A.+H.+Tangauthor=J.+A.+Burketauthor=A.+D.+Benson&title=NMDA+Receptors+on+the+Surface+of+Cancer+Cells%3A+Target+for+Chemotherapy%3F&doi=10.1016%2Fj.biopha.2014.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptors on the surface of cancer cells: Target for chemotherapy?</span></div><div class="casAuthors">Deutsch, Stephen I.; Tang, Amy H.; Burket, Jessica A.; Benson, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">493-496</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a therapeutic target for many types of cancers.  NMDA receptors regulate mTOR signalling activity; their inappropriate expression on several human cancer cell lines represents a potential therapeutic avenue to control dysregulated growth, division and invasiveness.  Targeting these receptors with selective ligands (e.g., glycine B site ligands) may be a less toxic and more tolerable approach than administering compds. acting at the mTORC1 complex itself, such as rapamycin and its derivs.  Thus, testing glycine B site ligands in relevant in vitro and in vivo paradigms with established human cancer cells that express NMDA receptors on their surface could provide proofs of concept/principle that would encourage exploration of these and other "non-toxic" strategies.  Interestingly, in some cancer models that express NMDA receptors on their surface, NMDA receptor antagonists, such as MK-801 (dizocilpine), were shown to possess anti-proliferative and anti-invasive effects, which conflict with hypotheses about promoting NMDA receptor activation as a cancer chemotherapeutic strategy.  Whether NMDA receptor activation or antagonism is assocd. with anti-proliferative and anti-invasive effects may reflect differences between cancer cell lines in terms of the proteins assocd. with the NMDA receptors on their cell surfaces, which, in turn, could lead to different "downstream" effects on cascades of intracellular phosphorylations.  Irresp. of whether activation or antagonism is assocd. with anti-proliferative and anti-invasive effects for specific types of cancer, data are emerging that support exploration of targeting NMDA receptors expressed on the surface of cancer cells as a therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFNZG8HVu1x7Vg90H21EOLACvtfcHk0lix2FxqDHdFJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmslaiu7k%253D&md5=76fcd808e86ddfdf04b0cea77668f018</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2014.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2014.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DDeutsch%26aufirst%3DS.%2BI.%26aulast%3DTang%26aufirst%3DA.%2BH.%26aulast%3DBurket%26aufirst%3DJ.%2BA.%26aulast%3DBenson%26aufirst%3DA.%2BD.%26atitle%3DNMDA%2520Receptors%2520on%2520the%2520Surface%2520of%2520Cancer%2520Cells%253A%2520Target%2520for%2520Chemotherapy%253F%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2014%26volume%3D68%26spage%3D493%26epage%3D496%26doi%3D10.1016%2Fj.biopha.2014.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ribeiro, M. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes-Correia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Custódio, J. B. A.</span><span> </span><span class="NLM_article-title">The Combination of Glutamate Receptor Antagonist MK-801 with Tamoxifen and Its Active Metabolites Potentiates Their Antiproliferative Activity in Mouse Melanoma K1735-M2 Cells</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.1016/j.yexcr.2013.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.yexcr.2013.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24240127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Gqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2014&pages=288-296&author=M.+P.+C.+Ribeiroauthor=I.+Nunes-Correiaauthor=A.+E.+Santosauthor=J.+B.+A.+Cust%C3%B3dio&title=The+Combination+of+Glutamate+Receptor+Antagonist+MK-801+with+Tamoxifen+and+Its+Active+Metabolites+Potentiates+Their+Antiproliferative+Activity+in+Mouse+Melanoma+K1735-M2+Cells&doi=10.1016%2Fj.yexcr.2013.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells</span></div><div class="casAuthors">Ribeiro, Mariana P. C.; Nunes-Correia, Isabel; Santos, Armanda E.; Custodio, Jose B. A.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-296</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent reports suggest that N-methyl-D-aspartate receptor (NMDAR) blockade by MK-801 decreases tumor growth.  Thus, we investigated whether other ionotropic glutamate receptor (iGluR) antagonists were also able to modulate the proliferation of melanoma cells.  On the other hand, the antiestrogen tamoxifen (TAM) decreases the proliferation of melanoma cells, and is included in combined therapies for melanoma.  As the efficacy of TAM is limited by its metab., we investigated the effects of the NMDAR antagonist MK-801 in combination with TAM and its active metabolites, 4-hydroxytamoxifen (OHTAM) and endoxifen (EDX).  The NMDAR blockers MK-801 and memantine decreased mouse melanoma K1735-M2 cell proliferation.  In contrast, the NMDAR competitive antagonist APV and the AMPA and kainate receptor antagonist NBQX did not affect cell proliferation, suggesting that among the iGluR antagonists only the NMDAR channel blockers inhibit melanoma cell proliferation.  The combination of antiestrogens with MK-801 potentiated their individual effects on cell biomass due to diminished cell proliferation, since it decreased the cell no. and DNA synthesis without increasing cell death.  Importantly, TAM metabolites combined with MK-801 promoted cell cycle arrest in G1.  Therefore, the data obtained suggest that the activity of MK-801 and antiestrogens in K1735-M2 cells is greatly enhanced when used in combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa4k9gpQA8gbVg90H21EOLACvtfcHk0lgKv4h8DB1qhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Gqt7k%253D&md5=da8f07a85632df541d83bd7570123138</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2013.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2013.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DM.%2BP.%2BC.%26aulast%3DNunes-Correia%26aufirst%3DI.%26aulast%3DSantos%26aufirst%3DA.%2BE.%26aulast%3DCust%25C3%25B3dio%26aufirst%3DJ.%2BB.%2BA.%26atitle%3DThe%2520Combination%2520of%2520Glutamate%2520Receptor%2520Antagonist%2520MK-801%2520with%2520Tamoxifen%2520and%2520Its%2520Active%2520Metabolites%2520Potentiates%2520Their%2520Antiproliferative%2520Activity%2520in%2520Mouse%2520Melanoma%2520K1735-M2%2520Cells%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2014%26volume%3D321%26spage%3D288%26epage%3D296%26doi%3D10.1016%2Fj.yexcr.2013.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Yamaguchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamitori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokuda, M.</span><span> </span><span class="NLM_article-title">FOXO/TXNIP Pathway Is Involved in the Suppression of Hepatocellular Carcinoma Growth by Glutamate Antagonist MK-801</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">468</span><span class="refDoi"> DOI: 10.1186/1471-2407-13-468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1186%2F1471-2407-13-468" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=468&author=F.+Yamaguchiauthor=Y.+Hirataauthor=H.+Akramauthor=K.+Kamitoriauthor=Y.+Dongauthor=L.+Suiauthor=M.+Tokuda&title=FOXO%2FTXNIP+Pathway+Is+Involved+in+the+Suppression+of+Hepatocellular+Carcinoma+Growth+by+Glutamate+Antagonist+MK-801&doi=10.1186%2F1471-2407-13-468"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-468%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DF.%26aulast%3DHirata%26aufirst%3DY.%26aulast%3DAkram%26aufirst%3DH.%26aulast%3DKamitori%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DSui%26aufirst%3DL.%26aulast%3DTokuda%26aufirst%3DM.%26atitle%3DFOXO%252FTXNIP%2520Pathway%2520Is%2520Involved%2520in%2520the%2520Suppression%2520of%2520Hepatocellular%2520Carcinoma%2520Growth%2520by%2520Glutamate%2520Antagonist%2520MK-801%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D468%26doi%3D10.1186%2F1471-2407-13-468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Bergeron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. T.</span><span> </span><span class="NLM_article-title">NAAG, NMDA Receptor and Psychosis</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1360</span><span class="NLM_x">–</span> <span class="NLM_lpage">1364</span><span class="refDoi"> DOI: 10.2174/092986712799462685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.2174%2F092986712799462685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=22304714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1360-1364&author=R.+Bergeronauthor=J.+T.+Coyle&title=NAAG%2C+NMDA+Receptor+and+Psychosis&doi=10.2174%2F092986712799462685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">NAAG, NMDA receptor and psychosis</span></div><div class="casAuthors">Bergeron, Richard; Coyle, Joseph T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1360-1364</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  At central synapses, glutamate is the main excitatory neurotransmitter.  Once released from presynaptic terminals, glutamate activates a no. of different glutamatergic receptors one of which is the ligand gated ionophore glutamatergic subtype N-methyl-D-aspartate receptors (NMDARs).  NMDARs play a crucial role in controlling various determinants of synaptic function.  N-acetylaspartylglutamate (NAAG) is the most prevalent peptide transmitter in the mammalian central nervous system.  NAAG is released upon neuronal depolarization by a calcium-dependent process from glutamatergic and GABAergic neurons.  It is cleaved by a specific peptidase located on astrocytes, glutamate carboxypeptidase type II (GCP-II), to N-acetylaspartate (NAA) and glutamate.  Current evidence supports the hypothesis that NAAG is an endogenous agonist at G protein coupled mGluR3 receptors and an antagonist at NMDAR.  In several disorders and animal models of human diseases, the levels of NAAG and the activity of GCP-II are altered in ways that are consistent with NAAG's role in regulation of glutamatergic neurotransmission.  Several lines of evidence suggest that a dysfunction in glutamatergic via the NMDAR might be involved in schizophrenia.  This hypothesis has evolved from findings that NMDAR antagonists such as phencyclidine (PCP or "angel dust"), produces a syndrome in normal individuals that closely resembles schizophrenia and exacerbates psychotic symptoms in patients with chronic schizophrenia.  Recent postmortem, metabolic and genetic studies have provided evidence that hypofunction of discrete populations of NMDAR can contribute to the symptoms of schizophrenia, at least in some patients.  The review outlines the role of endogenous NAAG at NMDAR neurotransmission and its putative role in the pathophysiol. of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsZoSWE5L4O7Vg90H21EOLACvtfcHk0lgKv4h8DB1qhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOnsro%253D&md5=07a809bfddd3977325d822dfb9912a5d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F092986712799462685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712799462685%26sid%3Dliteratum%253Aachs%26aulast%3DBergeron%26aufirst%3DR.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3DNAAG%252C%2520NMDA%2520Receptor%2520and%2520Psychosis%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D1360%26epage%3D1364%26doi%3D10.2174%2F092986712799462685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanadhan, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendoloski, J. J.</span><span> </span><span class="NLM_article-title">A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases</span> <span class="citation_source-journal">J. Comb. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1021/cc9800071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc9800071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFGrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=55-68&author=A.+K.+Ghoseauthor=V.+N.+Viswanadhanauthor=J.+J.+Wendoloski&title=A+Knowledge-Based+Approach+in+Designing+Combinatorial+or+Medicinal+Chemistry+Libraries+for+Drug+Discovery.+1.+A+Qualitative+and+Quantitative+Characterization+of+Known+Drug+Databases&doi=10.1021%2Fcc9800071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases</span></div><div class="casAuthors">Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of various protein/receptor targets from genomic research is expanding rapidly.  Along with the automation of org. synthesis and biochem. screening, this is bringing a major change in the whole field of drug discovery research.  In the traditional drug discovery process, the industry tests compds. in the thousands.  With automated synthesis, the no. of compds. to be tested could be in the millions.  This two-dimensional expansion will lead to a major demand for resources, unless the chem. libraries are made wisely.  The objective of this work is to provide both quant. and qual. characterization of known drugs which will help to generate "drug-like" libraries.  In this work the authors analyzed the Comprehensive Medicinal Chem. (CMC) database and seven different subsets belonging to different classes of drug mols.  These include some central nervous system active drugs and cardiovascular, cancer, inflammation, and infection disease states.  A quant. characterization based on computed physicochem. property profiles such as log P, molar refractivity, mol. wt., and no. of atoms as well as a qual. characterization based on the occurrence of functional groups and important substructures are developed here.  For the CMC database, the qualifying range (covering more than 80% of the compds.) of the calcd. log P is between -0.4 and 5.6, with an av. value of 2.52.  For mol. wt., the qualifying range is between 160 and 480, with an av. value of 357.  For molar refractivity, the qualifying range is between 40 and 130, with an av. value of 97.  For the total no. of atoms, the qualifying range is between 20 and 70, with an av. value of 48.  Benzene is by far the most abundant substructure in this drug database, slightly more abundant than all the heterocyclic rings combined.  Nonarom. heterocyclic rings are twice as abundant as the arom. heterocycles.  Tertiary aliph. amines, alc. OH and carboxamides are the most abundant functional groups in the drug database.  The effective range of physicochem. properties presented here can be used in the design of drug-like combinatorial libraries as well as in developing a more efficient corporate medicinal chem. library.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdtFV7c05Th7Vg90H21EOLACvtfcHk0lgKv4h8DB1qhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFGrurk%253D&md5=b2b0a40191e6cb71cf31c5266a7be8b2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fcc9800071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc9800071%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DWendoloski%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520Knowledge-Based%2520Approach%2520in%2520Designing%2520Combinatorial%2520or%2520Medicinal%2520Chemistry%2520Libraries%2520for%2520Drug%2520Discovery.%25201.%2520A%2520Qualitative%2520and%2520Quantitative%2520Characterization%2520of%2520Known%2520Drug%2520Databases%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D1999%26volume%3D1%26spage%3D55%26epage%3D68%26doi%3D10.1021%2Fcc9800071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Larsen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venskutonytė, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valadés, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Discovery of a New Class of Ionotropic Glutamate Receptor Antagonists by the Rational Design of (2S,3R)-3-(3-Carboxyphenyl)-Pyrrolidine-2-Carboxylic Acid</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1021/cn100093f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100093f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWhsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=107-114&author=A.+M.+Larsenauthor=R.+Venskutonyt%C4%97author=E.+A.+Valad%C3%A9sauthor=B.+Nielsenauthor=D.+S.+Pickeringauthor=L.+Bunch&title=Discovery+of+a+New+Class+of+Ionotropic+Glutamate+Receptor+Antagonists+by+the+Rational+Design+of+%282S%2C3R%29-3-%283-Carboxyphenyl%29-Pyrrolidine-2-Carboxylic+Acid&doi=10.1021%2Fcn100093f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Class of Ionotropic Glutamate Receptor Antagonists by the Rational Design of (2S,3R)-3-(3-Carboxyphenyl)-pyrrolidine-2-carboxylic Acid</span></div><div class="casAuthors">Larsen, Ann M.; Venskutonyte, Raminta; Valades, Elena Anton; Nielsen, Birgitte; Pickering, Darryl S.; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kainic acid (KA) receptors belong to the class of glutamate (Glu) receptors in the brain and constitute a promising target for the treatment of neurol. and/or psychiatric diseases such as schizophrenia, major depression, and epilepsy.  Five KA subtypes have been identified and named GluK1-5.  In this article, we present the discovery of (2S,3R)-3-(3-carboxyphenyl)-pyrrolidine-2-carboxylic acid (1) based on a rational design process.  Target compd. 1 was synthesized by a stereoselective strategy in 10 steps from com. available starting materials.  Binding affinities of 1 at native ionotropic Glu receptors were detd. to be in the micromolar range (AMPA, 51 μM; KA, 22 μM; NMDA 6 μM), with the highest affinity for cloned homomeric KA receptor subtypes GluK1,3 (3.0 and 8.1 μM, resp.).  Functional characterization of 1 by two electrode voltage clamp (TEVC) electrophysiol. at a nondesensitizing mutant of GluK1 showed full competitive antagonistic behavior with a Kb of 11.4 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe72VGdj51HrVg90H21EOLACvtfcHk0lh-7r4PVD2IlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWhsbvE&md5=dfe53691cb11fa493b0aaaec96a60909</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fcn100093f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100093f%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BM.%26aulast%3DVenskutonyt%25C4%2597%26aufirst%3DR.%26aulast%3DValad%25C3%25A9s%26aufirst%3DE.%2BA.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Class%2520of%2520Ionotropic%2520Glutamate%2520Receptor%2520Antagonists%2520by%2520the%2520Rational%2520Design%2520of%2520%25282S%252C3R%2529-3-%25283-Carboxyphenyl%2529-Pyrrolidine-2-Carboxylic%2520Acid%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D107%26epage%3D114%26doi%3D10.1021%2Fcn100093f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Krogsgaard-Larsen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storgaard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Møller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demmer, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monrad, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrup, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frydenvang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Structure-Activity Relationship Study of Ionotropic Glutamate Receptor Antagonist (2S,3R)-3-(3-Carboxyphenyl)pyrrolidine-2-Carboxylic Acid</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6131</span><span class="NLM_x">–</span> <span class="NLM_lpage">6150</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00750</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00750" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6131-6150&author=N.+Krogsgaard-Larsenauthor=M.+Storgaardauthor=C.+M%C3%B8llerauthor=C.+S.+Demmerauthor=J.+Hansenauthor=L.+Hanauthor=R.+N.+Monradauthor=B.+Nielsenauthor=D.+Tapkenauthor=D.+S.+Pickeringauthor=J.+S.+Kastrupauthor=K.+Frydenvangauthor=L.+Bunch&title=Structure-Activity+Relationship+Study+of+Ionotropic+Glutamate+Receptor+Antagonist+%282S%2C3R%29-3-%283-Carboxyphenyl%29pyrrolidine-2-Carboxylic+Acid&doi=10.1021%2Facs.jmedchem.5b00750"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00750%26sid%3Dliteratum%253Aachs%26aulast%3DKrogsgaard-Larsen%26aufirst%3DN.%26aulast%3DStorgaard%26aufirst%3DM.%26aulast%3DM%25C3%25B8ller%26aufirst%3DC.%26aulast%3DDemmer%26aufirst%3DC.%2BS.%26aulast%3DHansen%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DMonrad%26aufirst%3DR.%2BN.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DTapken%26aufirst%3DD.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DStructure-Activity%2520Relationship%2520Study%2520of%2520Ionotropic%2520Glutamate%2520Receptor%2520Antagonist%2520%25282S%252C3R%2529-3-%25283-Carboxyphenyl%2529pyrrolidine-2-Carboxylic%2520Acid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6131%26epage%3D6150%26doi%3D10.1021%2Facs.jmedchem.5b00750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Ogura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuyama, T.</span><span> </span><span class="NLM_article-title">Total Synthesis of (−)-Anisatin</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1632</span><span class="NLM_x">–</span> <span class="NLM_lpage">1635</span><span class="refDoi"> DOI: 10.1021/ol300390k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol300390k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=1632-1635&author=A.+Oguraauthor=K.+Yamadaauthor=S.+Yokoshimaauthor=T.+Fukuyama&title=Total+Synthesis+of+%28%E2%88%92%29-Anisatin&doi=10.1021%2Fol300390k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fol300390k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol300390k%26sid%3Dliteratum%253Aachs%26aulast%3DOgura%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DYokoshima%26aufirst%3DS.%26aulast%3DFukuyama%26aufirst%3DT.%26atitle%3DTotal%2520Synthesis%2520of%2520%2528%25E2%2588%2592%2529-Anisatin%26jtitle%3DOrg.%2520Lett.%26date%3D2012%26volume%3D14%26spage%3D1632%26epage%3D1635%26doi%3D10.1021%2Fol300390k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Bunch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogsgaard-Larsen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, U.</span><span> </span><span class="NLM_article-title">Mixed Cyano-Gilman Cuprates-Advances in Conjugate Addition to Alpha, Beta-Unsaturated Pyroglutaminol</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2002</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">33</span><span class="refDoi"> DOI: 10.1055/s-2002-19303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1055%2Fs-2002-19303" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2002&publication_year=2002&pages=31-33&author=L.+Bunchauthor=P.+Krogsgaard-Larsenauthor=U.+Madsen&title=Mixed+Cyano-Gilman+Cuprates-Advances+in+Conjugate+Addition+to+Alpha%2C+Beta-Unsaturated+Pyroglutaminol&doi=10.1055%2Fs-2002-19303"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-2002-19303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2002-19303%26sid%3Dliteratum%253Aachs%26aulast%3DBunch%26aufirst%3DL.%26aulast%3DKrogsgaard-Larsen%26aufirst%3DP.%26aulast%3DMadsen%26aufirst%3DU.%26atitle%3DMixed%2520Cyano-Gilman%2520Cuprates-Advances%2520in%2520Conjugate%2520Addition%2520to%2520Alpha%252C%2520Beta-Unsaturated%2520Pyroglutaminol%26jtitle%3DSynthesis%26date%3D2002%26volume%3D2002%26spage%3D31%26epage%3D33%26doi%3D10.1055%2Fs-2002-19303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="note"><p class="first last">Synthesis will be reported elsewhere.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräuner-Osborne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egebjerg, J.</span><span> </span><span class="NLM_article-title">Pharmacological Characterization of Ligands at Recombinant NMDA Receptor Subtypes by Electrophysiological Recordings and Intracellular Calcium Measurements</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.2174/138620708784246040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.2174%2F138620708784246040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=18473740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslCisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=304-315&author=K.+B.+Hansenauthor=H.+Br%C3%A4uner-Osborneauthor=J.+Egebjerg&title=Pharmacological+Characterization+of+Ligands+at+Recombinant+NMDA+Receptor+Subtypes+by+Electrophysiological+Recordings+and+Intracellular+Calcium+Measurements&doi=10.2174%2F138620708784246040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of ligands at recombinant NMDA receptor subtypes by electrophysiological recordings and intracellular calcium measurements</span></div><div class="casAuthors">Hansen, Kasper B.; Brauner-Osborne, Hans; Egebjerg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-315</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Generation of in vitro cellular assays using fluorescence measurements at heterologously expressed NMDA receptors would speed up the process of ligand characterization and enable high-throughput screening.  The major drawback to the development of such assays is the cytotoxicity caused by Ca2+-flux into the cell via NMDA receptors upon prolonged activation by agonists present in the culture medium.  In the present study, we established four cell lines with stable expression of NMDA receptor subtypes NR1/NR2A, NR1/NR2B, NR1/NR2C, or NR1/NR2D in BHK-21 cells.  To assess the usefulness of the stable cell lines in conjunction with intracellular calcium ([Ca2+]i) measurements for evaluation of NMDA receptor pharmacol., several ligands were characterized using this method.  The results were compared to parallel data obtained by electrophysiol. recordings at NMDA receptors expressed in Xenopus oocytes.  This comparison showed that agonist potencies detd. by [Ca2+]i measurements and electrophysiol. recordings correlated well, meaning that the stable cell lines in conjunction with [Ca2+]i measurements provide a useful tool for characterization of NMDA receptor ligands.  The agonist series of conformationally constrained glutamate analogs (2S,3R,4S)-α-(carboxycyclopropyl)glycine (CCG), 1-aminocyclobutane-r-1,cis-3-dicarboxylic acid (trans-ACBD), and (±)-1-aminocyclopentane-r-1,cis-3-dicarboxylic acid (cis-ACPD), as well as the highly potent agonist tetrazolylglycine were among the characterized ligands that were assessed with respect to subtype selectivity at NMDA receptors.  However, none of the characterized agonists displays more than 2-3 fold selectivity toward a specific NMDA receptor subtype.  Thus, the present study provides a broad pharmacol. characterization of structurally diverse ligands at recombinant NMDA receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYuZIWYgVeGbVg90H21EOLACvtfcHk0lh-7r4PVD2IlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslCisb4%253D&md5=4e07adfe9e1d8d9e4a0dd9f69ca15eeb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138620708784246040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620708784246040%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DBr%25C3%25A4uner-Osborne%26aufirst%3DH.%26aulast%3DEgebjerg%26aufirst%3DJ.%26atitle%3DPharmacological%2520Characterization%2520of%2520Ligands%2520at%2520Recombinant%2520NMDA%2520Receptor%2520Subtypes%2520by%2520Electrophysiological%2520Recordings%2520and%2520Intracellular%2520Calcium%2520Measurements%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2008%26volume%3D11%26spage%3D304%26epage%3D315%26doi%3D10.2174%2F138620708784246040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Yung-Chi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the Inhibition Constant (KI) and the Concentration of Inhibitor Which Causes 50 per Cent Inhibition (I50) of an Enzymatic Reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">–</span> <span class="NLM_lpage">3108</span><span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=4202581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+Inhibition+Constant+%28KI%29+and+the+Concentration+of+Inhibitor+Which+Causes+50+per+Cent+Inhibition+%28I50%29+of+an+Enzymatic+Reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520Inhibition%2520Constant%2520%2528KI%2529%2520and%2520the%2520Concentration%2520of%2520Inhibitor%2520Which%2520Causes%252050%2520per%2520Cent%2520Inhibition%2520%2528I50%2529%2520of%2520an%2520Enzymatic%2520Reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Hedegaard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräuner-Osborne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynelis, S. F.</span><span> </span><span class="NLM_article-title">Molecular Pharmacology of Human NMDA Receptors</span> <span class="citation_source-journal">Neurochem. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span><span class="refDoi"> DOI: 10.1016/j.neuint.2011.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.neuint.2011.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=22197913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=601-609&author=M.+Hedegaardauthor=K.+B.+Hansenauthor=K.+T.+Andersenauthor=H.+Br%C3%A4uner-Osborneauthor=S.+F.+Traynelis&title=Molecular+Pharmacology+of+Human+NMDA+Receptors&doi=10.1016%2Fj.neuint.2011.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pharmacology of human NMDA receptors</span></div><div class="casAuthors">Hedegaard, Maiken; Hansen, Kasper B.; Andersen, Karen T.; Brauner-Osborne, Hans; Traynelis, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-609</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">N-methyl-D-aspartate (NMDA) receptors are ionotropic glutamate receptors that mediate excitatory neurotransmission.  NMDA receptors are also important drug targets that are implicated in a no. of pathophysiol. conditions.  To facilitate the transition from lead compds. in pre-clin. animal models to drug candidates for human use, it is important to establish whether NMDA receptor ligands have similar properties at rodent and human NMDA receptors.  Here, we compare amino acid sequences for human and rat NMDA receptor subunits and discuss inter-species variation in the context of our current knowledge of the relationship between NMDA receptor structure and function.  We summarize studies on the biophys. properties of human NMDA receptors and compare these properties to those of rat orthologs.  Finally, we provide a comprehensive pharmacol. characterization that allows side-by-side comparison of agonists, un-competitive antagonists, GluN2B-selective non-competitive antagonists, and GluN2C/D-selective modulators at recombinant human and rat NMDA receptors.  The evaluation of biophys. properties and pharmacol. probes acting at different sites on the receptor suggest that the binding sites and conformational changes leading to channel gating in response to agonist binding are highly conserved between human and rat NMDA receptors.  In summary, the results of this study suggest that no major detectable differences exist in the pharmacol. and functional properties of human and rat NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS0vde2fdkdbVg90H21EOLACvtfcHk0lj-5tsvS7jKCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSktrfE&md5=97fbf713df306543c9bf801d4ad3b39f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2011.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2011.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DHedegaard%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DAndersen%26aufirst%3DK.%2BT.%26aulast%3DBr%25C3%25A4uner-Osborne%26aufirst%3DH.%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26atitle%3DMolecular%2520Pharmacology%2520of%2520Human%2520NMDA%2520Receptors%26jtitle%3DNeurochem.%2520Int.%26date%3D2012%26volume%3D61%26spage%3D601%26epage%3D609%26doi%3D10.1016%2Fj.neuint.2011.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Uchida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tachikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obuchi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoshi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terasaki, T.</span><span> </span><span class="NLM_article-title">A Study Protocol for Quantitative Targeted Absolute Proteomics (QTAP) by LC–MS/MS: Application for Inter-Strain Differences in Protein Expression Levels of Transporters, Receptors, Claudin-5, and Marker Proteins at the Blood–Brain Barrier in ddY, FVB, an</span> <span class="citation_source-journal">Fluids Barriers CNS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="refDoi"> DOI: 10.1186/2045-8118-10-21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1186%2F2045-8118-10-21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=23758935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFymsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=21&author=Y.+Uchidaauthor=M.+Tachikawaauthor=W.+Obuchiauthor=Y.+Hoshiauthor=Y.+Tomiokaauthor=S.+Ohtsukiauthor=T.+Terasaki&title=A+Study+Protocol+for+Quantitative+Targeted+Absolute+Proteomics+%28QTAP%29+by+LC%E2%80%93MS%2FMS%3A+Application+for+Inter-Strain+Differences+in+Protein+Expression+Levels+of+Transporters%2C+Receptors%2C+Claudin-5%2C+and+Marker+Proteins+at+the+Blood%E2%80%93Brain+Barrier+in+ddY%2C+FVB%2C+an&doi=10.1186%2F2045-8118-10-21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice</span></div><div class="casAuthors">Uchida, Yasuo; Tachikawa, Masanori; Obuchi, Wataru; Hoshi, Yutaro; Tomioka, Yusuke; Ohtsuki, Sumio; Terasaki, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Fluids and Barriers of the CNS</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>CODEN:
                <span class="NLM_cas:coden">FBCLA5</span>;
        ISSN:<span class="NLM_cas:issn">2045-8118</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Proteomics has opened a new horizon in biol. sciences.  Global proteomic anal. is a promising technol. for the discovery of thousands of proteins, post-translational modifications, polymorphisms, and mol. interactions in a variety of biol. systems.  The activities and roles of the identified proteins must also be elucidated, but this is complicated by the inability of conventional proteomic methods to yield quant. information for protein expression.  Thus, a variety of biol. systems remain "black boxes".  Quant. targeted abs. proteomics (QTAP) enables the detn. of abs. expression levels (mol) of any target protein, including low-abundance functional proteins, such as transporters and receptors.  Therefore, QTAP will be useful for understanding the activities and roles of individual proteins and their differences, including normal/disease, human/animal, or in vitro/in vivo.  Here, we describe the study protocols and precautions for QTAP expts. including in silico target peptide selection, detn. of peptide concn. by amino acid anal., setup of selected/multiple reaction monitoring (SRM/MRM) anal. in liq. chromatog.-tandem mass spectrometry, prepn. of protein samples (brain capillaries and plasma membrane fractions) followed by the prepn. of peptide samples, simultaneous abs. quantification of target proteins by SRM/MRM anal., data anal., and troubleshooting.  An application of QTAP in biol. sciences was introduced that utilizes data from inter-strain differences in the protein expression levels of transporters, receptors, tight junction proteins and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice.  Among 18 mols., 13 (abcb1a/mdr1a/P-gp, abcc4/mrp4, abcg2/bcrp, slc2a1/glut1, slc7a5/lat1, slc16a1/mct1, slc22a8/oat3, insr, lrp1, tfr1, claudin-5, Na+/K+-ATPase, and γ-gtp) were detected in the isolated brain capillaries, and their protein expression levels were within a range of 0.637-101 fmol/μg protein.  The largest difference in the levels between the three strains was 2.2-fold for 13 mols., although bcrp and mct1 displayed statistically significant differences between C57BL/6J and the other strain(s).  Highly sensitive simultaneous abs. quantification achieved by QTAP will increase the usefulness of proteomics in biol. sciences and is expected to advance the new research field of pharmacoproteomics (PPx).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgqG9zmyBJSLVg90H21EOLACvtfcHk0lj-5tsvS7jKCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFymsb7J&md5=f9a58deb2bc5a2313bc481b60bf9e787</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F2045-8118-10-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2045-8118-10-21%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DTachikawa%26aufirst%3DM.%26aulast%3DObuchi%26aufirst%3DW.%26aulast%3DHoshi%26aufirst%3DY.%26aulast%3DTomioka%26aufirst%3DY.%26aulast%3DOhtsuki%26aufirst%3DS.%26aulast%3DTerasaki%26aufirst%3DT.%26atitle%3DA%2520Study%2520Protocol%2520for%2520Quantitative%2520Targeted%2520Absolute%2520Proteomics%2520%2528QTAP%2529%2520by%2520LC%25E2%2580%2593MS%252FMS%253A%2520Application%2520for%2520Inter-Strain%2520Differences%2520in%2520Protein%2520Expression%2520Levels%2520of%2520Transporters%252C%2520Receptors%252C%2520Claudin-5%252C%2520and%2520Marker%2520Proteins%2520at%2520the%2520Blood%25E2%2580%2593Brain%2520Barrier%2520in%2520ddY%252C%2520FVB%252C%2520an%26jtitle%3DFluids%2520Barriers%2520CNS%26date%3D2013%26volume%3D10%26spage%3D21%26doi%3D10.1186%2F2045-8118-10-21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Rautio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balakrishnan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keogh, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunta, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. W.</span><span> </span><span class="NLM_article-title">In Vitro P-Glycoprotein Inhibition Assays for Assessment of Clinical Drug Interaction Potential of New Drug Candidates: A Recommendation for Probe Substrates</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1124/dmd.105.008615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fdmd.105.008615" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=786-792&author=J.+Rautioauthor=J.+E.+Humphreysauthor=L.+O.+Websterauthor=A.+Balakrishnanauthor=J.+P.+Keoghauthor=J.+R.+Kuntaauthor=C.+J.+Serabjit-Singhauthor=J.+W.+Polli&title=In+Vitro+P-Glycoprotein+Inhibition+Assays+for+Assessment+of+Clinical+Drug+Interaction+Potential+of+New+Drug+Candidates%3A+A+Recommendation+for+Probe+Substrates&doi=10.1124%2Fdmd.105.008615"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.008615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.008615%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DKeogh%26aufirst%3DJ.%2BP.%26aulast%3DKunta%26aufirst%3DJ.%2BR.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DIn%2520Vitro%2520P-Glycoprotein%2520Inhibition%2520Assays%2520for%2520Assessment%2520of%2520Clinical%2520Drug%2520Interaction%2520Potential%2520of%2520New%2520Drug%2520Candidates%253A%2520A%2520Recommendation%2520for%2520Probe%2520Substrates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D786%26epage%3D792%26doi%3D10.1124%2Fdmd.105.008615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Löscher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potschka, H.</span><span> </span><span class="NLM_article-title">Blood-Brain Barrier Active Efflux Transporters: ATP-Binding Cassette Gene Family</span> <span class="citation_source-journal">NeuroRx</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1602/neurorx.2.1.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1602%2Fneurorx.2.1.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=15717060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A280%3ADC%252BD2MzntVejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=86-98&author=W.+L%C3%B6scherauthor=H.+Potschka&title=Blood-Brain+Barrier+Active+Efflux+Transporters%3A+ATP-Binding+Cassette+Gene+Family&doi=10.1602%2Fneurorx.2.1.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-brain barrier active efflux transporters: ATP-binding cassette gene family</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-98</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from potentially harmful endogenous and exogenous substances.  BBB active drug efflux transporters of the ATP-binding cassette (ABC) gene family are increasingly recognized as important determinants of drug distribution to, and elimination from, the CNS.  The ABC efflux transporter P-glycoprotein (Pgp) has been demonstrated as a key element of the BBB that can actively transport a huge variety of lipophilic drugs out of the brain capillary endothelial cells that form the BBB.  In addition to Pgp, other ABC efflux transporters such as members of the multidrug resistance protein (MRP) family and breast cancer resistance protein (BCRP) seem to contribute to BBB function.  Consequences of ABC efflux transporters in the BBB include minimizing or avoiding neurotoxic adverse effects of drugs that otherwise would penetrate into the brain.  However, ABC efflux transporters may also limit the central distribution of drugs that are beneficial to treat CNS diseases.  Furthermore, neurological disorders such as epilepsy may be associated with overexpression of ABC efflux transporters at the BBB, resulting in pharmacoresistance to therapeutic medication.  Therefore, modulation of ABC efflux transporters at the BBB forms a novel strategy to enhance the penetration of drugs into the brain and may yield new therapeutic options for drug-resistant CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8zmuJRBq_DwvupmecNw_lfW6udTcc2eYi3_dxgQpq2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzntVejsA%253D%253D&md5=4de8b6e417fdc59a41aef2629475da8d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.1.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.1.86%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DBlood-Brain%2520Barrier%2520Active%2520Efflux%2520Transporters%253A%2520ATP-Binding%2520Cassette%2520Gene%2520Family%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D86%26epage%3D98%26doi%3D10.1602%2Fneurorx.2.1.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span> </span><span class="NLM_article-title">Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11851</span><span class="NLM_x">–</span> <span class="NLM_lpage">11858</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-1377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1158%2F0008-5472.CAN-06-1377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=17178882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlagu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11851-11858&author=L.+Liuauthor=Y.+Caoauthor=C.+Chenauthor=X.+Zhangauthor=A.+McNabolaauthor=D.+Wilkieauthor=S.+Wilhelmauthor=M.+Lynchauthor=C.+Carter&title=Sorafenib+Blocks+the+RAF%2FMEK%2FERK+Pathway%2C+Inhibits+Tumor+Angiogenesis%2C+and+Induces+Tumor+Cell+Apoptosis+in+Hepatocellular+Carcinoma+Model+PLC%2FPRF%2F5&doi=10.1158%2F0008-5472.CAN-06-1377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5</span></div><div class="casAuthors">Liu, Li; Cao, Yichen; Chen, Charles; Zhang, Xiaomei; McNabola, Angela; Wilkie, Dean; Wilhelm, Scott; Lynch, Mark; Carter, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11851-11858</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important roles in the development of hepatocellular carcinomas (HCC).  Sorafenib (BAY 43-9006, Nexavar) is a multikinase inhibitor with activity against Raf kinase and several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), FLT3, Ret, and c-Kit.  In this study, we investigated the in vitro effects of sorafenib on PLC/PRF/5 and HepG2 HCC cells and the in vivo antitumor efficacy and mechanism of action on PLC/PRF/5 human tumor xenografts in severe combined immunodeficient mice.  Sorafenib inhibited the phosphorylation of MEK and ERK and down-regulated cyclin D1 levels in these two cell lines.  Sorafenib also reduced the phosphorylation level of eIF4E and down-regulated the antiapoptotic protein Mcl-1 in a MEK/ERK-independent manner.  Consistent with the effects on both MEK/ERK-dependent and MEK/ERK-independent signaling pathways, sorafenib inhibited proliferation and induced apoptosis in both HCC cell lines.  In the PLC/PRF/5 xenograft model, sorafenib tosylate dosed at 10 mg/kg inhibited tumor growth by 49%.  At 30 mg/kg, sorafenib tosylate produced complete tumor growth inhibition.  A dose of 100 mg/kg produced partial tumor regressions in 50% of the mice.  In mechanism of action studies, sorafenib inhibited the phosphorylation of both ERK and eIF4E, reduced the microvessel area (assessed by CD34 immunohistochem.), and induced tumor cell apoptosis (assessed by terminal deoxynucleotidyl transferase-mediated nick end labeling) in PLC/PRF/5 tumor xenografts.  These results suggest that the antitumor activity of sorafenib in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppvphV4C1i-LVg90H21EOLACvtfcHk0lgRa-fB3GsRDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlagu73F&md5=79c8dd43356ab00fcc473423834e3c93</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-1377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-1377%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DC.%26atitle%3DSorafenib%2520Blocks%2520the%2520RAF%252FMEK%252FERK%2520Pathway%252C%2520Inhibits%2520Tumor%2520Angiogenesis%252C%2520and%2520Induces%2520Tumor%2520Cell%2520Apoptosis%2520in%2520Hepatocellular%2520Carcinoma%2520Model%2520PLC%252FPRF%252F5%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11851%26epage%3D11858%26doi%3D10.1158%2F0008-5472.CAN-06-1377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Si, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, A. G.</span><span> </span><span class="NLM_article-title">A Versatile Synthesis of Substituted Isoquinolines</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">10409</span><span class="NLM_x">–</span> <span class="NLM_lpage">10413</span><span class="refDoi"> DOI: 10.1002/anie.201104769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1002%2Fanie.201104769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCnt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=10409-10413&author=C.+Siauthor=A.+G.+Myers&title=A+Versatile+Synthesis+of+Substituted+Isoquinolines&doi=10.1002%2Fanie.201104769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Versatile Synthesis of Substituted Isoquinolines</span></div><div class="casAuthors">Si, Chong; Myers, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">10409-10413, S10409/1-S10409/71</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This communication present the direct assembly of substituted isoquinolines and biisoquinolines for use in versatile and unique methodologies for the construction of heterocyclic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQVSVG9HFyoLVg90H21EOLACvtfcHk0lhmXwjvjECyLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCnt7zI&md5=a883e7a9bb6ef7d3db76552032e2addd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201104769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201104769%26sid%3Dliteratum%253Aachs%26aulast%3DSi%26aufirst%3DC.%26aulast%3DMyers%26aufirst%3DA.%2BG.%26atitle%3DA%2520Versatile%2520Synthesis%2520of%2520Substituted%2520Isoquinolines%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D10409%26epage%3D10413%26doi%3D10.1002%2Fanie.201104769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Akazawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tachikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terasaki, T.</span><span> </span><span class="NLM_article-title">Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2456</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.6b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=2443-2456&author=T.+Akazawaauthor=Y.+Uchidaauthor=M.+Tachikawaauthor=S.+Ohtsukiauthor=T.+Terasaki&title=Quantitative+Targeted+Absolute+Proteomics+of+Transporters+and+Pharmacoproteomics-Based+Reconstruction+of+P-Glycoprotein+Function+in+Mouse+Small+Intestine&doi=10.1021%2Facs.molpharmaceut.6b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine</span></div><div class="casAuthors">Akazawa, Takanori; Uchida, Yasuo; Tachikawa, Masanori; Ohtsuki, Sumio; Terasaki, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2443-2456</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate whether a pharmacokinetic model integrating in vitro mdr1a efflux activity (which we previously reported) with in vitro/in vivo differences in protein expression level can reconstruct intestinal mdr1a function.  In situ intestinal permeability-surface area product ratio between wild-type and mdr1a/1b (-/-) mice is one of the parameters used to describe intestinal mdr1a function.  The reconstructed ratios of six mdr1a substrates (dexamethasone, digoxin, loperamide, quinidine, verapamil, vinblastine) and one nonsubstrate (diazepam) were consistent with the obsd. values reported by Adachi et al. within 2.1-fold difference.  Thus, intestinal mdr1a function can be reconstructed by our pharmacoproteomic modeling approach.  Furthermore, we evaluated regional differences in protein expression levels of mouse intestinal transporters.  Sixteen (mdr1a, mrp4, bcrp, abcg5, abcg8, glut1, 4f2hc, sglt1, lat2, pept1, mct1, slc22a18, ostβ, villin1, Na+/K+-ATPase, γ-gtp) out of 46 target mols. were detected by employing our established quant. targeted abs. proteomics technique.  The protein expression amts. of mdr1a and bcrp increased progressively from duodenum to ileum.  Sglt1, lat2, and 4f2hc were highly expressed in jejunum and ileum.  Mct1 and ostβ were highly expressed in ileum.  The quant. expression profiles established here should be helpful to understand and predict intestinal transporter functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfdG2_wq0SL7Vg90H21EOLACvtfcHk0lhmXwjvjECyLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCit70%253D&md5=fedbf3f4cb757695c6fbd05704ef0ac9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00196%26sid%3Dliteratum%253Aachs%26aulast%3DAkazawa%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DTachikawa%26aufirst%3DM.%26aulast%3DOhtsuki%26aufirst%3DS.%26aulast%3DTerasaki%26aufirst%3DT.%26atitle%3DQuantitative%2520Targeted%2520Absolute%2520Proteomics%2520of%2520Transporters%2520and%2520Pharmacoproteomics-Based%2520Reconstruction%2520of%2520P-Glycoprotein%2520Function%2520in%2520Mouse%2520Small%2520Intestine%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D2443%26epage%3D2456%26doi%3D10.1021%2Facs.molpharmaceut.6b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Gynther, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huttunen, K. M.</span><span> </span><span class="NLM_article-title">Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2484</span><span class="NLM_x">–</span> <span class="NLM_lpage">2491</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.6b00217</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00217" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=2484-2491&author=M.+Gyntherauthor=D.+S.+Pickeringauthor=J.+A.+Spicerauthor=W.+A.+Dennyauthor=K.+M.+Huttunen&title=Systemic+and+Brain+Pharmacokinetics+of+Perforin+Inhibitor+Prodrugs&doi=10.1021%2Facs.molpharmaceut.6b00217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs</span></div><div class="casAuthors">Gynther, Mikko; Pickering, Darryl S.; Spicer, Julie A.; Denny, William A.; Huttunen, Kristiina M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2484-2491</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have recently reported that by converting a perforin inhibitor into an L-type amino acid transporter 1 (LAT1)-utilizing prodrug its cellular uptake can be greatly increased.  The aim of the present study was to det. the in vivo and brain pharmacokinetics of two perforin inhibitors and their LAT1-utilizing prodrugs 1 and 2.  In addn., the brain uptake mechanism and entry into primary mouse cortical neurons and astrocytes were evaluated.  After 23 μmol/kg i.p. bolus injection, the prodrugs' unbound area under the concn. curve in brain was 0.3 nmol/g × min, whereas the parent drugs could not reach the brain.  The unbound brain concns. of the prodrugs after 100 μM in situ mouse brain perfusion were 521.4 ± 46.9 and 126.9 ± 19.9 pmol/g for prodrugs 1 and 2, resp.  The combination of competing transporter substrates for LAT1, L-tryptophan, and for org. anion transporting polypeptides, probenecid, decreased the brain concns. to 352.4 ± 44.5 and 70.9 ± 7.0 pmol/g, resp.  In addn., in vitro uptake studies showed that at 100 μM prodrug 1 had 3.4-fold and 4.5-fold higher uptake rate into neurons and astrocytes, resp., compared to its parent drug.  Thus, the prodrugs enhance significantly the therapeutic potential of the parent drugs for the treatment of disorders of central nervous system in which neuroinflammation is involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTu1P9Kh__1LVg90H21EOLACvtfcHk0lhmXwjvjECyLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCiurg%253D&md5=245bc7a347c3666e1ac09f3bf4d5a469</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00217%26sid%3Dliteratum%253Aachs%26aulast%3DGynther%26aufirst%3DM.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26atitle%3DSystemic%2520and%2520Brain%2520Pharmacokinetics%2520of%2520Perforin%2520Inhibitor%2520Prodrugs%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D2484%26epage%3D2491%26doi%3D10.1021%2Facs.molpharmaceut.6b00217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogden, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynelis, S. F.</span><span> </span><span class="NLM_article-title">Distinct Functional and Pharmacological Properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">1084</span><span class="NLM_x">–</span> <span class="NLM_lpage">1096</span><span class="refDoi"> DOI: 10.1016/j.neuron.2014.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.neuron.2014.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24607230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslKqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2014&pages=1084-1096&author=K.+B.+Hansenauthor=K.+K.+Ogdenauthor=H.+Yuanauthor=S.+F.+Traynelis&title=Distinct+Functional+and+Pharmacological+Properties+of+Triheteromeric+GluN1%2FGluN2A%2FGluN2B+NMDA+Receptors&doi=10.1016%2Fj.neuron.2014.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Functional and Pharmacological Properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors</span></div><div class="casAuthors">Hansen, Kasper B.; Ogden, Kevin K.; Yuan, Hongjie; Traynelis, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1084-1096</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">NMDA receptors are tetrameric ligand-gated ion channels comprised of GluN1, GluN2, and GluN3 subunits.  Two different GluN2 subunits have been identified in most NMDA receptor-expressing cells, and the majority of native receptors are triheteromers contg. two GluN1 and two different GluN2.  In contrast to diheteromeric NMDA receptors, little is known about the function of triheteromers.  We developed a method to provide selective cell-surface expression of recombinant GluN1/GluN2A/GluN2B triheteromers and compared properties of these receptors with those of GluN1/GluN2A and GluN1/GluN2B diheteromers.  We show that glutamate deactivation of triheteromers is distinct from those of GluN1/GluN2A and GluN1/GluN2B and reveal modulation of triheteromers by subunit-selective antagonists ifenprodil, CP-101,606, TCN-201, and extracellular Zn2+.  Furthermore, kinetic measurements suggest variation in the ifenprodil binding site of triheteromers compared to GluN1/GluN2B diheteromers.  This work provides insight into the distinct properties of GluN1/GluN2A/GluN2B triheteromers, which are presumably the most abundant NMDA receptors in the adult forebrain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6JuHTe09fw7Vg90H21EOLACvtfcHk0lhmXwjvjECyLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslKqur8%253D&md5=c0fb80e63e7ea59d2b493a3c9ce31852</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2014.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2014.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DOgden%26aufirst%3DK.%2BK.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26atitle%3DDistinct%2520Functional%2520and%2520Pharmacological%2520Properties%2520of%2520Triheteromeric%2520GluN1%252FGluN2A%252FGluN2B%2520NMDA%2520Receptors%26jtitle%3DNeuron%26date%3D2014%26volume%3D81%26spage%3D1084%26epage%3D1096%26doi%3D10.1016%2Fj.neuron.2014.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risgaard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perszyk, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jørgensen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vance, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogden, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furukawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynelis, S. F.</span><span> </span><span class="NLM_article-title">Structural Determinants of Agonist Efficacy at the Glutamate Binding Site of N-Methyl-D-Aspartate Receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span><span class="refDoi"> DOI: 10.1124/mol.113.085803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fmol.113.085803" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=114-127&author=K.+B.+Hansenauthor=N.+Tajimaauthor=R.+Risgaardauthor=R.+E.+Perszykauthor=L.+J%C3%B8rgensenauthor=K.+M.+Vanceauthor=K.+K.+Ogdenauthor=R.+P.+Clausenauthor=H.+Furukawaauthor=S.+F.+Traynelis&title=Structural+Determinants+of+Agonist+Efficacy+at+the+Glutamate+Binding+Site+of+N-Methyl-D-Aspartate+Receptors&doi=10.1124%2Fmol.113.085803"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.085803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.085803%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DTajima%26aufirst%3DN.%26aulast%3DRisgaard%26aufirst%3DR.%26aulast%3DPerszyk%26aufirst%3DR.%2BE.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DL.%26aulast%3DVance%26aufirst%3DK.%2BM.%26aulast%3DOgden%26aufirst%3DK.%2BK.%26aulast%3DClausen%26aufirst%3DR.%2BP.%26aulast%3DFurukawa%26aufirst%3DH.%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26atitle%3DStructural%2520Determinants%2520of%2520Agonist%2520Efficacy%2520at%2520the%2520Glutamate%2520Binding%2520Site%2520of%2520N-Methyl-D-Aspartate%2520Receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D114%26epage%3D127%26doi%3D10.1124%2Fmol.113.085803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Assaf, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venskutonytė, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahamsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajhede, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrup, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, A. a.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frydenvang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gefflaut, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Chemoenzymatic Synthesis of New 2,4-Syn-Functionalized (S)-Glutamate Analogues and Structure-Activity Relationship Studies at Ionotropic Glutamate Receptors and Excitatory Amino Acid Transporters</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1614</span><span class="NLM_x">–</span> <span class="NLM_lpage">1628</span><span class="refDoi"> DOI: 10.1021/jm301433m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301433m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Sktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1614-1628&author=Z.+Assafauthor=A.+P.+Larsenauthor=R.+Venskutonyt%C4%97author=L.+Hanauthor=B.+Abrahamsenauthor=B.+Nielsenauthor=M.+Gajhedeauthor=J.+S.+Kastrupauthor=A.+a.+Jensenauthor=D.+S.+Pickeringauthor=K.+Frydenvangauthor=T.+Gefflautauthor=L.+Bunch&title=Chemoenzymatic+Synthesis+of+New+2%2C4-Syn-Functionalized+%28S%29-Glutamate+Analogues+and+Structure-Activity+Relationship+Studies+at+Ionotropic+Glutamate+Receptors+and+Excitatory+Amino+Acid+Transporters&doi=10.1021%2Fjm301433m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoenzymatic synthesis of new 2,4-syn-functionalized (S)-glutamate analogues and structure-activity relationship studies at ionotropic glutamate receptors and excitatory amino acid transporters</span></div><div class="casAuthors">Assaf, Zeinab; Larsen, Anja P.; Venskutonyte, Raminta; Han, Liwei; Abrahamsen, Bjarke; Nielsen, Birgitte; Gajhede, Michael; Kastrup, Jette S.; Jensen, Anders A.; Pickering, Darryl S.; Frydenvang, Karla; Gefflaut, Thierry; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1614-1628</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the mammalian central nervous system, (S)-glutamate (Glu) is released from the presynaptic neuron where it activates a plethora of pre- and postsynaptic Glu receptors.  The fast acting ionotropic Glu receptors (iGluRs) are ligand gated ion channels and are believed to be involved in a vast no. of neurol. functions such as memory and learning, synaptic plasticity, and motor function.  The synthesis of 14 enantiopure 2,4-syn-Glu analogs, e.g. (I), (II), (III), is accessed by a short and efficient chemoenzymic approach starting from readily available cyclohexanone (IV).  Pharmacol. characterization at the iGluRs and EAAT1-3 subtypes revealed analog II as a selective GluK1 ligand with low nanomolar affinity.  Two X-ray crystal structures of the key analog II in the ligand-binding domain (LBD) of GluA2 and GluK3 were detd.  Partial domain closure was seen in the GluA2-LBD complex with II comparable to that induced by kainate.  In contrast, full domain closure was obsd. in the GluK3-LBD complex with II, similar to that of GluK3-LBD with glutamate bound.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNDU3_wI6ErbVg90H21EOLACvtfcHk0ljXlJ8-lfxlxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Sktbs%253D&md5=820d359e25bfc4d9505c20bc303cd67d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm301433m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301433m%26sid%3Dliteratum%253Aachs%26aulast%3DAssaf%26aufirst%3DZ.%26aulast%3DLarsen%26aufirst%3DA.%2BP.%26aulast%3DVenskutonyt%25C4%2597%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DAbrahamsen%26aufirst%3DB.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DGajhede%26aufirst%3DM.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26aulast%3DJensen%26aufirst%3DA.%2Ba.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DGefflaut%26aufirst%3DT.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DChemoenzymatic%2520Synthesis%2520of%2520New%25202%252C4-Syn-Functionalized%2520%2528S%2529-Glutamate%2520Analogues%2520and%2520Structure-Activity%2520Relationship%2520Studies%2520at%2520Ionotropic%2520Glutamate%2520Receptors%2520and%2520Excitatory%2520Amino%2520Acid%2520Transporters%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1614%26epage%3D1628%26doi%3D10.1021%2Fjm301433m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Sagot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umberti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensbøl, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapelet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gefflaut, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Chemo-Enzymatic Synthesis of a Series of 2,4-Syn-Functionalized (S)-Glutamate Analogues: New Insight into the Structure-Activity Relation of Ionotropic Glutamate Receptor Subtypes 5, 6, and 7</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4093</span><span class="NLM_x">–</span> <span class="NLM_lpage">4103</span><span class="refDoi"> DOI: 10.1021/jm800092x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800092x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsl2rsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4093-4103&author=E.+Sagotauthor=D.+S.+Pickeringauthor=X.+Puauthor=M.+Umbertiauthor=T.+B.+Stensb%C3%B8lauthor=B.+Nielsenauthor=M.+Chapeletauthor=J.+Bolteauthor=T.+Gefflautauthor=L.+Bunch&title=Chemo-Enzymatic+Synthesis+of+a+Series+of+2%2C4-Syn-Functionalized+%28S%29-Glutamate+Analogues%3A+New+Insight+into+the+Structure-Activity+Relation+of+Ionotropic+Glutamate+Receptor+Subtypes+5%2C+6%2C+and+7&doi=10.1021%2Fjm800092x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogs: New insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7</span></div><div class="casAuthors">Sagot, Emanuelle; Pickering, Darryl S.; Pu, Xiaosui; Umberti, Michelle; Stensboel, Tine B.; Nielsen, Birgitte; Chapelet, Marion; Bolte, Jean; Gefflaut, Thierry; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4093-4103</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(S)-Glutamic acid (Glu) is the major excitatory neurotransmitter in the central nervous system (CNS) activating the plethora of ionotropic Glu receptors (iGluRs) and metabotropic Glu receptors (mGluRs).  In this paper, we present a chemo-enzymic strategy for the enantioselective synthesis of five new Glu analogs (I) [R1 = CH2OH, CH2OCh2Ph, CH2CO2Me, (CH2)2CO2Me, (CH2)2CO2H, (CH2)2CONH2, (CH2)2CONHMe, (CH2)2CO2NHCH2Ph; R1 = (CH2)2CONH(CH)2Me is exempt] holding a functionalized substituent in the 4-position.  Nine Glu analogs I are characterized pharmacol. at native 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA), kainic acid (KA), and N-methyl-D-aspartic acid (NMDA) receptors in rat synaptosomes as well as in binding assays at cloned rat iGluR5-7 subtypes.  A detailed in silico study address as to why I [R1 = (CH2)2CONHMe] is a high-affinity ligand at iGluR5-7 (Ki = 3.81, 123, 57.3 nM, resp.), while I [R1 = (CH2)2CO2Me] is only a high affinity ligand at iGluR5 (Ki = 42.8 nM).  Furthermore, a small series of com. available iGluR ligands are characterized in iGluR5-7 binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpegN5n8XosULVg90H21EOLACvtfcHk0ljXlJ8-lfxlxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsl2rsbc%253D&md5=8a9c9c7964bf7884ea56f165e24c6188</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm800092x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800092x%26sid%3Dliteratum%253Aachs%26aulast%3DSagot%26aufirst%3DE.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DPu%26aufirst%3DX.%26aulast%3DUmberti%26aufirst%3DM.%26aulast%3DStensb%25C3%25B8l%26aufirst%3DT.%2BB.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DChapelet%26aufirst%3DM.%26aulast%3DBolte%26aufirst%3DJ.%26aulast%3DGefflaut%26aufirst%3DT.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DChemo-Enzymatic%2520Synthesis%2520of%2520a%2520Series%2520of%25202%252C4-Syn-Functionalized%2520%2528S%2529-Glutamate%2520Analogues%253A%2520New%2520Insight%2520into%2520the%2520Structure-Activity%2520Relation%2520of%2520Ionotropic%2520Glutamate%2520Receptor%2520Subtypes%25205%252C%25206%252C%2520and%25207%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4093%26epage%3D4103%26doi%3D10.1021%2Fjm800092x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Alcaide, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haym, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Møllerud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Synthesis and Pharmacological Characterization of the Selective GluK1 Radioligand (S)-2-Amino-3-(6-[ 3 H]-2,4-Dioxo-3,4-dihydrothieno[3,2-D]pyrimidin-1(2H)-Yl)propanoic Acid ([3H]-NF608)</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2136</span><span class="NLM_x">–</span> <span class="NLM_lpage">2144</span><span class="refDoi"> DOI: 10.1039/C6MD00339G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1039%2FC6MD00339G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2136-2144&author=A.+Alcaideauthor=L.+Marconiauthor=A.+Marekauthor=I.+Haymauthor=B.+Nielsenauthor=S.+M%C3%B8llerudauthor=M.+Jensenauthor=P.+Contiauthor=D.+S.+Pickeringauthor=L.+Bunch&title=Synthesis+and+Pharmacological+Characterization+of+the+Selective+GluK1+Radioligand+%28S%29-2-Amino-3-%286-%5B+3+H%5D-2%2C4-Dioxo-3%2C4-dihydrothieno%5B3%2C2-D%5Dpyrimidin-1%282H%29-Yl%29propanoic+Acid+%28%5B3H%5D-NF608%29&doi=10.1039%2FC6MD00339G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1039%2FC6MD00339G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00339G%26sid%3Dliteratum%253Aachs%26aulast%3DAlcaide%26aufirst%3DA.%26aulast%3DMarconi%26aufirst%3DL.%26aulast%3DMarek%26aufirst%3DA.%26aulast%3DHaym%26aufirst%3DI.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DM%25C3%25B8llerud%26aufirst%3DS.%26aulast%3DJensen%26aufirst%3DM.%26aulast%3DConti%26aufirst%3DP.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Characterization%2520of%2520the%2520Selective%2520GluK1%2520Radioligand%2520%2528S%2529-2-Amino-3-%25286-%255B%25203%2520H%255D-2%252C4-Dioxo-3%252C4-dihydrothieno%255B3%252C2-D%255Dpyrimidin-1%25282H%2529-Yl%2529propanoic%2520Acid%2520%2528%255B3H%255D-NF608%2529%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D2136%26epage%3D2144%26doi%3D10.1039%2FC6MD00339G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':[],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ahmed B. Montaser, Juulia Järvinen, Susanne Löffler, Johanna Huttunen, Seppo Auriola, Marko Lehtonen, Aaro Jalkanen, <span class="NLM_string-name hlFld-ContribAuthor">Kristiina M. Huttunen</span>. </span><span class="cited-content_cbyCitation_article-title">L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood–Brain Barrier and into Human and Mouse Brain Parenchymal Cells. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (24)
                                     , 4301-4315. <a href="https://doi.org/10.1021/acschemneuro.0c00564" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00564%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DL-Type%252BAmino%252BAcid%252BTransporter%252B1%252BEnables%252Bthe%252BEfficient%252BBrain%252BDelivery%252Bof%252BSmall-Sized%252BProdrug%252Bacross%252Bthe%252BBlood%2525E2%252580%252593Brain%252BBarrier%252Band%252Binto%252BHuman%252Band%252BMouse%252BBrain%252BParenchymal%252BCells%26aulast%3DMontaser%26aufirst%3DAhmed%2BB.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28082020%26date%3D06112020%26date%3D24112020%26volume%3D11%26issue%3D24%26spage%3D4301%26epage%3D4315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Silke Kayser, Jacob C. Hansen, Markus Staudt, Aleksandra Moroz, Younes Larsen, Piero Temperini, Feng Yi, Jed T. Syrenne, Niels Krogsgaard-Larsen, Stylianos Iliadis, Birgitte Nielsen, Kasper B. Hansen, Darryl S. Pickering, <span class="NLM_string-name hlFld-ContribAuthor">Lennart Bunch</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Synthesis of New (2S,3R)-3-Carboxyphenyl)pyrrolidine-2-carboxylic Acid Analogues Utilizing a C(sp3)–H Activation Strategy and Structure–Activity Relationship Studies at the Ionotropic Glutamate Receptors. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 674-701. <a href="https://doi.org/10.1021/acschemneuro.0c00003" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00003%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DStereoselective%252BSynthesis%252Bof%252BNew%252B%2525282S%25252C3R%252529-3-Carboxyphenyl%252529pyrrolidine-2-carboxylic%252BAcid%252BAnalogues%252BUtilizing%252Ba%252BC%252528sp3%252529%2525E2%252580%252593H%252BActivation%252BStrategy%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%252Bat%252Bthe%252BIonotropic%252BGlutamate%252BReceptors%26aulast%3DKayser%26aufirst%3DSilke%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D02012020%26date%3D27012020%26date%3D17022020%26volume%3D11%26issue%3D5%26spage%3D674%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Silke Kayser, Piero Temperini, Christian B. M. Poulie, Markus Staudt, Birgitte Nielsen, Darryl S. Pickering, <span class="NLM_string-name hlFld-ContribAuthor">Lennart Bunch</span>. </span><span class="cited-content_cbyCitation_article-title">A Diversity Oriented Synthesis Approach to New 2,3-trans-Substituted l-Proline Analogs as Potential Ligands for the Ionotropic Glutamate Receptors. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 702-714. <a href="https://doi.org/10.1021/acschemneuro.0c00005" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00005%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DA%252BDiversity%252BOriented%252BSynthesis%252BApproach%252Bto%252BNew%252B2%25252C3-trans-Substituted%252Bl-Proline%252BAnalogs%252Bas%252BPotential%252BLigands%252Bfor%252Bthe%252BIonotropic%252BGlutamate%252BReceptors%26aulast%3DKayser%26aufirst%3DSilke%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03012020%26date%3D03022020%26date%3D18022020%26volume%3D11%26issue%3D5%26spage%3D702%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elena Puris, Mikko Gynther, Elizabeth C.M. de Lange, Seppo Auriola, Margareta Hammarlund-Udenaes, Kristiina M. Huttunen, <span class="NLM_string-name hlFld-ContribAuthor">Irena Loryan</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (7)
                                     , 3261-3274. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b00502" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b00502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b00502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b00502%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DMechanistic%252BStudy%252Bon%252Bthe%252BUse%252Bof%252Bthe%252Bl-Type%252BAmino%252BAcid%252BTransporter%252B1%252Bfor%252BBrain%252BIntracellular%252BDelivery%252Bof%252BKetoprofen%252Bvia%252BProdrug%25253A%252BA%252BNovel%252BApproach%252BSupporting%252Bthe%252BDevelopment%252Bof%252BProdrugs%252Bfor%252BIntracellular%252BTargets%26aulast%3DPuris%26aufirst%3DElena%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08052019%26date%3D10062019%26date%3D18062019%26date%3D10062019%26volume%3D16%26issue%3D7%26spage%3D3261%26epage%3D3274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bingchen  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiali  Jiang</span>, <span class="hlFld-ContribAuthor ">Pengyu  Wu</span>, <span class="hlFld-ContribAuthor ">Junjie  Zou</span>, <span class="hlFld-ContribAuthor ">Jingqing  Le</span>, <span class="hlFld-ContribAuthor ">Juanfang  Lin</span>, <span class="hlFld-ContribAuthor ">Chao  Li</span>, <span class="hlFld-ContribAuthor ">Bangyue  Luo</span>, <span class="hlFld-ContribAuthor ">Yongjie  Zhang</span>, <span class="hlFld-ContribAuthor ">Rui  Huang</span>, <span class="hlFld-ContribAuthor ">Jingwei  Shao</span>. </span><span class="cited-content_cbyCitation_article-title">A smart dual-drug nanosystem based on co-assembly of plant and food-derived natural products for synergistic HCC immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     , 246-257. <a href="https://doi.org/10.1016/j.apsb.2020.07.026" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.07.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.07.026%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DA%252Bsmart%252Bdual-drug%252Bnanosystem%252Bbased%252Bon%252Bco-assembly%252Bof%252Bplant%252Band%252Bfood-derived%252Bnatural%252Bproducts%252Bfor%252Bsynergistic%252BHCC%252Bimmunotherapy%26aulast%3DZhang%26aufirst%3DBingchen%26date%3D2021%26volume%3D11%26issue%3D1%26spage%3D246%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhang  Cheng</span>, <span class="hlFld-ContribAuthor ">Jiang  Wei-Qi</span>, <span class="hlFld-ContribAuthor ">Ding  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2020,</strong> <em>1874 </em>
                                    (1)
                                     , 188382. <a href="https://doi.org/10.1016/j.bbcan.2020.188382" title="DOI URL">https://doi.org/10.1016/j.bbcan.2020.188382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2020.188382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2020.188382%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DNew%252Binsights%252Bon%252Bsorafenib%252Bresistance%252Bin%252Bliver%252Bcancer%252Bwith%252Bcorrelation%252Bof%252Bindividualized%252Btherapy%26aulast%3DCheng%26aufirst%3DZhang%26date%3D2020%26volume%3D1874%26issue%3D1%26spage%3D188382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  Montaser</span>, <span class="hlFld-ContribAuthor ">Marko  Lehtonen</span>, <span class="hlFld-ContribAuthor ">Mikko  Gynther</span>, <span class="hlFld-ContribAuthor ">Kristiina M.  Huttunen</span>. </span><span class="cited-content_cbyCitation_article-title">L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2020,</strong> <em>12 </em>
                                    (4)
                                     , 344. <a href="https://doi.org/10.3390/pharmaceutics12040344" title="DOI URL">https://doi.org/10.3390/pharmaceutics12040344</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics12040344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics12040344%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DL-Type%252BAmino%252BAcid%252BTransporter%252B1-Utilizing%252BProdrugs%252Bof%252BKetoprofen%252BCan%252BEfficiently%252BReduce%252BBrain%252BProstaglandin%252BLevels%26aulast%3DMontaser%26aufirst%3DAhmed%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D4%26spage%3D344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Johanna  Huttunen</span>, <span class="hlFld-ContribAuthor ">Soile  Peltokangas</span>, <span class="hlFld-ContribAuthor ">Mikko  Gynther</span>, <span class="hlFld-ContribAuthor ">Teemu  Natunen</span>, <span class="hlFld-ContribAuthor ">Mikko  Hiltunen</span>, <span class="hlFld-ContribAuthor ">Seppo  Auriola</span>, <span class="hlFld-ContribAuthor ">Marika  Ruponen</span>, <span class="hlFld-ContribAuthor ">Kati-Sisko  Vellonen</span>, <span class="hlFld-ContribAuthor ">Kristiina M.  Huttunen</span>. </span><span class="cited-content_cbyCitation_article-title">l-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-019-49009-z" title="DOI URL">https://doi.org/10.1038/s41598-019-49009-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-019-49009-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-019-49009-z%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3Dl-Type%252BAmino%252BAcid%252BTransporter%252B1%252B%252528LAT1%25252FLat1%252529-Utilizing%252BProdrugs%252BCan%252BImprove%252Bthe%252BDelivery%252Bof%252BDrugs%252Binto%252BNeurons%25252C%252BAstrocytes%252Band%252BMicroglia%26aulast%3DHuttunen%26aufirst%3DJohanna%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Johanna  Huttunen</span>, <span class="hlFld-ContribAuthor ">Mikko  Gynther</span>, <span class="hlFld-ContribAuthor ">Kati-Sisko  Vellonen</span>, <span class="hlFld-ContribAuthor ">Kristiina M.  Huttunen</span>. </span><span class="cited-content_cbyCitation_article-title">L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs). </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2019,</strong> <em>571 </em>, 118714. <a href="https://doi.org/10.1016/j.ijpharm.2019.118714" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2019.118714</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2019.118714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2019.118714%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DL-Type%252Bamino%252Bacid%252Btransporter%252B1%252B%252528LAT1%252529-utilizing%252Bprodrugs%252Bare%252Bcarrier-selective%252Bdespite%252Bhaving%252Blow%252Baffinity%252Bfor%252Borganic%252Banion%252Btransporting%252Bpolypeptides%252B%252528OATPs%252529%26aulast%3DHuttunen%26aufirst%3DJohanna%26date%3D2019%26volume%3D571%26spage%3D118714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniil  Zhukovsky</span>, <span class="hlFld-ContribAuthor ">Dmitry  Dar'in</span>, <span class="hlFld-ContribAuthor ">Grigory  Kantin</span>, <span class="hlFld-ContribAuthor ">Mikhail  Krasavin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Exploration of α-Diazo γ-Butyrolactams. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (13)
                                     , 2397-2400. <a href="https://doi.org/10.1002/ejoc.201900133" title="DOI URL">https://doi.org/10.1002/ejoc.201900133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900133%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthetic%252BExploration%252Bof%252B%2525CE%2525B1-Diazo%252B%2525CE%2525B3-Butyrolactams%26aulast%3DZhukovsky%26aufirst%3DDaniil%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D13%26spage%3D2397%26epage%3D2400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mikko  Gynther</span>, <span class="hlFld-ContribAuthor ">Elena  Puris</span>, <span class="hlFld-ContribAuthor ">Soile  Peltokangas</span>, <span class="hlFld-ContribAuthor ">Seppo  Auriola</span>, <span class="hlFld-ContribAuthor ">Katja M.  Kanninen</span>, <span class="hlFld-ContribAuthor ">Jari  Koistinaho</span>, <span class="hlFld-ContribAuthor ">Kristiina M.  Huttunen</span>, <span class="hlFld-ContribAuthor ">Marika  Ruponen</span>, <span class="hlFld-ContribAuthor ">Kati-Sisko  Vellonen</span>. </span><span class="cited-content_cbyCitation_article-title">Alzheimer’s Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2019,</strong> <em>36 </em>
                                    (1)
                                     <a href="https://doi.org/10.1007/s11095-018-2546-7" title="DOI URL">https://doi.org/10.1007/s11095-018-2546-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-018-2546-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-018-2546-7%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DAlzheimer%2525E2%252580%252599s%252BDisease%252BPhenotype%252Bor%252BInflammatory%252BInsult%252BDoes%252BNot%252BAlter%252BFunction%252Bof%252BL-Type%252BAmino%252BAcid%252BTransporter%252B1%252Bin%252BMouse%252BBlood-Brain%252BBarrier%252Band%252BPrimary%252BAstrocytes%26aulast%3DGynther%26aufirst%3DMikko%26date%3D2019%26date%3D2018%26volume%3D36%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erin T.  Pelkey</span>, <span class="hlFld-ContribAuthor ">Sarah J.  Pelkey</span>, <span class="hlFld-ContribAuthor ">Jessica G.  Greger</span>. </span><span class="cited-content_cbyCitation_article-title">Reactions of 3-pyrrolin-2-ones. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 433-565. <a href="https://doi.org/10.1016/bs.aihch.2018.10.004" title="DOI URL">https://doi.org/10.1016/bs.aihch.2018.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2018.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2018.10.004%26sid%3Dliteratum%253Aachs%26atitle%3DReactions%252Bof%252B3-pyrrolin-2-ones%26aulast%3DPelkey%26aufirst%3DErin%2BT.%26date%3D2019%26spage%3D433%26epage%3D565%26pub%3DElsevier%26date%3D2019%26volume%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teemu A.  Natunen</span>, <span class="hlFld-ContribAuthor ">Mikko  Gynther</span>, <span class="hlFld-ContribAuthor ">Hannah  Rostalski</span>, <span class="hlFld-ContribAuthor ">Külli  Jaako</span>, <span class="hlFld-ContribAuthor ">Aaro J.  Jalkanen</span>. </span><span class="cited-content_cbyCitation_article-title">Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target. </span><span class="cited-content_cbyCitation_journal-name">Basic & Clinical Pharmacology & Toxicology</span><span> <strong>2019,</strong> <em>124 </em>
                                    (1)
                                     , 40-49. <a href="https://doi.org/10.1111/bcpt.13094" title="DOI URL">https://doi.org/10.1111/bcpt.13094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcpt.13094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcpt.13094%26sid%3Dliteratum%253Aachs%26jtitle%3DBasic%2520%2526%2520Clinical%2520Pharmacology%2520%2526%2520Toxicology%26atitle%3DExtracellular%252Bprolyl%252Boligopeptidase%252Bderived%252Bfrom%252Bactivated%252Bmicroglia%252Bis%252Ba%252Bpotential%252Bneuroprotection%252Btarget%26aulast%3DNatunen%26aufirst%3DTeemu%2BA.%26date%3D2019%26date%3D2018%26volume%3D124%26issue%3D1%26spage%3D40%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Activation of the lipid signaling pathway by GluN1/GluN2A receptor and the creation of transporter mediated drug resistance. NMDA binding to the GluN1/GluN2A receptor allows the influx of Ca<sup>2+</sup> into the cell, which leads to cPLA2 activation and the release of arachidonic acid (AA) from phospholipids. Arachidonic acid is metabolized to PGE<sub>2</sub>, which is transported by ABCC transporters out of the cell allowing the PGE<sub>2</sub> binding to EP-R. The EP-R activation leads to nuclear translocation of NF-κB followed by ABCG2 protein transcription and MDR.<a onclick="showRef(event, 'ref12 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref12 ref14 ref15 ref16 ref17">(12, 14-17)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of Glu, selective uncompetitive NMDA receptor antagonist MK-801, selective competitive NMDA receptor antagonists D-AP5, (<i>R</i>)-CPP, and competitive iGluR antagonist <b>1a</b>, including published analogs <b>1b,c</b> with relevance to the SAR study reported herein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Key Alcohol Intermediates <b>6b,d–f,j</b> via Rhodium(I)-Catalyzed 1,4 Addition of Respective Boronic Acids <b>3a,b,d–f,j</b> to Enone <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) [Rh(cod)Cl]<sub>2</sub>, H<sub>2</sub>O, Cs<sub>2</sub>CO<sub>3</sub>, enone <b>2</b>, THF or dioxane, rt (52–67%); (b) LiBEt<sub>3</sub>H, THF, −78 °C; (c) HSiEt<sub>3</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, DCM, −78 °C (31–78%).</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>1d</b>–<b>f</b> from Alcohols <b>6d</b>–<b>f</b>, Respectively<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O, NaIO<sub>4</sub>, EtOAc/MeCN/H<sub>2</sub>O (49–86%); (b) TFA, DCM, rt; (c) 1 M HCl (12–78%).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 3-Cyano Analog <b>1g</b> from Alcohol <b>6b</b> and 3-Carbamido Analog <b>1h</b> from <b>7g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TBSCl, imidazole, DMF, rt (73%, three steps from <b>4b</b>); (b) Zn(CN)<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, DMA, 120 °C; (c) TBAF, THF, rt (71%, two steps); (d) RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O, NaIO<sub>4</sub>, EtOAc/MeCN/H<sub>2</sub>O (76%); (e) TFA, DCM, rt; (f) 1 M HCl (81%, two steps); (g) 30% H<sub>2</sub>O<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, EtOH/H<sub>2</sub>O, rt (66%); (h) TFA, DCM, rt; (i) 1 M HCl (59% after three steps).</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 3-Boronic Acid Analog <b>1i</b>, Starting from Bromine <b>8b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) KOAc, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, DMF (61%); (b) TBAF, THF, rt (60%); (c) RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O, NaIO<sub>4</sub>, EtOAc/MeCN/H<sub>2</sub>O (65%); (d) TFA, DCM, rt; (e) 1 M HCl (40%, two steps).</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>1j</b> from Alcohol <b>6j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IBX, DMSO, rt; (b) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, 2-methyl-2-butene, <i>tert</i>-BuOH/H<sub>2</sub>O, rt (66%, two steps); (c) BBr<sub>3</sub>, DCM (8% after recrystallization from MeOH).</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>1k</b>–<b>l</b> via Copper(I)-Catalyzed Addition to Enone <b>2</b> and <b>1m</b> via Rhodium(I)-Catalyzed Addition to Enone <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) for <b>3k,l</b>, <i>n</i>-BuLi, CuCN, then enone <b>2</b>, Et<sub>2</sub>O, −78 to −42 °C (46% and 73%); (b) for <b>3m</b>, (Bpin)<sub>2</sub>, KOAc, (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub> (quant); (c) [Rh(cod)Cl]<sub>2</sub>, H<sub>2</sub>O, Cs<sub>2</sub>CO<sub>3</sub>, enone <b>2</b>, rt (41%); (d) for <b>4k,l</b>, LiBEt<sub>3</sub>H, THF, −78 °C, then HSiEt<sub>3</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, DCM, −78 °C; (e) for <b>4m</b>, BH<sub>3</sub>·SMe<sub>2</sub>, THF, reflux; (f) TBAF, THF, rt. (20% and 49%); (g) RuCl<sub>3</sub>·<i>x</i>H<sub>2</sub>O, NaIO<sub>4</sub>, EtOAc/MeCN/H<sub>2</sub>O (20–97%); (h) TFA, DCM, rt; (i) 1 M HCl (56–60%).</p></p></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Concentration–inhibition data for <b>1l</b> at recombinant NMDA receptor subtypes GluN1/GluN2A-D. Responses were measured using two-electrode voltage-clamp electrophysiology and were activated by coapplication of 100 μM glycine and Glu to <i>Xenopus</i> oocytes expressing recombinant NMDA receptors subtypes. Ten micromolar Glu was used for GluN1/GluN2A, 3 μM Glu for GluN1/GluN2B and GluN1/GluN2C, and 1 μM Glu for GluN1/GluN2D receptors. Data are mean ± SD (error bars are mostly contained within the symbols). See <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> for IC<sub>50</sub> and estimated <i>K</i><sub>i</sub> values.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ca<sup>2+</sup> transients via NMDA receptors in murine HCC cells. (A) Ca<sup>2+</sup> transients in HCC cells activated by NMDA applications (15 s) with and without NMDA receptor antagonists (<b>1l</b> and D-AP5). (B) Histogram showing percentage of induced Ca<sup>2+</sup> transients in a response to NMDA application and absence of the activation while applied together with <b>1l</b> at 25 or 41 μM concentration and D-AP5 at 20 μM concentration. Quantitative data were expressed as mean ± SEM (<i>n</i> = 5). The statistical significance was assessed with the Student-paired <i>t</i> test or Mann–Whitney <i>t</i> test for nonparametric data. Statistically significant differences were set at *<i>P</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of compound <b>1l</b> and D-AP5 on PGE<sub>2</sub> levels in HCC cells. Compounds <b>1l</b> and D-AP5 at 10 μM and compound <b>1l</b> at 100 μM reduced the concentration of PGE<sub>2</sub> after 24 h incubation to 68 ± 5%, 58 ± 6%, and 48 ± 6%, respectively. The addition of LPS (2.5 μg/mL) increased the PGE<sub>2</sub> concentration to 162 ± 7%, and the addition of compounds <b>1l</b> and D-AP5 at 10 μM as well as compound <b>1l</b> at 100 μM prevented the effect of LPS, reducing the PGE<sub>2</sub> concentrations to 127 ± 4%, 110 ± 7%, and 96 ± 17%, respectively. The data is presented as mean ± SEM, <i>n</i> = 3. The statistical significance of differences in PGE<sub>2</sub> concentrations between treatments was determined using one-way ANOVA and Tukey’s test (*<i>P</i> < 0.05, **<i>P</i> < 0.01).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound <b>1l</b> on cell accumulation of efflux probes [<sup>3</sup>H]-digoxin, fluorescein, and sorafenib. The incubation of the HCC cells with 10 μM compound <b>1l</b> increased the cell accumulation of (A) [<sup>3</sup>H]-digoxin, (B) fluorescein, and (C) sorafenib to 149% ± 10%, 201% ± 9%, and 152% ± 11%, respectively. The analyte concentrations are normalized by the amount of protein in each sample. The statistical difference between compound <b>1l</b>-treated cell and the control cells was determined using unpaired two-tailed <i>t</i> test (**<i>P</i> < 0.01, ***<i>P</i> < 0.001). Data are presented as mean ± SEM (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>1l</b> on cell accumulation of Slc2a1 and Slc7a5 transporter substrates [<sup>14</sup>C]-<span class="smallcaps smallerCapital">d</span>-glucose and [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine. The incubation of the HCC cells with 10 μM compound <b>1l</b> reduced the cell accumulation of (A) [<sup>14</sup>C]-<span class="smallcaps smallerCapital">d</span>-glucose and (B) [<sup>14</sup>C]-<span class="smallcaps smallerCapital">l</span>-leucine to 84% ± 8% and 81% ± 6%, respectively. The analyte concentrations are normalized by the amount of protein in each sample. The statistical difference between compound <b>1l</b>-treated cell and the control cells was determined using unpaired two-tailed <i>t</i> test (*<i>P</i> < 0.05). Data are presented as mean ± SEM (<i>n</i> = 4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/medium/jm-2017-016247_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Concentration-dependent antiproliferative efficacy of sorafenib in HCC cells after 72 h. IC<sub>50</sub> value was 7.4 ± 1.7 μM. Ability of compound <b>1l</b> to potentiate the cytotoxic efficacy of sorafenib in mouse HCC cells. (B) Potentiating effect of compound <b>1l</b> on sorafenib antiproliferative efficacy in murine HCC cells. Compared to sorafenib effect alone, the cell viability was further reduced in the presence of 100 μM compound <b>1l</b> from 88 ± 3% to 33 ± 3%, 82 ± 3% to 30 ± 2%, 72 ± 1% to 35 ± 2%, and 31 ± 2% to 24 ± 1%, at 1, 2.5, 5, and 10 μM sorafenib, respectively. Compound <b>1l</b> at 100 μM without sorafenib was able to reduce the cell viability to 84 ± 2%. (C) Potentiating effect of D-AP5 on sorafenib antiproliferative efficacy in murine HCC cells. The cell viability was reduced to 70 ± 3%, 63 ± 1%, 44 ± 1%, and 16 ± 1%, in combination of 100 μM D-AP5 and 1, 2.5, 5, and 10 μM sorafenib, respectively. D-AP5 at 100 μM without sorafenib was able to reduce the cell viability to 79 ± 2%. The remaining viability is presented as mean ± SEM (<i>n</i> = 3–6). The statistical difference between groups were determined by one-way ANOVA followed by Tukey’s multiple comparison test (*<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01624/20171215/images/large/jm-2017-016247_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01624&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i88">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60183" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60183" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Holohan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span> </span><span class="NLM_article-title">Cancer Drug Resistance: An Evolving Paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+Drug+Resistance%3A+An+Evolving+Paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0lhscYINkyI99Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520Drug%2520Resistance%253A%2520An%2520Evolving%2520Paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Rudalska, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longerich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McJunkin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuestefeld, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, T.-W. T.-W. T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leibold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Thun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirmacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, K.-H. K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, N. P. N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, S. W. S. W. S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geffers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zender, L.</span><span> </span><span class="NLM_article-title">In Vivo RNAi Screening Identifies a Mechanism of Sorafenib Resistance in Liver Cancer</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span><span class="refDoi"> DOI: 10.1038/nm.3679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1038%2Fnm.3679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=25216638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOlt7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1138-1146&author=R.+Rudalskaauthor=D.+Dauchauthor=T.+Longerichauthor=K.+McJunkinauthor=T.+Wuestefeldauthor=T.-W.+T.-W.+T.-W.+Kangauthor=A.+Hohmeyerauthor=M.+Pesicauthor=J.+Leiboldauthor=A.+von+Thunauthor=P.+Schirmacherauthor=J.+Zuberauthor=K.-H.+K.-H.+Weissauthor=S.+Powersauthor=N.+P.+N.+P.+Malekauthor=M.+Eilersauthor=B.+Siposauthor=S.+W.+S.+W.+S.+W.+Loweauthor=R.+Geffersauthor=S.+Lauferauthor=L.+Zender&title=In+Vivo+RNAi+Screening+Identifies+a+Mechanism+of+Sorafenib+Resistance+in+Liver+Cancer&doi=10.1038%2Fnm.3679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer</span></div><div class="casAuthors">Rudalska, Ramona; Dauch, Daniel; Longerich, Thomas; McJunkin, Katherine; Wuestefeld, Torsten; Kang, Tae-Won; Hohmeyer, Anja; Pesic, Marina; Leibold, Josef; von Thun, Anne; Schirmacher, Peter; Zuber, Johannes; Weiss, Karl-Heinz; Powers, Scott; Malek, Nisar P.; Eilers, Martin; Sipos, Bence; Lowe, Scott W.; Geffers, Robert; Laufer, Stefan; Zender, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1138-1146</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In solid tumors, resistance to therapy inevitably develops upon treatment with cytotoxic drugs or molecularly targeted therapies.  Here, we describe a system that enables pooled shRNA screening directly in mouse hepatocellular carcinomas (HCC) in vivo to identify genes likely to be involved in therapy resistance.  Using a focused shRNA library targeting genes located within focal genomic amplifications of human HCC, we screened for genes whose inhibition increased the therapeutic efficacy of the multikinase inhibitor sorafenib.  Both shRNA-mediated and pharmacol. silencing of Mapk14 (p38α) were found to sensitize mouse HCC to sorafenib therapy and prolong survival by abrogating Mapk14-dependent activation of Mek-Erk and Atf2 signaling.  Elevated Mapk14-Atf2 signaling predicted poor response to sorafenib therapy in human HCC, and sorafenib resistance of p-Mapk14-expressing HCC cells could be reverted by silencing Mapk14.  Our results suggest that a combination of sorafenib and Mapk14 blockade is a promising approach to overcoming therapy resistance of human HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquN9Poy48vIbVg90H21EOLACvtfcHk0lhscYINkyI99Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOlt7rL&md5=a843ee6d8060b9dcd04083cf1991f97c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnm.3679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3679%26sid%3Dliteratum%253Aachs%26aulast%3DRudalska%26aufirst%3DR.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DLongerich%26aufirst%3DT.%26aulast%3DMcJunkin%26aufirst%3DK.%26aulast%3DWuestefeld%26aufirst%3DT.%26aulast%3DKang%26aufirst%3DT.-W.%2BT.-W.%2BT.-W.%26aulast%3DHohmeyer%26aufirst%3DA.%26aulast%3DPesic%26aufirst%3DM.%26aulast%3DLeibold%26aufirst%3DJ.%26aulast%3Dvon%2BThun%26aufirst%3DA.%26aulast%3DSchirmacher%26aufirst%3DP.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DK.-H.%2BK.-H.%26aulast%3DPowers%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DN.%2BP.%2BN.%2BP.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DSipos%26aufirst%3DB.%26aulast%3DLowe%26aufirst%3DS.%2BW.%2BS.%2BW.%2BS.%2BW.%26aulast%3DGeffers%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DZender%26aufirst%3DL.%26atitle%3DIn%2520Vivo%2520RNAi%2520Screening%2520Identifies%2520a%2520Mechanism%2520of%2520Sorafenib%2520Resistance%2520in%2520Liver%2520Cancer%26jtitle%3DNat.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D1138%26epage%3D1146%26doi%3D10.1038%2Fnm.3679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Szakács, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth-Genthe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Targeting Multidrug Resistance in Cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1038/nrd1984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1038%2Fnrd1984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=16518375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=219-234&author=G.+Szak%C3%A1csauthor=J.+K.+Patersonauthor=J.+A.+Ludwigauthor=C.+Booth-Gentheauthor=M.+M.+Gottesman&title=Targeting+Multidrug+Resistance+in+Cancer&doi=10.1038%2Fnrd1984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting multidrug resistance in cancer</span></div><div class="casAuthors">Szakacs, Gergely; Paterson, Jill K.; Ludwig, Joseph A.; Booth-Genthe, Catherine; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-234</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy.  In most cases, multiple drugs are used, as resistance to single agents occurs almost universally.  For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chem. structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years.  Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters.  We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7LUp3JikHr7Vg90H21EOLACvtfcHk0lhMyXzI4_096g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D&md5=67ca376f65aa58a71288167f6815a896</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1984%26sid%3Dliteratum%253Aachs%26aulast%3DSzak%25C3%25A1cs%26aufirst%3DG.%26aulast%3DPaterson%26aufirst%3DJ.%2BK.%26aulast%3DLudwig%26aufirst%3DJ.%2BA.%26aulast%3DBooth-Genthe%26aufirst%3DC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DTargeting%2520Multidrug%2520Resistance%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D219%26epage%3D234%26doi%3D10.1038%2Fnrd1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Zhang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.-S.</span><span> </span><span class="NLM_article-title">Multidrug Resistance Proteins (MRPs) and Cancer Therapy</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">–</span> <span class="NLM_lpage">812</span><span class="refDoi"> DOI: 10.1208/s12248-015-9757-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1208%2Fs12248-015-9757-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=802-812&author=Y.-K.+Zhangauthor=Y.-J.+Wangauthor=P.+Guptaauthor=Z.-S.+Chen&title=Multidrug+Resistance+Proteins+%28MRPs%29+and+Cancer+Therapy&doi=10.1208%2Fs12248-015-9757-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1208%2Fs12248-015-9757-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-015-9757-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DZ.-S.%26atitle%3DMultidrug%2520Resistance%2520Proteins%2520%2528MRPs%2529%2520and%2520Cancer%2520Therapy%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26spage%3D802%26epage%3D812%26doi%3D10.1208%2Fs12248-015-9757-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Stacy, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span><span class="refDoi"> DOI: 10.1124/mol.113.088609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fmol.113.088609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24021215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=655-669&author=A.+E.+Stacyauthor=P.+J.+Janssonauthor=D.+R.+Richardson&title=Molecular+Pharmacology+of+ABCG2+and+Its+Role+in+Chemoresistance&doi=10.1124%2Fmol.113.088609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pharmacology of ABCG2 and its role in chemoresistance</span></div><div class="casAuthors">Stacy, Alexandra E.; Jansson, Patric J.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-669</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The ATP-binding cassette, subfamily G, isoform 2 protein (ABCG2) is an important member of the ABC transporter superfamily, which has been suggested to be involved in multidrug resistance (MDR) in cancer.  Its diverse range of substrates includes many common chemotherapeutics such as imatinib, doxorubicin, and mitoxantrone.  Physiol., ABCG2 is highly expressed in areas such as the blood-brain barrier and gastrointestinal tract, where it is thought to play a role in protection against xenobiotic exposure.  High ABCG2 expression has also been found in a variety of solid tumors and in hematol. malignancies and has been correlated with poorer clin. outcomes.  Furthermore, ABCG2 expression is a characteristic feature of cancer stem cells, which are able to self-renew and differentiate.  These cancer stem cells have been postulated to play an important role in MDR, where their inherent ABCG2 expression may allow them to survive chemotherapy and repopulate the tumor after exposure to chemotherapeutics.  This observation raises the exciting possibility that by inhibiting ABCG2, cancer stem cells and other cancers may be targeted and eradicated, at which point conventional chemotherapeutics would be sufficient to eliminate the remaining tumor cells.  Inhibitors of ABCG2, such as tyrosine kinase inhibitors, phosphodiesterase-5 inhibitors, and the fumitremorgin-type indolyl diketopiperazine, Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester], could potentially be used for this purpose.  However, these agents are still awaiting comprehensive clin. assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplO8F0Ak6Zp7Vg90H21EOLACvtfcHk0lhMyXzI4_096g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLjP&md5=d619971aca497b3b66e70c3c5bcca0bb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.088609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.088609%26sid%3Dliteratum%253Aachs%26aulast%3DStacy%26aufirst%3DA.%2BE.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DMolecular%2520Pharmacology%2520of%2520ABCG2%2520and%2520Its%2520Role%2520in%2520Chemoresistance%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D655%26epage%3D669%26doi%3D10.1124%2Fmol.113.088609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gillet, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efferth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remacle, J.</span><span> </span><span class="NLM_article-title">Chemotherapy-Induced Resistance by ATP-Binding Cassette Transporter Genes</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1775</span><span class="NLM_x">, </span> <span class="NLM_fpage">237</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1016/j.bbcan.2007.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.bbcan.2007.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=17572300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFKmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1775&publication_year=2007&pages=237-262&author=J.-P.+Gilletauthor=T.+Efferthauthor=J.+Remacle&title=Chemotherapy-Induced+Resistance+by+ATP-Binding+Cassette+Transporter+Genes&doi=10.1016%2Fj.bbcan.2007.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy-induced resistance by ATP-binding cassette transporter genes</span></div><div class="casAuthors">Gillet, Jean-Pierre; Efferth, Thomas; Remacle, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1775</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-262</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A key issue in the treatment of many cancers is the development of resistance to chemotherapeutic drugs.  Resistance mechanisms are numerous and complex.  One of them is mediated by the overexpression of ATP-binding cassette (ABC) transporters able to efflux drugs out of the tumor cell.  The last two decades have seen notable growth of knowledge concerning the involvement of ABC transporters in resistance to chemotherapy.  This review emphasizes these transporters, their clin. relevance and the diagnostic methods and strategies to circumvent multidrug resistance (MDR) mediated by ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDLF7Lt3bkrVg90H21EOLACvtfcHk0lhMyXzI4_096g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFKmtLY%253D&md5=3c28f2eb4b0913b7893b011638143e88</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2007.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2007.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DGillet%26aufirst%3DJ.-P.%26aulast%3DEfferth%26aufirst%3DT.%26aulast%3DRemacle%26aufirst%3DJ.%26atitle%3DChemotherapy-Induced%2520Resistance%2520by%2520ATP-Binding%2520Cassette%2520Transporter%2520Genes%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2007%26volume%3D1775%26spage%3D237%26epage%3D262%26doi%3D10.1016%2Fj.bbcan.2007.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Wu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. S.</span><span> </span><span class="NLM_article-title">The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1996</span><span class="NLM_x">–</span> <span class="NLM_lpage">2011</span><span class="refDoi"> DOI: 10.1021/mp200261n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200261n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlert74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=1996-2011&author=C.+P.+Wuauthor=C.+H.+Hsiehauthor=Y.+S.+Wu&title=The+Emergence+of+Drug+Transporter-Mediated+Multidrug+Resistance+to+Cancer+Chemotherapy&doi=10.1021%2Fmp200261n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy</span></div><div class="casAuthors">Wu, Chung-Pu; Hsieh, Chia-Hung; Wu, Yu-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1996-2011</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Chemotherapy is currently one of the most effective ways to treat metastatic cancers.  However, of the various mechanisms that are involved in conferring resistance, upregulation of drug efflux ATP-binding cassette (ABC) transporters, such as P-glycoprotein (ABCB1), multidrug resistance protein 1 (ABCC1) and ABCG2, has become a major obstacle to cancer chemotherapy and seriously affects the clin. outcome.  To date, at least 15 ABC drug transporters have been identified and characterized to transport and confer resistance to practically the entire spectrum of cancer drugs, causing multidrug resistance (MDR) in cancers.  Unfortunately, despite decades of research, there is still no real soln. to MDR.  This review highlights some of the major findings, the roles and problems assocd. with MDR-linked ABC drug transporters in metastatic cancers and solid tumors, and the current strategies to improve the clin. outcome in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRXYw8gOc5m7Vg90H21EOLACvtfcHk0li67xnwOKFsQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlert74%253D&md5=f28ff271be9eceb7cebbfe1cd3676c20</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fmp200261n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200261n%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DHsieh%26aufirst%3DC.%2BH.%26aulast%3DWu%26aufirst%3DY.%2BS.%26atitle%3DThe%2520Emergence%2520of%2520Drug%2520Transporter-Mediated%2520Multidrug%2520Resistance%2520to%2520Cancer%2520Chemotherapy%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2011%26volume%3D8%26spage%3D1996%26epage%3D2011%26doi%3D10.1021%2Fmp200261n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Rigalli, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciriaci, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceballos, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, S. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luquita, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mottino, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghanem, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catania, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, M. L.</span><span> </span><span class="NLM_article-title">Regulation of Multidrug Resistance Proteins by Genistein in a Hepatocarcinoma Cell Line: Impact on Sorafenib Cytotoxicity</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0119502</span><span class="refDoi"> DOI: 10.1371/journal.pone.0119502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1371%2Fjournal.pone.0119502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=25781341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0119502&author=J.+P.+Rigalliauthor=N.+Ciriaciauthor=A.+Ariasauthor=M.+P.+Ceballosauthor=S.+S.+M.+Villanuevaauthor=M.+G.+Luquitaauthor=A.+D.+Mottinoauthor=C.+I.+Ghanemauthor=V.+A.+Cataniaauthor=M.+L.+Ruiz&title=Regulation+of+Multidrug+Resistance+Proteins+by+Genistein+in+a+Hepatocarcinoma+Cell+Line%3A+Impact+on+Sorafenib+Cytotoxicity&doi=10.1371%2Fjournal.pone.0119502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity</span></div><div class="casAuthors">Rigalli, Juan Pablo; Ciriaci, Nadia; Arias, Agostina; Ceballos, Maria Paula; Villanueva, Silvina Stella Maris; Luquita, Marcelo Gabriel; Mottino, Aldo Domingo; Ghanem, Carolina Ines; Catania, Viviana Alicia; Ruiz, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0119502/1-e0119502/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide.  Sorafenib is the only drug available that improves the overall survival of HCC patients.  P-glycoprotein (P-gp), Multidrug resistance-assocd. proteins 2 and 3 (MRP2 and 3) and Breast cancer resistance protein (BCRP) are efflux pumps that play a key role in cancer chemoresistance.  Their modulation by dietary compds. may affect the intracellular accumulation and therapeutic efficacy of drugs that are substrates of these transporters.  Genistein (GNT) is a phytoestrogen abundant in soybean that exerts its genomic effects through Estrogen-Receptors and Pregnane-X-Receptor (PXR), which are involved in the regulation of the above-mentioned transporters.  We evaluated the effect of GNT on the expression and activity of P-gp, MRP2, MRP3 and BCRP in HCC-derived HepG2 cells.  GNT (at 1.0 and 10 μM) increased P-gp and MRP2 protein expression and activity, correlating well with an increased resistance to sorafenib cytotoxicity as detected by the methylthiazole tetrazolium (MTT) assay.  GNT induced P-gp and MRP2 mRNA expression at 10 but not at 1.0 μM concn. suggesting a different pattern of regulation depending on the concn.  Induction of both transporters by 1.0 μM GNT was prevented by cycloheximide, suggesting translational regulation.  Downregulation of expression of the miR-379 by GNT could be assocd. with translational regulation of MRP2.  Silencing of PXR abolished P-gp induction by GNT (at 1.0 and 10 μM) and MRP2 induction by GNT (only at 10 μM), suggesting partial mediation of GNT effects by PXR.  Taken together, the data suggest the possibility of nutrient-drug interactions leading to enhanced chemoresistance in HCC when GNT is ingested with soy rich diets or dietary supplements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHKBOckFJ4lrVg90H21EOLACvtfcHk0li67xnwOKFsQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSitb0%253D&md5=5f43b958387029d6c311c76aea700f0d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0119502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0119502%26sid%3Dliteratum%253Aachs%26aulast%3DRigalli%26aufirst%3DJ.%2BP.%26aulast%3DCiriaci%26aufirst%3DN.%26aulast%3DArias%26aufirst%3DA.%26aulast%3DCeballos%26aufirst%3DM.%2BP.%26aulast%3DVillanueva%26aufirst%3DS.%2BS.%2BM.%26aulast%3DLuquita%26aufirst%3DM.%2BG.%26aulast%3DMottino%26aufirst%3DA.%2BD.%26aulast%3DGhanem%26aufirst%3DC.%2BI.%26aulast%3DCatania%26aufirst%3DV.%2BA.%26aulast%3DRuiz%26aufirst%3DM.%2BL.%26atitle%3DRegulation%2520of%2520Multidrug%2520Resistance%2520Proteins%2520by%2520Genistein%2520in%2520a%2520Hepatocarcinoma%2520Cell%2520Line%253A%2520Impact%2520on%2520Sorafenib%2520Cytotoxicity%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0119502%26doi%3D10.1371%2Fjournal.pone.0119502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Huang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. J.</span><span> </span><span class="NLM_article-title">BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e83627</span><span class="refDoi"> DOI: 10.1371/journal.pone.0083627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1371%2Fjournal.pone.0083627" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e83627&author=W.+C.+Huangauthor=Y.+L.+Hsiehauthor=C.+M.+Hungauthor=P.+H.+Chienauthor=Y.+F.+Chienauthor=L.+C.+Chenauthor=C.+Y.+Tuauthor=C.+H.+Chenauthor=S.+C.+Hsuauthor=Y.+M.+Linauthor=Y.+J.+Chen&title=BCRP%2FABCG2+Inhibition+Sensitizes+Hepatocellular+Carcinoma+Cells+to+Sorafenib&doi=10.1371%2Fjournal.pone.0083627"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0083627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0083627%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DHsieh%26aufirst%3DY.%2BL.%26aulast%3DHung%26aufirst%3DC.%2BM.%26aulast%3DChien%26aufirst%3DP.%2BH.%26aulast%3DChien%26aufirst%3DY.%2BF.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DTu%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DHsu%26aufirst%3DS.%2BC.%26aulast%3DLin%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26atitle%3DBCRP%252FABCG2%2520Inhibition%2520Sensitizes%2520Hepatocellular%2520Carcinoma%2520Cells%2520to%2520Sorafenib%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De83627%26doi%3D10.1371%2Fjournal.pone.0083627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Gnoth, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radtke, M.</span><span> </span><span class="NLM_article-title">In Vitro to in Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1341</span><span class="NLM_x">–</span> <span class="NLM_lpage">1346</span><span class="refDoi"> DOI: 10.1124/dmd.110.032052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fdmd.110.032052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=20413726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWktrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1341-1346&author=M.+J.+Gnothauthor=S.+Sandmannauthor=K.+Engelauthor=M.+Radtke&title=In+Vitro+to+in+Vivo+Comparison+of+the+Substrate+Characteristics+of+Sorafenib+Tosylate+toward+P-Glycoprotein&doi=10.1124%2Fdmd.110.032052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro to in vivo comparison of the substrate characteristics of sorafenib toward P-glycoprotein</span></div><div class="casAuthors">Gnoth, M. J.; Sandmann, S.; Engel, K.; Radtke, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1341-1346</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sorafenib (Nexavar) is a novel oral Raf kinase and vascular endothelial growth factor receptor inhibitor.  Most anticancer drugs are substrates for ATP-binding cassette efflux pumps esp. for P-glycoprotein (P-gp).  To evaluate the influence of P-gp on the pharmacokinetics of sorafenib substrate properties for this transporter were investigated.  Therefore, permeability of sorafenib across Caco-2 and P-gp-overexpressing cells was detd.  To det. the in vivo relevance of these in vitro findings, pharmacokinetics of sorafenib in mdr1a/1b(-/-) and wild-type (WT) mice was studied.  Sorafenib is highly permeable and exhibits a slight efflux across Caco-2 cells.  In P-gp-overexpressing cells, a small concn.-dependent efflux was obsd., which was completely blocked by the addn. of ivermectin.  In mdr1a/1b(-/-) and WT mice, unchanged compd. represented by far the majority of radioactivity in plasma.  After i.v. and oral administration, brain/plasma concn. ratios in mdr1a/1b(-/-) mice were 1.3- to 1.5-fold higher than those in WT mice.  However, after i.v. or oral administration, plasma concns. were similar in both mouse strains.  In conclusion, sorafenib is highly permeable and a weak P-gp substrate in vitro.  These findings were confirmed by the small factor of 1.3 to 1.5 obsd. for the brain/plasma ratios in mdr1a/1b(-/-) vs. WT mice in vivo.  Based on these in vitro and in vivo results, it is unlikely that P-gp has a major effect on the plasma concns. of sorafenib in humans.  Because of the high permeability and low P-gp-mediated transport, sorafenib might be able to cross the blood-brain barrier and target tumors within the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj5f9alyzuZbVg90H21EOLACvtfcHk0ljD0DlFGy_qzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWktrjL&md5=571551e695e075bc679c1da7507e2def</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032052%26sid%3Dliteratum%253Aachs%26aulast%3DGnoth%26aufirst%3DM.%2BJ.%26aulast%3DSandmann%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DK.%26aulast%3DRadtke%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520to%2520in%2520Vivo%2520Comparison%2520of%2520the%2520Substrate%2520Characteristics%2520of%2520Sorafenib%2520Tosylate%2520toward%2520P-Glycoprotein%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1341%26epage%3D1346%26doi%3D10.1124%2Fdmd.110.032052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Callaghan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luk, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebawy, M.</span><span> </span><span class="NLM_article-title">Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">631</span><span class="refDoi"> DOI: 10.1124/dmd.113.056176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fdmd.113.056176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24492893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFGjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=623-631&author=R.+Callaghanauthor=F.+Lukauthor=M.+Bebawy&title=Inhibition+of+the+Multidrug+Resistance+P-Glycoprotein%3A+Time+for+a+Change+of+Strategy%3F&doi=10.1124%2Fdmd.113.056176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?</span></div><div class="casAuthors">Callaghan, Richard; Luk, Frederick; Bebawy, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-631, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  P-glycoprotein (P-gp) is a key player in the multidrug-resistant phenotype in cancer.  The protein confers resistance by mediating the ATP-dependent efflux of an astonishing array of anticancer drugs.  Its broad specificity has been the subject of numerous attempts to inhibit the protein and restore the efficacy of anticancer drugs.  The general strategy has been to develop compds. that either compete with anticancer drugs for transport or act as direct inhibitors of P-gp.  Despite considerable in vitro success, there are no compds. currently available to "block" P-gp-mediated resistance in the clinic.  The failure may be attributed to toxicity, adverse drug interaction, and numerous pharmacokinetic issues.  This review provides a description of several alternative approaches to overcome the activity of P-gp in drug-resistant cells.  These include 1) drugs that specifically target resistant cells, 2) novel nanotechnologies to provide high-dose, targeted delivery of anticancer drugs, 3) compds. that interfere with nongenomic transfer of resistance, and 4) approaches to reduce the expression of P-gp within tumors.  Such approaches have been developed through the pursuit of greater understanding of resistance mediators such as P-gp, and they show considerable potential for further application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepn0xRcaTyLVg90H21EOLACvtfcHk0ljD0DlFGy_qzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFGjsbk%253D&md5=89c38218dc0c75a76309295453a5bd5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.056176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.056176%26sid%3Dliteratum%253Aachs%26aulast%3DCallaghan%26aufirst%3DR.%26aulast%3DLuk%26aufirst%3DF.%26aulast%3DBebawy%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520the%2520Multidrug%2520Resistance%2520P-Glycoprotein%253A%2520Time%2520for%2520a%2520Change%2520of%2520Strategy%253F%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D623%26epage%3D631%26doi%3D10.1124%2Fdmd.113.056176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Fletcher, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, M. D.</span><span> </span><span class="NLM_article-title">ABC Transporters in Cancer: More than Just Drug Efflux Pumps</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1038/nrc2789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1038%2Fnrc2789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=20075923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=147-156&author=J.+I.+Fletcherauthor=M.+Haberauthor=M.+J.+Hendersonauthor=M.+D.+Norris&title=ABC+Transporters+in+Cancer%3A+More+than+Just+Drug+Efflux+Pumps&doi=10.1038%2Fnrc2789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters in cancer: more than just drug efflux pumps</span></div><div class="casAuthors">Fletcher, Jamie I.; Haber, Michelle; Henderson, Michelle J.; Norris, Murray D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Multidrug transporter proteins are best known for their contributions to chemoresistance through the efflux of anticancer drugs from cancer cells.  However, a considerable body of evidence also points to their importance in cancer extending beyond drug transport to fundamental roles in tumor biol.  Currently, much of the evidence for these addnl. roles is correlative and definitive studies are needed to confirm causality.  We propose that delineating the precise roles of these transporters in tumorigenesis and treatment response will be important for the development of more effective targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpquOxf0jnPG7Vg90H21EOLACvtfcHk0ljD0DlFGy_qzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGlsQ%253D%253D&md5=bb2ff0eae5cdcf8e7087f17f23ab5100</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrc2789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2789%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DJ.%2BI.%26aulast%3DHaber%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DNorris%26aufirst%3DM.%2BD.%26atitle%3DABC%2520Transporters%2520in%2520Cancer%253A%2520More%2520than%2520Just%2520Drug%2520Efflux%2520Pumps%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D147%26epage%3D156%26doi%3D10.1038%2Fnrc2789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Traynelis, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollmuth, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBain, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vance, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogden, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingledine, R.</span><span> </span><span class="NLM_article-title">Glutamate Receptor Ion Channels: Structure, Regulation, and Function</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.1124/pr.109.002451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fpr.109.002451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=20716669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=405-496&author=S.+F.+Traynelisauthor=L.+P.+Wollmuthauthor=C.+J.+McBainauthor=F.+S.+Mennitiauthor=K.+M.+Vanceauthor=K.+K.+Ogdenauthor=K.+B.+Hansenauthor=H.+Yuanauthor=S.+J.+Myersauthor=R.+Dingledine&title=Glutamate+Receptor+Ion+Channels%3A+Structure%2C+Regulation%2C+and+Function&doi=10.1124%2Fpr.109.002451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate receptor ion channels: structure, regulation, and function</span></div><div class="casAuthors">Traynelis, Stephen F.; Wollmuth, Lonnie P.; McBain, Chris J.; Menniti, Frank S.; Vance, Katie M.; Ogden, Kevin K.; Hansen, Kasper B.; Yuan, Hongjie; Myers, Scott J.; Dingledine, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-496</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The mammalian ionotropic glutamate receptor family encodes 18 gene products that coassemble to form ligand-gated ion channels contg. an agonist recognition site, a transmembrane ion permeation pathway, and gating elements that couple agonist-induced conformational changes to the opening or closing of the permeation pore.  Glutamate receptors mediate fast excitatory synaptic transmission in the central nervous system and are localized on neuronal and non-neuronal cells.  These receptors regulate a broad spectrum of processes in the brain, spinal cord, retina, and peripheral nervous system.  Glutamate receptors are postulated to play important roles in numerous neurol. diseases and have attracted intense scrutiny.  The description of glutamate receptor structure, including its transmembrane elements, reveals a complex assembly of multiple semiautonomous extracellular domains linked to a pore-forming element with striking resemblance to an inverted potassium channel.  In this review we discuss International Union of Basic and Clin. Pharmacol. glutamate receptor nomenclature, structure, assembly, accessory subunits, interacting proteins, gene expression and translation, post-translational modifications, agonist and antagonist pharmacol., allosteric modulation, mechanisms of gating and permeation, roles in normal physiol. function, as well as the potential therapeutic use of pharmacol. agents acting at glutamate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov0rj4nMr5ObVg90H21EOLACvtfcHk0li1HP2qzK_o-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbJ&md5=5d0a7945b5ad99113adf9f6312bafe13</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fpr.109.002451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.109.002451%26sid%3Dliteratum%253Aachs%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26aulast%3DWollmuth%26aufirst%3DL.%2BP.%26aulast%3DMcBain%26aufirst%3DC.%2BJ.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DVance%26aufirst%3DK.%2BM.%26aulast%3DOgden%26aufirst%3DK.%2BK.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DMyers%26aufirst%3DS.%2BJ.%26aulast%3DDingledine%26aufirst%3DR.%26atitle%3DGlutamate%2520Receptor%2520Ion%2520Channels%253A%2520Structure%252C%2520Regulation%252C%2520and%2520Function%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D405%26epage%3D496%26doi%3D10.1124%2Fpr.109.002451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Qosa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotti, D.</span><span> </span><span class="NLM_article-title">Regulation of ABC Efflux Transporters at Blood-Brain Barrier in Health and Neurological Disorders</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1628</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span><span class="refDoi"> DOI: 10.1016/j.brainres.2015.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.brainres.2015.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=26187753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2hs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1628&publication_year=2015&pages=298-316&author=H.+Qosaauthor=D.+S.+Millerauthor=P.+Pasinelliauthor=D.+Trotti&title=Regulation+of+ABC+Efflux+Transporters+at+Blood-Brain+Barrier+in+Health+and+Neurological+Disorders&doi=10.1016%2Fj.brainres.2015.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders</span></div><div class="casAuthors">Qosa, Hisham; Miller, David S.; Pasinelli, Piera; Trotti, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1628</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">298-316</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The strength of the blood-brain barrier (BBB) in providing protection to the central nervous system from exposure to circulating chems. is maintained by tight junctions between endothelial cells and by a broad range of transporter proteins that regulate exchange between CNS and blood.  The most important transporters that restrict the permeability of large no. of toxins as well as therapeutic agents are the ABC transporters.  Among them, P-gp, BCRP, MRP1 and MRP2 are the utmost studied.  These efflux transporters are neuroprotective, limiting the brain entry of neurotoxins; however, they could also restrict the entry of many therapeutics and contribute to CNS pharmacoresistance.  Characterization of several regulatory pathways that govern expression and activity of ABC efflux transporters in the endothelium of brain capillaries have led to an emerging consensus that these processes are complex and contain several cellular and mol. elements.  Alterations in ABC efflux transporters expression and/or activity occur in several neurol. diseases.  Here, we review the signaling pathways that regulate expression and transport activity of P-gp, BCRP, MRP1 and MRP2 as well as how their expression/activity changes in neurol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDwi6W7psSR7Vg90H21EOLACvtfcHk0li1HP2qzK_o-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2hs7vK&md5=3cb682ce23196b2f4bbb125ed5a4b094</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2015.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2015.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DQosa%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DD.%2BS.%26aulast%3DPasinelli%26aufirst%3DP.%26aulast%3DTrotti%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520ABC%2520Efflux%2520Transporters%2520at%2520Blood-Brain%2520Barrier%2520in%2520Health%2520and%2520Neurological%2520Disorders%26jtitle%3DBrain%2520Res.%26date%3D2015%26volume%3D1628%26spage%3D298%26epage%3D316%26doi%3D10.1016%2Fj.brainres.2015.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Leslie, C. C.</span><span> </span><span class="NLM_article-title">Properties and Regulation of Cytosolic Phospholipase A2</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">16709</span><span class="NLM_x">–</span> <span class="NLM_lpage">16712</span><span class="refDoi"> DOI: 10.1074/jbc.272.27.16709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1074%2Fjbc.272.27.16709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=9201969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADyaK2sXksVentb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=16709-16712&author=C.+C.+Leslie&title=Properties+and+Regulation+of+Cytosolic+Phospholipase+A2&doi=10.1074%2Fjbc.272.27.16709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Properties and regulation of cytosolic phospholipase A2</span></div><div class="casAuthors">Leslie, Christina C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">16709-16712</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review, with 77 refs., on the properties and regulation of phospholipase A2, which plays an important role in mediating arachidonic acid release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAy56BGk_IwbVg90H21EOLACvtfcHk0lgTPJUOnBpWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksVentb8%253D&md5=f7c23ebb7d10d0d32d1404406fa86c01</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.27.16709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.27.16709%26sid%3Dliteratum%253Aachs%26aulast%3DLeslie%26aufirst%3DC.%2BC.%26atitle%3DProperties%2520and%2520Regulation%2520of%2520Cytosolic%2520Phospholipase%2520A2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D16709%26epage%3D16712%26doi%3D10.1074%2Fjbc.272.27.16709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Maeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omata, M.</span><span> </span><span class="NLM_article-title">Inflammation and Cancer: Role of Nuclear Factor-kappaB Activation</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">836</span><span class="NLM_x">–</span> <span class="NLM_lpage">842</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2008.00763.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1111%2Fj.1349-7006.2008.00763.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=18294278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslCrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=836-842&author=S.+Maedaauthor=M.+Omata&title=Inflammation+and+Cancer%3A+Role+of+Nuclear+Factor-kappaB+Activation&doi=10.1111%2Fj.1349-7006.2008.00763.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and cancer: role of nuclear factor-kappaB activation</span></div><div class="casAuthors">Maeda, Shin; Omata, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">836-842</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been thought that there is a strong relationship between inflammation and carcinogenesis so that the development of cancer occurs with chronic inflammation in many organs.  An in-depth understanding of the mechanism by which inflammation can lead to carcinogenesis may enable the development of drugs targeted at important mols., providing a powerful tool for preventing cancer development.  In this review, we focused on a signal transduction system, the nuclear factor-kappaB (NF-κB) pathway, which is thought to play a role in the process leading from inflammation to carcinogenesis, and may thus serve as a candidate for targeted intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8gz2S24BurVg90H21EOLACvtfcHk0lgTPJUOnBpWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslCrsLk%253D&md5=d4291bbff88fee41f1143146e309162f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00763.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00763.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DS.%26aulast%3DOmata%26aufirst%3DM.%26atitle%3DInflammation%2520and%2520Cancer%253A%2520Role%2520of%2520Nuclear%2520Factor-kappaB%2520Activation%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26spage%3D836%26epage%3D842%26doi%3D10.1111%2Fj.1349-7006.2008.00763.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sai, W.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, D.-F.</span><span> </span><span class="NLM_article-title">Chemosensitization of HepG2 Cells by Suppression of NF-kappaB/p65 Gene Transcription with Specific-siRNA</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">12814</span><span class="NLM_x">–</span> <span class="NLM_lpage">12821</span><span class="refDoi"> DOI: 10.3748/wjg.v21.i45.12814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.3748%2Fwjg.v21.i45.12814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=26668505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsFSjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=12814-12821&author=Y.+Shiauthor=S.-Y.+Wangauthor=M.+Yaoauthor=W.-L.+Saiauthor=W.+Wuauthor=J.-L.+Yangauthor=Y.+Caiauthor=W.-J.+Zhengauthor=D.-F.+Yao&title=Chemosensitization+of+HepG2+Cells+by+Suppression+of+NF-kappaB%2Fp65+Gene+Transcription+with+Specific-siRNA&doi=10.3748%2Fwjg.v21.i45.12814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA</span></div><div class="casAuthors">Shi, Yun; Wang, Si-Ye; Yao, Min; Sai, Wen-Li; Wu, Wei; Yang, Jun-Ling; Cai, Yin; Zheng, Wen-Jie; Yao, Deng-Fu</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">12814-12821</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">2219-2840</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Inc.</span>)
        </div><div class="casAbstract">AIM: To investigate small interfering RNA (siRNA)- mediated inhibition of nuclear factor-kappa B (NF-κB) activation and multidrug-resistant (MDR) phenotype formation in human HepG2 cells.  METHODS: Total RNA was extd. from human HepG2 or LO2 cells.  NF-κB/p65 mRNA was amplified by nested reverse transcription polymerase chain reaction and confirmed by sequencing.  NF-κB/p65 was analyzed by immunohistochem.  Specific-siRNA was transfected to HepG2 cells to knock down NF-κB/p65 expression.  The effects on cell proliferation, survival, and apoptosis were assessed, and the level of NF- κB/p65 or P-glycoprotein (P-gp) was quant. analyzed by ELISA.  RESULTS: HepG2 cells express NF-κB/p65 and express relatively less phosphorylated p65 (P-p65) and little P-gp.  After treatment of HepG2 cells with different doses of doxorubicin, the expression of NF-κB/p65, P-p65, and esp. P-gp were dose-dependently upregulated.  After HepG2 cells were transfected with NF-κB/p65 siRNA (100 nmol/L), the expression of NF-κB/p65, P-p65, and P-gp were downregulated significantly and dose-dependently.  The viability of HepG2 cells was decreased to 23% in the combination NF-κB/p65 siRNA (100 nmol/L) and doxorubicin (0.5 μmol/L) group and 47% in the doxorubicin (0.5 μmol/L) group (t = 7.043, P < 0.001).  CONCLUSION: Knockdown of NF-κB/p65 with siRNA is an effective strategy for inhibiting HepG2 cell growth by downregulating P-gp expression assocd. chemosensitization and apoptosis induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCkiloH4Noo7Vg90H21EOLACvtfcHk0lhIMPPBLk6zpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsFSjt78%253D&md5=1ce3ecd247c03e61eb7b16a3cbc1ad1e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v21.i45.12814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v21.i45.12814%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DSai%26aufirst%3DW.-L.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.-L.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DW.-J.%26aulast%3DYao%26aufirst%3DD.-F.%26atitle%3DChemosensitization%2520of%2520HepG2%2520Cells%2520by%2520Suppression%2520of%2520NF-kappaB%252Fp65%2520Gene%2520Transcription%2520with%2520Specific-siRNA%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2015%26volume%3D21%26spage%3D12814%26epage%3D12821%26doi%3D10.3748%2Fwjg.v21.i45.12814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Deutsch, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burket, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, A. D.</span><span> </span><span class="NLM_article-title">NMDA Receptors on the Surface of Cancer Cells: Target for Chemotherapy?</span> <span class="citation_source-journal">Biomed. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.1016/j.biopha.2014.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.biopha.2014.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24751001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmslaiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2014&pages=493-496&author=S.+I.+Deutschauthor=A.+H.+Tangauthor=J.+A.+Burketauthor=A.+D.+Benson&title=NMDA+Receptors+on+the+Surface+of+Cancer+Cells%3A+Target+for+Chemotherapy%3F&doi=10.1016%2Fj.biopha.2014.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptors on the surface of cancer cells: Target for chemotherapy?</span></div><div class="casAuthors">Deutsch, Stephen I.; Tang, Amy H.; Burket, Jessica A.; Benson, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">493-496</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a therapeutic target for many types of cancers.  NMDA receptors regulate mTOR signalling activity; their inappropriate expression on several human cancer cell lines represents a potential therapeutic avenue to control dysregulated growth, division and invasiveness.  Targeting these receptors with selective ligands (e.g., glycine B site ligands) may be a less toxic and more tolerable approach than administering compds. acting at the mTORC1 complex itself, such as rapamycin and its derivs.  Thus, testing glycine B site ligands in relevant in vitro and in vivo paradigms with established human cancer cells that express NMDA receptors on their surface could provide proofs of concept/principle that would encourage exploration of these and other "non-toxic" strategies.  Interestingly, in some cancer models that express NMDA receptors on their surface, NMDA receptor antagonists, such as MK-801 (dizocilpine), were shown to possess anti-proliferative and anti-invasive effects, which conflict with hypotheses about promoting NMDA receptor activation as a cancer chemotherapeutic strategy.  Whether NMDA receptor activation or antagonism is assocd. with anti-proliferative and anti-invasive effects may reflect differences between cancer cell lines in terms of the proteins assocd. with the NMDA receptors on their cell surfaces, which, in turn, could lead to different "downstream" effects on cascades of intracellular phosphorylations.  Irresp. of whether activation or antagonism is assocd. with anti-proliferative and anti-invasive effects for specific types of cancer, data are emerging that support exploration of targeting NMDA receptors expressed on the surface of cancer cells as a therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFNZG8HVu1x7Vg90H21EOLACvtfcHk0lhIMPPBLk6zpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmslaiu7k%253D&md5=76fcd808e86ddfdf04b0cea77668f018</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2014.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2014.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DDeutsch%26aufirst%3DS.%2BI.%26aulast%3DTang%26aufirst%3DA.%2BH.%26aulast%3DBurket%26aufirst%3DJ.%2BA.%26aulast%3DBenson%26aufirst%3DA.%2BD.%26atitle%3DNMDA%2520Receptors%2520on%2520the%2520Surface%2520of%2520Cancer%2520Cells%253A%2520Target%2520for%2520Chemotherapy%253F%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2014%26volume%3D68%26spage%3D493%26epage%3D496%26doi%3D10.1016%2Fj.biopha.2014.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ribeiro, M. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes-Correia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Custódio, J. B. A.</span><span> </span><span class="NLM_article-title">The Combination of Glutamate Receptor Antagonist MK-801 with Tamoxifen and Its Active Metabolites Potentiates Their Antiproliferative Activity in Mouse Melanoma K1735-M2 Cells</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.1016/j.yexcr.2013.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.yexcr.2013.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24240127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Gqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2014&pages=288-296&author=M.+P.+C.+Ribeiroauthor=I.+Nunes-Correiaauthor=A.+E.+Santosauthor=J.+B.+A.+Cust%C3%B3dio&title=The+Combination+of+Glutamate+Receptor+Antagonist+MK-801+with+Tamoxifen+and+Its+Active+Metabolites+Potentiates+Their+Antiproliferative+Activity+in+Mouse+Melanoma+K1735-M2+Cells&doi=10.1016%2Fj.yexcr.2013.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells</span></div><div class="casAuthors">Ribeiro, Mariana P. C.; Nunes-Correia, Isabel; Santos, Armanda E.; Custodio, Jose B. A.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-296</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent reports suggest that N-methyl-D-aspartate receptor (NMDAR) blockade by MK-801 decreases tumor growth.  Thus, we investigated whether other ionotropic glutamate receptor (iGluR) antagonists were also able to modulate the proliferation of melanoma cells.  On the other hand, the antiestrogen tamoxifen (TAM) decreases the proliferation of melanoma cells, and is included in combined therapies for melanoma.  As the efficacy of TAM is limited by its metab., we investigated the effects of the NMDAR antagonist MK-801 in combination with TAM and its active metabolites, 4-hydroxytamoxifen (OHTAM) and endoxifen (EDX).  The NMDAR blockers MK-801 and memantine decreased mouse melanoma K1735-M2 cell proliferation.  In contrast, the NMDAR competitive antagonist APV and the AMPA and kainate receptor antagonist NBQX did not affect cell proliferation, suggesting that among the iGluR antagonists only the NMDAR channel blockers inhibit melanoma cell proliferation.  The combination of antiestrogens with MK-801 potentiated their individual effects on cell biomass due to diminished cell proliferation, since it decreased the cell no. and DNA synthesis without increasing cell death.  Importantly, TAM metabolites combined with MK-801 promoted cell cycle arrest in G1.  Therefore, the data obtained suggest that the activity of MK-801 and antiestrogens in K1735-M2 cells is greatly enhanced when used in combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa4k9gpQA8gbVg90H21EOLACvtfcHk0lhIMPPBLk6zpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Gqt7k%253D&md5=da8f07a85632df541d83bd7570123138</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2013.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2013.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DM.%2BP.%2BC.%26aulast%3DNunes-Correia%26aufirst%3DI.%26aulast%3DSantos%26aufirst%3DA.%2BE.%26aulast%3DCust%25C3%25B3dio%26aufirst%3DJ.%2BB.%2BA.%26atitle%3DThe%2520Combination%2520of%2520Glutamate%2520Receptor%2520Antagonist%2520MK-801%2520with%2520Tamoxifen%2520and%2520Its%2520Active%2520Metabolites%2520Potentiates%2520Their%2520Antiproliferative%2520Activity%2520in%2520Mouse%2520Melanoma%2520K1735-M2%2520Cells%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2014%26volume%3D321%26spage%3D288%26epage%3D296%26doi%3D10.1016%2Fj.yexcr.2013.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Yamaguchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akram, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamitori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokuda, M.</span><span> </span><span class="NLM_article-title">FOXO/TXNIP Pathway Is Involved in the Suppression of Hepatocellular Carcinoma Growth by Glutamate Antagonist MK-801</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">468</span><span class="refDoi"> DOI: 10.1186/1471-2407-13-468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1186%2F1471-2407-13-468" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=468&author=F.+Yamaguchiauthor=Y.+Hirataauthor=H.+Akramauthor=K.+Kamitoriauthor=Y.+Dongauthor=L.+Suiauthor=M.+Tokuda&title=FOXO%2FTXNIP+Pathway+Is+Involved+in+the+Suppression+of+Hepatocellular+Carcinoma+Growth+by+Glutamate+Antagonist+MK-801&doi=10.1186%2F1471-2407-13-468"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-468%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DF.%26aulast%3DHirata%26aufirst%3DY.%26aulast%3DAkram%26aufirst%3DH.%26aulast%3DKamitori%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DSui%26aufirst%3DL.%26aulast%3DTokuda%26aufirst%3DM.%26atitle%3DFOXO%252FTXNIP%2520Pathway%2520Is%2520Involved%2520in%2520the%2520Suppression%2520of%2520Hepatocellular%2520Carcinoma%2520Growth%2520by%2520Glutamate%2520Antagonist%2520MK-801%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D468%26doi%3D10.1186%2F1471-2407-13-468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Bergeron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. T.</span><span> </span><span class="NLM_article-title">NAAG, NMDA Receptor and Psychosis</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1360</span><span class="NLM_x">–</span> <span class="NLM_lpage">1364</span><span class="refDoi"> DOI: 10.2174/092986712799462685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.2174%2F092986712799462685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=22304714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1360-1364&author=R.+Bergeronauthor=J.+T.+Coyle&title=NAAG%2C+NMDA+Receptor+and+Psychosis&doi=10.2174%2F092986712799462685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">NAAG, NMDA receptor and psychosis</span></div><div class="casAuthors">Bergeron, Richard; Coyle, Joseph T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1360-1364</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  At central synapses, glutamate is the main excitatory neurotransmitter.  Once released from presynaptic terminals, glutamate activates a no. of different glutamatergic receptors one of which is the ligand gated ionophore glutamatergic subtype N-methyl-D-aspartate receptors (NMDARs).  NMDARs play a crucial role in controlling various determinants of synaptic function.  N-acetylaspartylglutamate (NAAG) is the most prevalent peptide transmitter in the mammalian central nervous system.  NAAG is released upon neuronal depolarization by a calcium-dependent process from glutamatergic and GABAergic neurons.  It is cleaved by a specific peptidase located on astrocytes, glutamate carboxypeptidase type II (GCP-II), to N-acetylaspartate (NAA) and glutamate.  Current evidence supports the hypothesis that NAAG is an endogenous agonist at G protein coupled mGluR3 receptors and an antagonist at NMDAR.  In several disorders and animal models of human diseases, the levels of NAAG and the activity of GCP-II are altered in ways that are consistent with NAAG's role in regulation of glutamatergic neurotransmission.  Several lines of evidence suggest that a dysfunction in glutamatergic via the NMDAR might be involved in schizophrenia.  This hypothesis has evolved from findings that NMDAR antagonists such as phencyclidine (PCP or "angel dust"), produces a syndrome in normal individuals that closely resembles schizophrenia and exacerbates psychotic symptoms in patients with chronic schizophrenia.  Recent postmortem, metabolic and genetic studies have provided evidence that hypofunction of discrete populations of NMDAR can contribute to the symptoms of schizophrenia, at least in some patients.  The review outlines the role of endogenous NAAG at NMDAR neurotransmission and its putative role in the pathophysiol. of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsZoSWE5L4O7Vg90H21EOLACvtfcHk0lhZrMP0kDQpew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOnsro%253D&md5=07a809bfddd3977325d822dfb9912a5d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F092986712799462685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712799462685%26sid%3Dliteratum%253Aachs%26aulast%3DBergeron%26aufirst%3DR.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3DNAAG%252C%2520NMDA%2520Receptor%2520and%2520Psychosis%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D1360%26epage%3D1364%26doi%3D10.2174%2F092986712799462685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanadhan, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendoloski, J. J.</span><span> </span><span class="NLM_article-title">A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases</span> <span class="citation_source-journal">J. Comb. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1021/cc9800071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc9800071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFGrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=55-68&author=A.+K.+Ghoseauthor=V.+N.+Viswanadhanauthor=J.+J.+Wendoloski&title=A+Knowledge-Based+Approach+in+Designing+Combinatorial+or+Medicinal+Chemistry+Libraries+for+Drug+Discovery.+1.+A+Qualitative+and+Quantitative+Characterization+of+Known+Drug+Databases&doi=10.1021%2Fcc9800071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases</span></div><div class="casAuthors">Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of various protein/receptor targets from genomic research is expanding rapidly.  Along with the automation of org. synthesis and biochem. screening, this is bringing a major change in the whole field of drug discovery research.  In the traditional drug discovery process, the industry tests compds. in the thousands.  With automated synthesis, the no. of compds. to be tested could be in the millions.  This two-dimensional expansion will lead to a major demand for resources, unless the chem. libraries are made wisely.  The objective of this work is to provide both quant. and qual. characterization of known drugs which will help to generate "drug-like" libraries.  In this work the authors analyzed the Comprehensive Medicinal Chem. (CMC) database and seven different subsets belonging to different classes of drug mols.  These include some central nervous system active drugs and cardiovascular, cancer, inflammation, and infection disease states.  A quant. characterization based on computed physicochem. property profiles such as log P, molar refractivity, mol. wt., and no. of atoms as well as a qual. characterization based on the occurrence of functional groups and important substructures are developed here.  For the CMC database, the qualifying range (covering more than 80% of the compds.) of the calcd. log P is between -0.4 and 5.6, with an av. value of 2.52.  For mol. wt., the qualifying range is between 160 and 480, with an av. value of 357.  For molar refractivity, the qualifying range is between 40 and 130, with an av. value of 97.  For the total no. of atoms, the qualifying range is between 20 and 70, with an av. value of 48.  Benzene is by far the most abundant substructure in this drug database, slightly more abundant than all the heterocyclic rings combined.  Nonarom. heterocyclic rings are twice as abundant as the arom. heterocycles.  Tertiary aliph. amines, alc. OH and carboxamides are the most abundant functional groups in the drug database.  The effective range of physicochem. properties presented here can be used in the design of drug-like combinatorial libraries as well as in developing a more efficient corporate medicinal chem. library.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdtFV7c05Th7Vg90H21EOLACvtfcHk0lhZrMP0kDQpew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFGrurk%253D&md5=b2b0a40191e6cb71cf31c5266a7be8b2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fcc9800071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc9800071%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DWendoloski%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520Knowledge-Based%2520Approach%2520in%2520Designing%2520Combinatorial%2520or%2520Medicinal%2520Chemistry%2520Libraries%2520for%2520Drug%2520Discovery.%25201.%2520A%2520Qualitative%2520and%2520Quantitative%2520Characterization%2520of%2520Known%2520Drug%2520Databases%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D1999%26volume%3D1%26spage%3D55%26epage%3D68%26doi%3D10.1021%2Fcc9800071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Larsen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venskutonytė, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valadés, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Discovery of a New Class of Ionotropic Glutamate Receptor Antagonists by the Rational Design of (2S,3R)-3-(3-Carboxyphenyl)-Pyrrolidine-2-Carboxylic Acid</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1021/cn100093f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100093f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWhsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=107-114&author=A.+M.+Larsenauthor=R.+Venskutonyt%C4%97author=E.+A.+Valad%C3%A9sauthor=B.+Nielsenauthor=D.+S.+Pickeringauthor=L.+Bunch&title=Discovery+of+a+New+Class+of+Ionotropic+Glutamate+Receptor+Antagonists+by+the+Rational+Design+of+%282S%2C3R%29-3-%283-Carboxyphenyl%29-Pyrrolidine-2-Carboxylic+Acid&doi=10.1021%2Fcn100093f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Class of Ionotropic Glutamate Receptor Antagonists by the Rational Design of (2S,3R)-3-(3-Carboxyphenyl)-pyrrolidine-2-carboxylic Acid</span></div><div class="casAuthors">Larsen, Ann M.; Venskutonyte, Raminta; Valades, Elena Anton; Nielsen, Birgitte; Pickering, Darryl S.; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kainic acid (KA) receptors belong to the class of glutamate (Glu) receptors in the brain and constitute a promising target for the treatment of neurol. and/or psychiatric diseases such as schizophrenia, major depression, and epilepsy.  Five KA subtypes have been identified and named GluK1-5.  In this article, we present the discovery of (2S,3R)-3-(3-carboxyphenyl)-pyrrolidine-2-carboxylic acid (1) based on a rational design process.  Target compd. 1 was synthesized by a stereoselective strategy in 10 steps from com. available starting materials.  Binding affinities of 1 at native ionotropic Glu receptors were detd. to be in the micromolar range (AMPA, 51 μM; KA, 22 μM; NMDA 6 μM), with the highest affinity for cloned homomeric KA receptor subtypes GluK1,3 (3.0 and 8.1 μM, resp.).  Functional characterization of 1 by two electrode voltage clamp (TEVC) electrophysiol. at a nondesensitizing mutant of GluK1 showed full competitive antagonistic behavior with a Kb of 11.4 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe72VGdj51HrVg90H21EOLACvtfcHk0li8B7Mv1gqn_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWhsbvE&md5=dfe53691cb11fa493b0aaaec96a60909</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fcn100093f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100093f%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BM.%26aulast%3DVenskutonyt%25C4%2597%26aufirst%3DR.%26aulast%3DValad%25C3%25A9s%26aufirst%3DE.%2BA.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Class%2520of%2520Ionotropic%2520Glutamate%2520Receptor%2520Antagonists%2520by%2520the%2520Rational%2520Design%2520of%2520%25282S%252C3R%2529-3-%25283-Carboxyphenyl%2529-Pyrrolidine-2-Carboxylic%2520Acid%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D107%26epage%3D114%26doi%3D10.1021%2Fcn100093f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Krogsgaard-Larsen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storgaard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Møller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demmer, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monrad, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrup, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frydenvang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Structure-Activity Relationship Study of Ionotropic Glutamate Receptor Antagonist (2S,3R)-3-(3-Carboxyphenyl)pyrrolidine-2-Carboxylic Acid</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6131</span><span class="NLM_x">–</span> <span class="NLM_lpage">6150</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00750</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00750" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6131-6150&author=N.+Krogsgaard-Larsenauthor=M.+Storgaardauthor=C.+M%C3%B8llerauthor=C.+S.+Demmerauthor=J.+Hansenauthor=L.+Hanauthor=R.+N.+Monradauthor=B.+Nielsenauthor=D.+Tapkenauthor=D.+S.+Pickeringauthor=J.+S.+Kastrupauthor=K.+Frydenvangauthor=L.+Bunch&title=Structure-Activity+Relationship+Study+of+Ionotropic+Glutamate+Receptor+Antagonist+%282S%2C3R%29-3-%283-Carboxyphenyl%29pyrrolidine-2-Carboxylic+Acid&doi=10.1021%2Facs.jmedchem.5b00750"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00750%26sid%3Dliteratum%253Aachs%26aulast%3DKrogsgaard-Larsen%26aufirst%3DN.%26aulast%3DStorgaard%26aufirst%3DM.%26aulast%3DM%25C3%25B8ller%26aufirst%3DC.%26aulast%3DDemmer%26aufirst%3DC.%2BS.%26aulast%3DHansen%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DMonrad%26aufirst%3DR.%2BN.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DTapken%26aufirst%3DD.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DStructure-Activity%2520Relationship%2520Study%2520of%2520Ionotropic%2520Glutamate%2520Receptor%2520Antagonist%2520%25282S%252C3R%2529-3-%25283-Carboxyphenyl%2529pyrrolidine-2-Carboxylic%2520Acid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6131%26epage%3D6150%26doi%3D10.1021%2Facs.jmedchem.5b00750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Ogura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuyama, T.</span><span> </span><span class="NLM_article-title">Total Synthesis of (−)-Anisatin</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1632</span><span class="NLM_x">–</span> <span class="NLM_lpage">1635</span><span class="refDoi"> DOI: 10.1021/ol300390k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol300390k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=1632-1635&author=A.+Oguraauthor=K.+Yamadaauthor=S.+Yokoshimaauthor=T.+Fukuyama&title=Total+Synthesis+of+%28%E2%88%92%29-Anisatin&doi=10.1021%2Fol300390k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fol300390k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol300390k%26sid%3Dliteratum%253Aachs%26aulast%3DOgura%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DYokoshima%26aufirst%3DS.%26aulast%3DFukuyama%26aufirst%3DT.%26atitle%3DTotal%2520Synthesis%2520of%2520%2528%25E2%2588%2592%2529-Anisatin%26jtitle%3DOrg.%2520Lett.%26date%3D2012%26volume%3D14%26spage%3D1632%26epage%3D1635%26doi%3D10.1021%2Fol300390k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Bunch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogsgaard-Larsen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, U.</span><span> </span><span class="NLM_article-title">Mixed Cyano-Gilman Cuprates-Advances in Conjugate Addition to Alpha, Beta-Unsaturated Pyroglutaminol</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2002</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">33</span><span class="refDoi"> DOI: 10.1055/s-2002-19303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1055%2Fs-2002-19303" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2002&publication_year=2002&pages=31-33&author=L.+Bunchauthor=P.+Krogsgaard-Larsenauthor=U.+Madsen&title=Mixed+Cyano-Gilman+Cuprates-Advances+in+Conjugate+Addition+to+Alpha%2C+Beta-Unsaturated+Pyroglutaminol&doi=10.1055%2Fs-2002-19303"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-2002-19303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2002-19303%26sid%3Dliteratum%253Aachs%26aulast%3DBunch%26aufirst%3DL.%26aulast%3DKrogsgaard-Larsen%26aufirst%3DP.%26aulast%3DMadsen%26aufirst%3DU.%26atitle%3DMixed%2520Cyano-Gilman%2520Cuprates-Advances%2520in%2520Conjugate%2520Addition%2520to%2520Alpha%252C%2520Beta-Unsaturated%2520Pyroglutaminol%26jtitle%3DSynthesis%26date%3D2002%26volume%3D2002%26spage%3D31%26epage%3D33%26doi%3D10.1055%2Fs-2002-19303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="note"><p class="first last">Synthesis will be reported elsewhere.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräuner-Osborne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egebjerg, J.</span><span> </span><span class="NLM_article-title">Pharmacological Characterization of Ligands at Recombinant NMDA Receptor Subtypes by Electrophysiological Recordings and Intracellular Calcium Measurements</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.2174/138620708784246040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.2174%2F138620708784246040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=18473740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslCisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=304-315&author=K.+B.+Hansenauthor=H.+Br%C3%A4uner-Osborneauthor=J.+Egebjerg&title=Pharmacological+Characterization+of+Ligands+at+Recombinant+NMDA+Receptor+Subtypes+by+Electrophysiological+Recordings+and+Intracellular+Calcium+Measurements&doi=10.2174%2F138620708784246040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of ligands at recombinant NMDA receptor subtypes by electrophysiological recordings and intracellular calcium measurements</span></div><div class="casAuthors">Hansen, Kasper B.; Brauner-Osborne, Hans; Egebjerg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-315</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Generation of in vitro cellular assays using fluorescence measurements at heterologously expressed NMDA receptors would speed up the process of ligand characterization and enable high-throughput screening.  The major drawback to the development of such assays is the cytotoxicity caused by Ca2+-flux into the cell via NMDA receptors upon prolonged activation by agonists present in the culture medium.  In the present study, we established four cell lines with stable expression of NMDA receptor subtypes NR1/NR2A, NR1/NR2B, NR1/NR2C, or NR1/NR2D in BHK-21 cells.  To assess the usefulness of the stable cell lines in conjunction with intracellular calcium ([Ca2+]i) measurements for evaluation of NMDA receptor pharmacol., several ligands were characterized using this method.  The results were compared to parallel data obtained by electrophysiol. recordings at NMDA receptors expressed in Xenopus oocytes.  This comparison showed that agonist potencies detd. by [Ca2+]i measurements and electrophysiol. recordings correlated well, meaning that the stable cell lines in conjunction with [Ca2+]i measurements provide a useful tool for characterization of NMDA receptor ligands.  The agonist series of conformationally constrained glutamate analogs (2S,3R,4S)-α-(carboxycyclopropyl)glycine (CCG), 1-aminocyclobutane-r-1,cis-3-dicarboxylic acid (trans-ACBD), and (±)-1-aminocyclopentane-r-1,cis-3-dicarboxylic acid (cis-ACPD), as well as the highly potent agonist tetrazolylglycine were among the characterized ligands that were assessed with respect to subtype selectivity at NMDA receptors.  However, none of the characterized agonists displays more than 2-3 fold selectivity toward a specific NMDA receptor subtype.  Thus, the present study provides a broad pharmacol. characterization of structurally diverse ligands at recombinant NMDA receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYuZIWYgVeGbVg90H21EOLACvtfcHk0lhZkfgJuJYrLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslCisb4%253D&md5=4e07adfe9e1d8d9e4a0dd9f69ca15eeb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138620708784246040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620708784246040%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DBr%25C3%25A4uner-Osborne%26aufirst%3DH.%26aulast%3DEgebjerg%26aufirst%3DJ.%26atitle%3DPharmacological%2520Characterization%2520of%2520Ligands%2520at%2520Recombinant%2520NMDA%2520Receptor%2520Subtypes%2520by%2520Electrophysiological%2520Recordings%2520and%2520Intracellular%2520Calcium%2520Measurements%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2008%26volume%3D11%26spage%3D304%26epage%3D315%26doi%3D10.2174%2F138620708784246040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Yung-Chi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the Inhibition Constant (KI) and the Concentration of Inhibitor Which Causes 50 per Cent Inhibition (I50) of an Enzymatic Reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">–</span> <span class="NLM_lpage">3108</span><span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=4202581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+Inhibition+Constant+%28KI%29+and+the+Concentration+of+Inhibitor+Which+Causes+50+per+Cent+Inhibition+%28I50%29+of+an+Enzymatic+Reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520Inhibition%2520Constant%2520%2528KI%2529%2520and%2520the%2520Concentration%2520of%2520Inhibitor%2520Which%2520Causes%252050%2520per%2520Cent%2520Inhibition%2520%2528I50%2529%2520of%2520an%2520Enzymatic%2520Reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Hedegaard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräuner-Osborne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynelis, S. F.</span><span> </span><span class="NLM_article-title">Molecular Pharmacology of Human NMDA Receptors</span> <span class="citation_source-journal">Neurochem. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span><span class="refDoi"> DOI: 10.1016/j.neuint.2011.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.neuint.2011.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=22197913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=601-609&author=M.+Hedegaardauthor=K.+B.+Hansenauthor=K.+T.+Andersenauthor=H.+Br%C3%A4uner-Osborneauthor=S.+F.+Traynelis&title=Molecular+Pharmacology+of+Human+NMDA+Receptors&doi=10.1016%2Fj.neuint.2011.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pharmacology of human NMDA receptors</span></div><div class="casAuthors">Hedegaard, Maiken; Hansen, Kasper B.; Andersen, Karen T.; Brauner-Osborne, Hans; Traynelis, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-609</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">N-methyl-D-aspartate (NMDA) receptors are ionotropic glutamate receptors that mediate excitatory neurotransmission.  NMDA receptors are also important drug targets that are implicated in a no. of pathophysiol. conditions.  To facilitate the transition from lead compds. in pre-clin. animal models to drug candidates for human use, it is important to establish whether NMDA receptor ligands have similar properties at rodent and human NMDA receptors.  Here, we compare amino acid sequences for human and rat NMDA receptor subunits and discuss inter-species variation in the context of our current knowledge of the relationship between NMDA receptor structure and function.  We summarize studies on the biophys. properties of human NMDA receptors and compare these properties to those of rat orthologs.  Finally, we provide a comprehensive pharmacol. characterization that allows side-by-side comparison of agonists, un-competitive antagonists, GluN2B-selective non-competitive antagonists, and GluN2C/D-selective modulators at recombinant human and rat NMDA receptors.  The evaluation of biophys. properties and pharmacol. probes acting at different sites on the receptor suggest that the binding sites and conformational changes leading to channel gating in response to agonist binding are highly conserved between human and rat NMDA receptors.  In summary, the results of this study suggest that no major detectable differences exist in the pharmacol. and functional properties of human and rat NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS0vde2fdkdbVg90H21EOLACvtfcHk0lhZkfgJuJYrLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSktrfE&md5=97fbf713df306543c9bf801d4ad3b39f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2011.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2011.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DHedegaard%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DAndersen%26aufirst%3DK.%2BT.%26aulast%3DBr%25C3%25A4uner-Osborne%26aufirst%3DH.%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26atitle%3DMolecular%2520Pharmacology%2520of%2520Human%2520NMDA%2520Receptors%26jtitle%3DNeurochem.%2520Int.%26date%3D2012%26volume%3D61%26spage%3D601%26epage%3D609%26doi%3D10.1016%2Fj.neuint.2011.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Uchida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tachikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obuchi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoshi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terasaki, T.</span><span> </span><span class="NLM_article-title">A Study Protocol for Quantitative Targeted Absolute Proteomics (QTAP) by LC–MS/MS: Application for Inter-Strain Differences in Protein Expression Levels of Transporters, Receptors, Claudin-5, and Marker Proteins at the Blood–Brain Barrier in ddY, FVB, an</span> <span class="citation_source-journal">Fluids Barriers CNS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="refDoi"> DOI: 10.1186/2045-8118-10-21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1186%2F2045-8118-10-21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=23758935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFymsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=21&author=Y.+Uchidaauthor=M.+Tachikawaauthor=W.+Obuchiauthor=Y.+Hoshiauthor=Y.+Tomiokaauthor=S.+Ohtsukiauthor=T.+Terasaki&title=A+Study+Protocol+for+Quantitative+Targeted+Absolute+Proteomics+%28QTAP%29+by+LC%E2%80%93MS%2FMS%3A+Application+for+Inter-Strain+Differences+in+Protein+Expression+Levels+of+Transporters%2C+Receptors%2C+Claudin-5%2C+and+Marker+Proteins+at+the+Blood%E2%80%93Brain+Barrier+in+ddY%2C+FVB%2C+an&doi=10.1186%2F2045-8118-10-21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice</span></div><div class="casAuthors">Uchida, Yasuo; Tachikawa, Masanori; Obuchi, Wataru; Hoshi, Yutaro; Tomioka, Yusuke; Ohtsuki, Sumio; Terasaki, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Fluids and Barriers of the CNS</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>CODEN:
                <span class="NLM_cas:coden">FBCLA5</span>;
        ISSN:<span class="NLM_cas:issn">2045-8118</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Proteomics has opened a new horizon in biol. sciences.  Global proteomic anal. is a promising technol. for the discovery of thousands of proteins, post-translational modifications, polymorphisms, and mol. interactions in a variety of biol. systems.  The activities and roles of the identified proteins must also be elucidated, but this is complicated by the inability of conventional proteomic methods to yield quant. information for protein expression.  Thus, a variety of biol. systems remain "black boxes".  Quant. targeted abs. proteomics (QTAP) enables the detn. of abs. expression levels (mol) of any target protein, including low-abundance functional proteins, such as transporters and receptors.  Therefore, QTAP will be useful for understanding the activities and roles of individual proteins and their differences, including normal/disease, human/animal, or in vitro/in vivo.  Here, we describe the study protocols and precautions for QTAP expts. including in silico target peptide selection, detn. of peptide concn. by amino acid anal., setup of selected/multiple reaction monitoring (SRM/MRM) anal. in liq. chromatog.-tandem mass spectrometry, prepn. of protein samples (brain capillaries and plasma membrane fractions) followed by the prepn. of peptide samples, simultaneous abs. quantification of target proteins by SRM/MRM anal., data anal., and troubleshooting.  An application of QTAP in biol. sciences was introduced that utilizes data from inter-strain differences in the protein expression levels of transporters, receptors, tight junction proteins and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice.  Among 18 mols., 13 (abcb1a/mdr1a/P-gp, abcc4/mrp4, abcg2/bcrp, slc2a1/glut1, slc7a5/lat1, slc16a1/mct1, slc22a8/oat3, insr, lrp1, tfr1, claudin-5, Na+/K+-ATPase, and γ-gtp) were detected in the isolated brain capillaries, and their protein expression levels were within a range of 0.637-101 fmol/μg protein.  The largest difference in the levels between the three strains was 2.2-fold for 13 mols., although bcrp and mct1 displayed statistically significant differences between C57BL/6J and the other strain(s).  Highly sensitive simultaneous abs. quantification achieved by QTAP will increase the usefulness of proteomics in biol. sciences and is expected to advance the new research field of pharmacoproteomics (PPx).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgqG9zmyBJSLVg90H21EOLACvtfcHk0lhZkfgJuJYrLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFymsb7J&md5=f9a58deb2bc5a2313bc481b60bf9e787</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F2045-8118-10-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2045-8118-10-21%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DTachikawa%26aufirst%3DM.%26aulast%3DObuchi%26aufirst%3DW.%26aulast%3DHoshi%26aufirst%3DY.%26aulast%3DTomioka%26aufirst%3DY.%26aulast%3DOhtsuki%26aufirst%3DS.%26aulast%3DTerasaki%26aufirst%3DT.%26atitle%3DA%2520Study%2520Protocol%2520for%2520Quantitative%2520Targeted%2520Absolute%2520Proteomics%2520%2528QTAP%2529%2520by%2520LC%25E2%2580%2593MS%252FMS%253A%2520Application%2520for%2520Inter-Strain%2520Differences%2520in%2520Protein%2520Expression%2520Levels%2520of%2520Transporters%252C%2520Receptors%252C%2520Claudin-5%252C%2520and%2520Marker%2520Proteins%2520at%2520the%2520Blood%25E2%2580%2593Brain%2520Barrier%2520in%2520ddY%252C%2520FVB%252C%2520an%26jtitle%3DFluids%2520Barriers%2520CNS%26date%3D2013%26volume%3D10%26spage%3D21%26doi%3D10.1186%2F2045-8118-10-21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Rautio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balakrishnan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keogh, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunta, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. W.</span><span> </span><span class="NLM_article-title">In Vitro P-Glycoprotein Inhibition Assays for Assessment of Clinical Drug Interaction Potential of New Drug Candidates: A Recommendation for Probe Substrates</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1124/dmd.105.008615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fdmd.105.008615" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=786-792&author=J.+Rautioauthor=J.+E.+Humphreysauthor=L.+O.+Websterauthor=A.+Balakrishnanauthor=J.+P.+Keoghauthor=J.+R.+Kuntaauthor=C.+J.+Serabjit-Singhauthor=J.+W.+Polli&title=In+Vitro+P-Glycoprotein+Inhibition+Assays+for+Assessment+of+Clinical+Drug+Interaction+Potential+of+New+Drug+Candidates%3A+A+Recommendation+for+Probe+Substrates&doi=10.1124%2Fdmd.105.008615"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.008615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.008615%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DKeogh%26aufirst%3DJ.%2BP.%26aulast%3DKunta%26aufirst%3DJ.%2BR.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DIn%2520Vitro%2520P-Glycoprotein%2520Inhibition%2520Assays%2520for%2520Assessment%2520of%2520Clinical%2520Drug%2520Interaction%2520Potential%2520of%2520New%2520Drug%2520Candidates%253A%2520A%2520Recommendation%2520for%2520Probe%2520Substrates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D786%26epage%3D792%26doi%3D10.1124%2Fdmd.105.008615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Löscher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potschka, H.</span><span> </span><span class="NLM_article-title">Blood-Brain Barrier Active Efflux Transporters: ATP-Binding Cassette Gene Family</span> <span class="citation_source-journal">NeuroRx</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1602/neurorx.2.1.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1602%2Fneurorx.2.1.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=15717060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A280%3ADC%252BD2MzntVejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=86-98&author=W.+L%C3%B6scherauthor=H.+Potschka&title=Blood-Brain+Barrier+Active+Efflux+Transporters%3A+ATP-Binding+Cassette+Gene+Family&doi=10.1602%2Fneurorx.2.1.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-brain barrier active efflux transporters: ATP-binding cassette gene family</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-98</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from potentially harmful endogenous and exogenous substances.  BBB active drug efflux transporters of the ATP-binding cassette (ABC) gene family are increasingly recognized as important determinants of drug distribution to, and elimination from, the CNS.  The ABC efflux transporter P-glycoprotein (Pgp) has been demonstrated as a key element of the BBB that can actively transport a huge variety of lipophilic drugs out of the brain capillary endothelial cells that form the BBB.  In addition to Pgp, other ABC efflux transporters such as members of the multidrug resistance protein (MRP) family and breast cancer resistance protein (BCRP) seem to contribute to BBB function.  Consequences of ABC efflux transporters in the BBB include minimizing or avoiding neurotoxic adverse effects of drugs that otherwise would penetrate into the brain.  However, ABC efflux transporters may also limit the central distribution of drugs that are beneficial to treat CNS diseases.  Furthermore, neurological disorders such as epilepsy may be associated with overexpression of ABC efflux transporters at the BBB, resulting in pharmacoresistance to therapeutic medication.  Therefore, modulation of ABC efflux transporters at the BBB forms a novel strategy to enhance the penetration of drugs into the brain and may yield new therapeutic options for drug-resistant CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8zmuJRBq_DwvupmecNw_lfW6udTcc2eaNnvU39jeEirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzntVejsA%253D%253D&md5=4de8b6e417fdc59a41aef2629475da8d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.1.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.1.86%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DBlood-Brain%2520Barrier%2520Active%2520Efflux%2520Transporters%253A%2520ATP-Binding%2520Cassette%2520Gene%2520Family%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D86%26epage%3D98%26doi%3D10.1602%2Fneurorx.2.1.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span> </span><span class="NLM_article-title">Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11851</span><span class="NLM_x">–</span> <span class="NLM_lpage">11858</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-1377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1158%2F0008-5472.CAN-06-1377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=17178882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlagu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11851-11858&author=L.+Liuauthor=Y.+Caoauthor=C.+Chenauthor=X.+Zhangauthor=A.+McNabolaauthor=D.+Wilkieauthor=S.+Wilhelmauthor=M.+Lynchauthor=C.+Carter&title=Sorafenib+Blocks+the+RAF%2FMEK%2FERK+Pathway%2C+Inhibits+Tumor+Angiogenesis%2C+and+Induces+Tumor+Cell+Apoptosis+in+Hepatocellular+Carcinoma+Model+PLC%2FPRF%2F5&doi=10.1158%2F0008-5472.CAN-06-1377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5</span></div><div class="casAuthors">Liu, Li; Cao, Yichen; Chen, Charles; Zhang, Xiaomei; McNabola, Angela; Wilkie, Dean; Wilhelm, Scott; Lynch, Mark; Carter, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11851-11858</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important roles in the development of hepatocellular carcinomas (HCC).  Sorafenib (BAY 43-9006, Nexavar) is a multikinase inhibitor with activity against Raf kinase and several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), FLT3, Ret, and c-Kit.  In this study, we investigated the in vitro effects of sorafenib on PLC/PRF/5 and HepG2 HCC cells and the in vivo antitumor efficacy and mechanism of action on PLC/PRF/5 human tumor xenografts in severe combined immunodeficient mice.  Sorafenib inhibited the phosphorylation of MEK and ERK and down-regulated cyclin D1 levels in these two cell lines.  Sorafenib also reduced the phosphorylation level of eIF4E and down-regulated the antiapoptotic protein Mcl-1 in a MEK/ERK-independent manner.  Consistent with the effects on both MEK/ERK-dependent and MEK/ERK-independent signaling pathways, sorafenib inhibited proliferation and induced apoptosis in both HCC cell lines.  In the PLC/PRF/5 xenograft model, sorafenib tosylate dosed at 10 mg/kg inhibited tumor growth by 49%.  At 30 mg/kg, sorafenib tosylate produced complete tumor growth inhibition.  A dose of 100 mg/kg produced partial tumor regressions in 50% of the mice.  In mechanism of action studies, sorafenib inhibited the phosphorylation of both ERK and eIF4E, reduced the microvessel area (assessed by CD34 immunohistochem.), and induced tumor cell apoptosis (assessed by terminal deoxynucleotidyl transferase-mediated nick end labeling) in PLC/PRF/5 tumor xenografts.  These results suggest that the antitumor activity of sorafenib in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppvphV4C1i-LVg90H21EOLACvtfcHk0ljggNsX1pwK8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlagu73F&md5=79c8dd43356ab00fcc473423834e3c93</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-1377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-1377%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DC.%26atitle%3DSorafenib%2520Blocks%2520the%2520RAF%252FMEK%252FERK%2520Pathway%252C%2520Inhibits%2520Tumor%2520Angiogenesis%252C%2520and%2520Induces%2520Tumor%2520Cell%2520Apoptosis%2520in%2520Hepatocellular%2520Carcinoma%2520Model%2520PLC%252FPRF%252F5%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11851%26epage%3D11858%26doi%3D10.1158%2F0008-5472.CAN-06-1377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Si, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, A. G.</span><span> </span><span class="NLM_article-title">A Versatile Synthesis of Substituted Isoquinolines</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">10409</span><span class="NLM_x">–</span> <span class="NLM_lpage">10413</span><span class="refDoi"> DOI: 10.1002/anie.201104769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1002%2Fanie.201104769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCnt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=10409-10413&author=C.+Siauthor=A.+G.+Myers&title=A+Versatile+Synthesis+of+Substituted+Isoquinolines&doi=10.1002%2Fanie.201104769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Versatile Synthesis of Substituted Isoquinolines</span></div><div class="casAuthors">Si, Chong; Myers, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">10409-10413, S10409/1-S10409/71</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This communication present the direct assembly of substituted isoquinolines and biisoquinolines for use in versatile and unique methodologies for the construction of heterocyclic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQVSVG9HFyoLVg90H21EOLACvtfcHk0lhGwU8vftDxIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCnt7zI&md5=a883e7a9bb6ef7d3db76552032e2addd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201104769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201104769%26sid%3Dliteratum%253Aachs%26aulast%3DSi%26aufirst%3DC.%26aulast%3DMyers%26aufirst%3DA.%2BG.%26atitle%3DA%2520Versatile%2520Synthesis%2520of%2520Substituted%2520Isoquinolines%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D10409%26epage%3D10413%26doi%3D10.1002%2Fanie.201104769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Akazawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tachikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terasaki, T.</span><span> </span><span class="NLM_article-title">Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2456</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.6b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=2443-2456&author=T.+Akazawaauthor=Y.+Uchidaauthor=M.+Tachikawaauthor=S.+Ohtsukiauthor=T.+Terasaki&title=Quantitative+Targeted+Absolute+Proteomics+of+Transporters+and+Pharmacoproteomics-Based+Reconstruction+of+P-Glycoprotein+Function+in+Mouse+Small+Intestine&doi=10.1021%2Facs.molpharmaceut.6b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine</span></div><div class="casAuthors">Akazawa, Takanori; Uchida, Yasuo; Tachikawa, Masanori; Ohtsuki, Sumio; Terasaki, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2443-2456</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate whether a pharmacokinetic model integrating in vitro mdr1a efflux activity (which we previously reported) with in vitro/in vivo differences in protein expression level can reconstruct intestinal mdr1a function.  In situ intestinal permeability-surface area product ratio between wild-type and mdr1a/1b (-/-) mice is one of the parameters used to describe intestinal mdr1a function.  The reconstructed ratios of six mdr1a substrates (dexamethasone, digoxin, loperamide, quinidine, verapamil, vinblastine) and one nonsubstrate (diazepam) were consistent with the obsd. values reported by Adachi et al. within 2.1-fold difference.  Thus, intestinal mdr1a function can be reconstructed by our pharmacoproteomic modeling approach.  Furthermore, we evaluated regional differences in protein expression levels of mouse intestinal transporters.  Sixteen (mdr1a, mrp4, bcrp, abcg5, abcg8, glut1, 4f2hc, sglt1, lat2, pept1, mct1, slc22a18, ostβ, villin1, Na+/K+-ATPase, γ-gtp) out of 46 target mols. were detected by employing our established quant. targeted abs. proteomics technique.  The protein expression amts. of mdr1a and bcrp increased progressively from duodenum to ileum.  Sglt1, lat2, and 4f2hc were highly expressed in jejunum and ileum.  Mct1 and ostβ were highly expressed in ileum.  The quant. expression profiles established here should be helpful to understand and predict intestinal transporter functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfdG2_wq0SL7Vg90H21EOLACvtfcHk0lhGwU8vftDxIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCit70%253D&md5=fedbf3f4cb757695c6fbd05704ef0ac9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00196%26sid%3Dliteratum%253Aachs%26aulast%3DAkazawa%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DTachikawa%26aufirst%3DM.%26aulast%3DOhtsuki%26aufirst%3DS.%26aulast%3DTerasaki%26aufirst%3DT.%26atitle%3DQuantitative%2520Targeted%2520Absolute%2520Proteomics%2520of%2520Transporters%2520and%2520Pharmacoproteomics-Based%2520Reconstruction%2520of%2520P-Glycoprotein%2520Function%2520in%2520Mouse%2520Small%2520Intestine%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D2443%26epage%3D2456%26doi%3D10.1021%2Facs.molpharmaceut.6b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Gynther, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huttunen, K. M.</span><span> </span><span class="NLM_article-title">Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2484</span><span class="NLM_x">–</span> <span class="NLM_lpage">2491</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.6b00217</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00217" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=2484-2491&author=M.+Gyntherauthor=D.+S.+Pickeringauthor=J.+A.+Spicerauthor=W.+A.+Dennyauthor=K.+M.+Huttunen&title=Systemic+and+Brain+Pharmacokinetics+of+Perforin+Inhibitor+Prodrugs&doi=10.1021%2Facs.molpharmaceut.6b00217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs</span></div><div class="casAuthors">Gynther, Mikko; Pickering, Darryl S.; Spicer, Julie A.; Denny, William A.; Huttunen, Kristiina M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2484-2491</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have recently reported that by converting a perforin inhibitor into an L-type amino acid transporter 1 (LAT1)-utilizing prodrug its cellular uptake can be greatly increased.  The aim of the present study was to det. the in vivo and brain pharmacokinetics of two perforin inhibitors and their LAT1-utilizing prodrugs 1 and 2.  In addn., the brain uptake mechanism and entry into primary mouse cortical neurons and astrocytes were evaluated.  After 23 μmol/kg i.p. bolus injection, the prodrugs' unbound area under the concn. curve in brain was 0.3 nmol/g × min, whereas the parent drugs could not reach the brain.  The unbound brain concns. of the prodrugs after 100 μM in situ mouse brain perfusion were 521.4 ± 46.9 and 126.9 ± 19.9 pmol/g for prodrugs 1 and 2, resp.  The combination of competing transporter substrates for LAT1, L-tryptophan, and for org. anion transporting polypeptides, probenecid, decreased the brain concns. to 352.4 ± 44.5 and 70.9 ± 7.0 pmol/g, resp.  In addn., in vitro uptake studies showed that at 100 μM prodrug 1 had 3.4-fold and 4.5-fold higher uptake rate into neurons and astrocytes, resp., compared to its parent drug.  Thus, the prodrugs enhance significantly the therapeutic potential of the parent drugs for the treatment of disorders of central nervous system in which neuroinflammation is involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTu1P9Kh__1LVg90H21EOLACvtfcHk0lhGwU8vftDxIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCiurg%253D&md5=245bc7a347c3666e1ac09f3bf4d5a469</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00217%26sid%3Dliteratum%253Aachs%26aulast%3DGynther%26aufirst%3DM.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26atitle%3DSystemic%2520and%2520Brain%2520Pharmacokinetics%2520of%2520Perforin%2520Inhibitor%2520Prodrugs%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D2484%26epage%3D2491%26doi%3D10.1021%2Facs.molpharmaceut.6b00217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogden, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynelis, S. F.</span><span> </span><span class="NLM_article-title">Distinct Functional and Pharmacological Properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">1084</span><span class="NLM_x">–</span> <span class="NLM_lpage">1096</span><span class="refDoi"> DOI: 10.1016/j.neuron.2014.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1016%2Fj.neuron.2014.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=24607230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslKqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2014&pages=1084-1096&author=K.+B.+Hansenauthor=K.+K.+Ogdenauthor=H.+Yuanauthor=S.+F.+Traynelis&title=Distinct+Functional+and+Pharmacological+Properties+of+Triheteromeric+GluN1%2FGluN2A%2FGluN2B+NMDA+Receptors&doi=10.1016%2Fj.neuron.2014.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Functional and Pharmacological Properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors</span></div><div class="casAuthors">Hansen, Kasper B.; Ogden, Kevin K.; Yuan, Hongjie; Traynelis, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1084-1096</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">NMDA receptors are tetrameric ligand-gated ion channels comprised of GluN1, GluN2, and GluN3 subunits.  Two different GluN2 subunits have been identified in most NMDA receptor-expressing cells, and the majority of native receptors are triheteromers contg. two GluN1 and two different GluN2.  In contrast to diheteromeric NMDA receptors, little is known about the function of triheteromers.  We developed a method to provide selective cell-surface expression of recombinant GluN1/GluN2A/GluN2B triheteromers and compared properties of these receptors with those of GluN1/GluN2A and GluN1/GluN2B diheteromers.  We show that glutamate deactivation of triheteromers is distinct from those of GluN1/GluN2A and GluN1/GluN2B and reveal modulation of triheteromers by subunit-selective antagonists ifenprodil, CP-101,606, TCN-201, and extracellular Zn2+.  Furthermore, kinetic measurements suggest variation in the ifenprodil binding site of triheteromers compared to GluN1/GluN2B diheteromers.  This work provides insight into the distinct properties of GluN1/GluN2A/GluN2B triheteromers, which are presumably the most abundant NMDA receptors in the adult forebrain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6JuHTe09fw7Vg90H21EOLACvtfcHk0lhGwU8vftDxIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslKqur8%253D&md5=c0fb80e63e7ea59d2b493a3c9ce31852</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2014.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2014.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DOgden%26aufirst%3DK.%2BK.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26atitle%3DDistinct%2520Functional%2520and%2520Pharmacological%2520Properties%2520of%2520Triheteromeric%2520GluN1%252FGluN2A%252FGluN2B%2520NMDA%2520Receptors%26jtitle%3DNeuron%26date%3D2014%26volume%3D81%26spage%3D1084%26epage%3D1096%26doi%3D10.1016%2Fj.neuron.2014.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risgaard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perszyk, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jørgensen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vance, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogden, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furukawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynelis, S. F.</span><span> </span><span class="NLM_article-title">Structural Determinants of Agonist Efficacy at the Glutamate Binding Site of N-Methyl-D-Aspartate Receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span><span class="refDoi"> DOI: 10.1124/mol.113.085803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1124%2Fmol.113.085803" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=114-127&author=K.+B.+Hansenauthor=N.+Tajimaauthor=R.+Risgaardauthor=R.+E.+Perszykauthor=L.+J%C3%B8rgensenauthor=K.+M.+Vanceauthor=K.+K.+Ogdenauthor=R.+P.+Clausenauthor=H.+Furukawaauthor=S.+F.+Traynelis&title=Structural+Determinants+of+Agonist+Efficacy+at+the+Glutamate+Binding+Site+of+N-Methyl-D-Aspartate+Receptors&doi=10.1124%2Fmol.113.085803"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.085803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.085803%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DTajima%26aufirst%3DN.%26aulast%3DRisgaard%26aufirst%3DR.%26aulast%3DPerszyk%26aufirst%3DR.%2BE.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DL.%26aulast%3DVance%26aufirst%3DK.%2BM.%26aulast%3DOgden%26aufirst%3DK.%2BK.%26aulast%3DClausen%26aufirst%3DR.%2BP.%26aulast%3DFurukawa%26aufirst%3DH.%26aulast%3DTraynelis%26aufirst%3DS.%2BF.%26atitle%3DStructural%2520Determinants%2520of%2520Agonist%2520Efficacy%2520at%2520the%2520Glutamate%2520Binding%2520Site%2520of%2520N-Methyl-D-Aspartate%2520Receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D114%26epage%3D127%26doi%3D10.1124%2Fmol.113.085803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Assaf, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venskutonytė, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahamsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajhede, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrup, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, A. a.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frydenvang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gefflaut, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Chemoenzymatic Synthesis of New 2,4-Syn-Functionalized (S)-Glutamate Analogues and Structure-Activity Relationship Studies at Ionotropic Glutamate Receptors and Excitatory Amino Acid Transporters</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1614</span><span class="NLM_x">–</span> <span class="NLM_lpage">1628</span><span class="refDoi"> DOI: 10.1021/jm301433m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301433m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Sktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1614-1628&author=Z.+Assafauthor=A.+P.+Larsenauthor=R.+Venskutonyt%C4%97author=L.+Hanauthor=B.+Abrahamsenauthor=B.+Nielsenauthor=M.+Gajhedeauthor=J.+S.+Kastrupauthor=A.+a.+Jensenauthor=D.+S.+Pickeringauthor=K.+Frydenvangauthor=T.+Gefflautauthor=L.+Bunch&title=Chemoenzymatic+Synthesis+of+New+2%2C4-Syn-Functionalized+%28S%29-Glutamate+Analogues+and+Structure-Activity+Relationship+Studies+at+Ionotropic+Glutamate+Receptors+and+Excitatory+Amino+Acid+Transporters&doi=10.1021%2Fjm301433m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoenzymatic synthesis of new 2,4-syn-functionalized (S)-glutamate analogues and structure-activity relationship studies at ionotropic glutamate receptors and excitatory amino acid transporters</span></div><div class="casAuthors">Assaf, Zeinab; Larsen, Anja P.; Venskutonyte, Raminta; Han, Liwei; Abrahamsen, Bjarke; Nielsen, Birgitte; Gajhede, Michael; Kastrup, Jette S.; Jensen, Anders A.; Pickering, Darryl S.; Frydenvang, Karla; Gefflaut, Thierry; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1614-1628</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the mammalian central nervous system, (S)-glutamate (Glu) is released from the presynaptic neuron where it activates a plethora of pre- and postsynaptic Glu receptors.  The fast acting ionotropic Glu receptors (iGluRs) are ligand gated ion channels and are believed to be involved in a vast no. of neurol. functions such as memory and learning, synaptic plasticity, and motor function.  The synthesis of 14 enantiopure 2,4-syn-Glu analogs, e.g. (I), (II), (III), is accessed by a short and efficient chemoenzymic approach starting from readily available cyclohexanone (IV).  Pharmacol. characterization at the iGluRs and EAAT1-3 subtypes revealed analog II as a selective GluK1 ligand with low nanomolar affinity.  Two X-ray crystal structures of the key analog II in the ligand-binding domain (LBD) of GluA2 and GluK3 were detd.  Partial domain closure was seen in the GluA2-LBD complex with II comparable to that induced by kainate.  In contrast, full domain closure was obsd. in the GluK3-LBD complex with II, similar to that of GluK3-LBD with glutamate bound.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNDU3_wI6ErbVg90H21EOLACvtfcHk0li9fPhxmBnbxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Sktbs%253D&md5=820d359e25bfc4d9505c20bc303cd67d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm301433m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301433m%26sid%3Dliteratum%253Aachs%26aulast%3DAssaf%26aufirst%3DZ.%26aulast%3DLarsen%26aufirst%3DA.%2BP.%26aulast%3DVenskutonyt%25C4%2597%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DAbrahamsen%26aufirst%3DB.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DGajhede%26aufirst%3DM.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26aulast%3DJensen%26aufirst%3DA.%2Ba.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DGefflaut%26aufirst%3DT.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DChemoenzymatic%2520Synthesis%2520of%2520New%25202%252C4-Syn-Functionalized%2520%2528S%2529-Glutamate%2520Analogues%2520and%2520Structure-Activity%2520Relationship%2520Studies%2520at%2520Ionotropic%2520Glutamate%2520Receptors%2520and%2520Excitatory%2520Amino%2520Acid%2520Transporters%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1614%26epage%3D1628%26doi%3D10.1021%2Fjm301433m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Sagot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umberti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensbøl, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapelet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gefflaut, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Chemo-Enzymatic Synthesis of a Series of 2,4-Syn-Functionalized (S)-Glutamate Analogues: New Insight into the Structure-Activity Relation of Ionotropic Glutamate Receptor Subtypes 5, 6, and 7</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4093</span><span class="NLM_x">–</span> <span class="NLM_lpage">4103</span><span class="refDoi"> DOI: 10.1021/jm800092x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800092x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsl2rsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4093-4103&author=E.+Sagotauthor=D.+S.+Pickeringauthor=X.+Puauthor=M.+Umbertiauthor=T.+B.+Stensb%C3%B8lauthor=B.+Nielsenauthor=M.+Chapeletauthor=J.+Bolteauthor=T.+Gefflautauthor=L.+Bunch&title=Chemo-Enzymatic+Synthesis+of+a+Series+of+2%2C4-Syn-Functionalized+%28S%29-Glutamate+Analogues%3A+New+Insight+into+the+Structure-Activity+Relation+of+Ionotropic+Glutamate+Receptor+Subtypes+5%2C+6%2C+and+7&doi=10.1021%2Fjm800092x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogs: New insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7</span></div><div class="casAuthors">Sagot, Emanuelle; Pickering, Darryl S.; Pu, Xiaosui; Umberti, Michelle; Stensboel, Tine B.; Nielsen, Birgitte; Chapelet, Marion; Bolte, Jean; Gefflaut, Thierry; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4093-4103</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(S)-Glutamic acid (Glu) is the major excitatory neurotransmitter in the central nervous system (CNS) activating the plethora of ionotropic Glu receptors (iGluRs) and metabotropic Glu receptors (mGluRs).  In this paper, we present a chemo-enzymic strategy for the enantioselective synthesis of five new Glu analogs (I) [R1 = CH2OH, CH2OCh2Ph, CH2CO2Me, (CH2)2CO2Me, (CH2)2CO2H, (CH2)2CONH2, (CH2)2CONHMe, (CH2)2CO2NHCH2Ph; R1 = (CH2)2CONH(CH)2Me is exempt] holding a functionalized substituent in the 4-position.  Nine Glu analogs I are characterized pharmacol. at native 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA), kainic acid (KA), and N-methyl-D-aspartic acid (NMDA) receptors in rat synaptosomes as well as in binding assays at cloned rat iGluR5-7 subtypes.  A detailed in silico study address as to why I [R1 = (CH2)2CONHMe] is a high-affinity ligand at iGluR5-7 (Ki = 3.81, 123, 57.3 nM, resp.), while I [R1 = (CH2)2CO2Me] is only a high affinity ligand at iGluR5 (Ki = 42.8 nM).  Furthermore, a small series of com. available iGluR ligands are characterized in iGluR5-7 binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpegN5n8XosULVg90H21EOLACvtfcHk0li9fPhxmBnbxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsl2rsbc%253D&md5=8a9c9c7964bf7884ea56f165e24c6188</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm800092x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800092x%26sid%3Dliteratum%253Aachs%26aulast%3DSagot%26aufirst%3DE.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DPu%26aufirst%3DX.%26aulast%3DUmberti%26aufirst%3DM.%26aulast%3DStensb%25C3%25B8l%26aufirst%3DT.%2BB.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DChapelet%26aufirst%3DM.%26aulast%3DBolte%26aufirst%3DJ.%26aulast%3DGefflaut%26aufirst%3DT.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DChemo-Enzymatic%2520Synthesis%2520of%2520a%2520Series%2520of%25202%252C4-Syn-Functionalized%2520%2528S%2529-Glutamate%2520Analogues%253A%2520New%2520Insight%2520into%2520the%2520Structure-Activity%2520Relation%2520of%2520Ionotropic%2520Glutamate%2520Receptor%2520Subtypes%25205%252C%25206%252C%2520and%25207%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4093%26epage%3D4103%26doi%3D10.1021%2Fjm800092x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Alcaide, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haym, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Møllerud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunch, L.</span><span> </span><span class="NLM_article-title">Synthesis and Pharmacological Characterization of the Selective GluK1 Radioligand (S)-2-Amino-3-(6-[ 3 H]-2,4-Dioxo-3,4-dihydrothieno[3,2-D]pyrimidin-1(2H)-Yl)propanoic Acid ([3H]-NF608)</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2136</span><span class="NLM_x">–</span> <span class="NLM_lpage">2144</span><span class="refDoi"> DOI: 10.1039/C6MD00339G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;key=10.1039%2FC6MD00339G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2136-2144&author=A.+Alcaideauthor=L.+Marconiauthor=A.+Marekauthor=I.+Haymauthor=B.+Nielsenauthor=S.+M%C3%B8llerudauthor=M.+Jensenauthor=P.+Contiauthor=D.+S.+Pickeringauthor=L.+Bunch&title=Synthesis+and+Pharmacological+Characterization+of+the+Selective+GluK1+Radioligand+%28S%29-2-Amino-3-%286-%5B+3+H%5D-2%2C4-Dioxo-3%2C4-dihydrothieno%5B3%2C2-D%5Dpyrimidin-1%282H%29-Yl%29propanoic+Acid+%28%5B3H%5D-NF608%29&doi=10.1039%2FC6MD00339G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1039%2FC6MD00339G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00339G%26sid%3Dliteratum%253Aachs%26aulast%3DAlcaide%26aufirst%3DA.%26aulast%3DMarconi%26aufirst%3DL.%26aulast%3DMarek%26aufirst%3DA.%26aulast%3DHaym%26aufirst%3DI.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DM%25C3%25B8llerud%26aufirst%3DS.%26aulast%3DJensen%26aufirst%3DM.%26aulast%3DConti%26aufirst%3DP.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Characterization%2520of%2520the%2520Selective%2520GluK1%2520Radioligand%2520%2528S%2529-2-Amino-3-%25286-%255B%25203%2520H%255D-2%252C4-Dioxo-3%252C4-dihydrothieno%255B3%252C2-D%255Dpyrimidin-1%25282H%2529-Yl%2529propanoic%2520Acid%2520%2528%255B3H%255D-NF608%2529%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D2136%26epage%3D2144%26doi%3D10.1039%2FC6MD00339G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=U11418" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=U11418','Genbank','U11418'); return false;">Genbank: U11418</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=U08261" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=U08261','Genbank','U08261'); return false;">Genbank: U08261</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=D13211" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=D13211','Genbank','D13211'); return false;">Genbank: D13211</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=U11419" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=U11419','Genbank','U11419'); return false;">Genbank: U11419</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=M91563" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=M91563','Genbank','M91563'); return false;">Genbank: M91563</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=L31611" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=L31611','Genbank','L31611'); return false;">Genbank: L31611</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-NOTES-d53e6813-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01624">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_03310"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01624">10.1021/acs.jmedchem.7b01624</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">SMILES (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01624/suppl_file/jm7b01624_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01624/suppl_file/jm7b01624_si_001.csv">jm7b01624_si_001.csv (1.11 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01624&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01624" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01624" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c2f15d031239","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
